Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 118
Encontrada(s) 2 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Repeated intravenous doses of human umbilical cord-derived mesenchymal stromal cells for bronchopulmonary dysplasia: results of a phase 1 clinical trial with 2-year follow-up

  • Cerro Marín, Maria Jesús del
  • Moreno Gutiérrez, Laura
  • Vento Torres, Máximo
Background: Currently, there is a lack of effective treatments or preventive strategies for bronchopulmonary dysplasia (BPD). Pre-clinical studies with mesenchymal stromal cells (MSCs) have yielded encouraging results. The safety of administering repeated intravenous doses of umbilical cord tissue-derived mesenchymal stromal cells (UC-MSCs) has not yet been tested in extremely-low-gestational-age newborns (ELGANs). Aims: to test the safety and feasibility of administering three sequential intravenous doses of UC-MSCs every 7 days to ELGANs at risk of developing BPD. Methods: In this phase 1 clinical trial, we recruited ELGANs (birth weight ≤1250 g and ≤28 weeks in gestational age [GA]) who were on invasive mechanical ventilation (IMV) with FiO2 ≥ 0.3 at postnatal days 7-14. Three doses of 5 × 106/kg of UC-MSCs were intravenously administered at weekly intervals. Adverse effects and prematurity-related morbidities were recorded. Results: From April 2019 to July 2020, 10 patients were recruited with a mean GA of 25.2 ± 0.8 weeks and a mean birth weight of 659.8 ± 153.8 g. All patients received three intravenous UC-MSC doses. The first dose was administered at a mean of 16.6 ± 2.9 postnatal days. All patients were diagnosed with BPD. All patients were discharged from the hospital. No deaths or any serious adverse events related to the infusion of UC-MSCs were observed during administration, hospital stays or at 2-year follow-up. Conclusions: The administration of repeated intravenous infusion of UC-MSCs in ELGANs at a high risk of developing BPD was feasible and safe in the short- and mid-term follow-up.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lung Transplant Improves Survival and Quality of Life Regardless of Telomere Dysfunction

  • Planas-Cerezales, Lurdes|||0000-0001-7636-444X
  • Arias-Salgado, Elena G.
  • Berastegui García, Cristina|||0000-0001-9774-9349
  • Montes-Worboys, Ana|||0000-0002-3204-779X
  • González-Montelongo, Rafaela
  • Lorenzo-Salazar, José. M.
  • Vicens-Zygmunt, Vanesa|||0000-0002-0940-3215
  • Garcia-Moyano, Marta
  • Dorca, Jordi|||0000-0002-8137-878X
  • Flores, Carlos|||0000-0001-5352-069X
  • Perona, Rosario|||0000-0002-2973-5153
  • Roman Broto, Antonio|||0000-0002-9417-3484
  • Molina Molina, Maria|||0000-0002-1852-1723
Introduction: Fibrotic interstitial lung diseases (ILDs) are the first indication for lung transplantation (LT). Telomere dysfunction has been associated with poor post-transplant outcomes. The aim of the study was to evaluate the morbi-mortality and quality of life in fibrotic ILDs after lung transplant depending on telomere biology. Methods: Fibrotic ILD patients that underwent lung transplant were allocated to two arms; with or without telomere dysfunction at diagnosis based on the telomere length and telomerase related gene mutations revealed by whole-exome sequencing. Post-transplant evaluation included: (1) short and long-term mortality and complications and (2) quality of life. Results: Fifty-five percent of patients that underwent LT carried rare coding mutations in telomerase-related genes. Patients with telomere shortening more frequently needed extracorporeal circulation and presented a higher rate of early post-transplant hematological complications, longer stay in the intensive care unit (ICU), and a higher number of long-term hospital admissions. However, post-transplant 1-year survival was higher than 80% regardless of telomere dysfunction, with improvement in the quality of life and oxygen therapy withdrawal. Conclusions: Post-transplant morbidity is higher in patients with telomere dysfunction and differs according to elapsed time from transplantation. However, lung transplant improves survival and quality of life and the associated complications are manageable.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficacy of Tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial

  • Sellarès-Nadal, Júlia|||0000-0002-0209-6494
  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Guillén-Del-Castillo, Alfredo|||0000-0003-0626-507X
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Bañares-Sánchez, Joan
  • Prio-Ruatg, Alba
  • Martínez-Valle, Ferran
  • Kirkegaard, Cristina|||0000-0001-9035-1450
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
Background: The objective of this clinical trial is to evaluate the efficacy and safety of IL-6 driven personalized treatment strategy with tocilizumab in patients with severe COVID-19 pneumonia. Trial design: Randomized, controlled, open-label, single-center trial of a tocilizumab treatment strategy in adult patients hospitalized with severe COVID-19 pneumonia and IL-6 serum levels.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission, a randomised placebo-controlled clinical trial of GETECCU

  • P. Gisbert, Javier|||0000-0003-2090-3445
  • Donday, María G.
  • Riestra, Sabino|||0000-0002-9383-3698
  • Lucendo, Alfredo J.|||0000-0003-1183-1072
  • Benítez, José Manuel|||0000-0001-8898-3141
  • Navarro-Llavat, Mercè|||0000-0002-1132-0427
  • Barrio, Jesús|||0000-0001-7087-3921
  • Morales-Alvarado, Víctor J.
  • Rivero, Montserrat|||0000-0002-5834-1559
  • Busquets, David|||0000-0002-9385-1415
  • Leo Carnerero, Eduardo|||0000-0002-1267-5211
  • Merino, Olga|||0000-0002-1362-4475
  • Nantes Castillejo, Óscar|||0000-0002-3587-1039
  • Navarro, Pablo|||0000-0001-6228-3462
  • Van Domselaar, Manuel|||0000-0002-9950-2216
  • Gutiérrez Casbas, Ana|||0000-0002-5460-4139
  • Alonso-Abreu, Inmaculada|||0000-0003-0406-029X
  • Mejuto, Rafael
  • Fernández-Salazar, Luis|||0000-0002-9951-7979
  • Iborra, Marisa|||0000-0001-7360-7581
  • Martín-Arranz, María Dolores|||0000-0002-1872-0917
  • Pineda, Juan Ramón
  • Sampedro, Manuela Josefa
  • Serra Nilsson, Katja
  • Bouhmidi, Abdel
  • Batista, Lissette
  • Muñoz-Villafranca, Carmen|||0000-0002-8060-8889
  • Rodríguez-Lago, Iago|||0000-0003-1133-4578
  • Ceballos, Daniel
  • Guerra, Iván|||0000-0002-5175-2515
  • Mañosa i Ciria, Míriam|||0000-0002-9051-2581
  • Marín Jiménez, Ignacio|||0000-0001-5424-2484
  • Torrella, Emilio
  • Vera Mendoza, Maribel
  • Casanova, María José|||0000-0001-8233-9638
  • de Francisco, Ruth|||0000-0001-8476-1672
  • Arias-González, Laura|||0000-0003-2132-9350
  • Marín Pedrosa, Sandra
  • García-Bosch, Orlando
  • García Alonso, Francisco Javier
  • Delgado-Guillena, Pedro|||0000-0002-5798-5491
  • García García, María José|||0000-0002-6517-7005
  • Torrealba, Leyanira|||0000-0002-3144-3408
  • Núñez Ortiz, Andrea
  • Vicuña Arregui, Miren
  • Bosca-Watts, Marta Maia|||0000-0001-7495-8797
  • Blázquez, Isabel|||0000-0003-2429-8174
  • Acosta, Diana|||0000-0001-8347-6642
  • Garre, Ana
  • Baldán, Montse|||0000-0003-0848-8154
  • Martínez, Concepción
  • Barreiro de-Acosta, Manuel|||0000-0001-5915-1477
  • Domènech, Eugeni|||0000-0002-2315-7196
  • Esteve, Maria|||0000-0001-7716-0027
  • García-Sánchez, Valle
  • Nos, Pilar|||0000-0002-6619-1511
  • Panés, Julián|||0000-0002-4971-6902
  • Chaparro, María|||0000-0002-9275-4242
  • Ramírez, Esther
  • Alvarez-Manceñido, Felipe
  • Sánchez-Casanueva, Tomás
  • Cárdenas Aranzana, Manuel J.
  • Gracia García, Berta
  • Caro-Patón, Tomás
  • Seguí Solanes, Carlos
  • Giménez Poderós, Teresa|||0000-0002-7611-7358
  • Castelló Nòria, Àngela
  • Villalba Moreno, Angela|||0000-0002-8658-120X
  • Bustinza Txertudi, Alazne
  • Aranda Alcántara, María
  • Guillot Yacyszyn, Verónica
  • Morales Martínez, Lorena
  • Gracia, Ángel
  • Virgós Aller, Tirso
  • Espino Paisán, Esther
  • Hernando Verdugo, Mercedes
  • Tordera, María
  • Cárdenas, Cristina
  • Sánchez Ulayar, Azhara
  • Ferrer-Artola, Anna|||0000-0003-0424-7353
  • Ventura López, Purificación
  • Loizaga Diaz, Irunne
  • Santos, Amaya
  • Amat López, Mireya
  • Hernández Musiesa, Belén
  • Quiñones Ribas, Carles|||0000-0003-2974-2086
  • Mur Mur, Ana
  • García Motos, Consuelo
  • Sánchez Guerrero, Amelia
Background and objectives: Primary objectives: to compare the rates of sustained clinical remission at 12 months in patients treated with antitumour necrosis factor (anti-TNF) and immunomodulators who withdraw anti-TNF treatment versus those who maintain it. Secondary objectives: to evaluate the effect of anti-TNF withdrawal on relapse-free time, endoscopic and radiological activity, safety, quality of life and work productivity; and to identify predictive factors for relapse. Design: Prospective, quadruple-blind, multicentre, randomised, controlled trial. Patients with ulcerative colitis or Crohn's disease in clinical remission for.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Transcriptomic analyses reveal groups of co-expressed, syntenic lncRNAs in four species of the genus Caenorhabditis

  • Pegueroles Queralt, Maria Cinta|||0000-0003-0701-9866
  • Iraola-Guzmán, Susana|||0000-0003-3359-1241
  • Chorostecki, Uciel Pablo|||0000-0003-2229-6853
  • Ksiezopolska, Ewa|||0000-0002-2021-4343
  • Saus, Ester|||0000-0002-2519-111X
  • Gabaldón, Toni|||0000-0003-0019-1735
Long non-coding RNAs (lncRNAs) are a heterogeneous class of genes that do not code for proteins. Since lncRNAs (or a fraction thereof) are expected to be functional, many efforts have been dedicated to catalog lncRNAs in numerous organisms, but our knowledge of lncRNAs in non vertebrate species remains very limited. Here, we annotated lncRNAs using transcriptomic data from the same larval stage of four Caenorhabditis species. The number of annotated lncRNAs in self-fertile nematodes was lower than in out-crossing species. We used a combination of approaches to identify putatively homologous lncRNAs: synteny, sequence conservation, and structural conservation. We classified a total of 1,532 out of 7,635 genes from the four species into families of lncRNAs with conserved synteny and expression at the larval stage, suggesting that a large fraction of the predicted lncRNAs may be species specific. Despite both sequence and local secondary structure seem to be poorly conserved, sequences within families frequently shared BLASTn hits and short sequence motifs, which were more likely to be unpaired in the predicted structures. We provide the first multi-species catalog of lncRNAs in nematodes and identify groups of lncRNAs with conserved synteny and expression, that share exposed motifs.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Selection for environmental variance of litter size in rabbits involves genes in pathways controlling animal resilience

  • Casto-Rebollo, Cristina|||0000-0003-4646-345X
  • Blasco Mateu, Agustín|||0000-0003-3558-0810
  • Ibáñez-Escriche, Noelia|||0000-0002-6221-3576
  • Argente, María José
  • García, María Luz
[EN] Background Environmental variance (V-E) is partially under genetic control, which means that the V-E of individuals that share the same environment can differ because they have different genotypes. Previously, a divergent selection experiment for V-E of litter size (LS) during 13 generations in rabbit yielded a successful response and revealed differences in resilience between the divergent lines. The aim of the current study was to identify signatures of selection in these divergent lines to better understand the molecular mechanisms and pathways that control V-E of LS and animal resilience. Three methods (F-ST, ROH and varLD) were used to identify signatures of selection in a set of 473 genotypes from these rabbit lines (377) and a base population (96). A whole-genome sequencing (WGS) analysis was performed on 54 animals to detect genes with functional mutations. Results By combining signatures of selection and WGS data, we detected 373 genes with functional mutations in their transcription units, among which 111 had functions related to the immune system, stress response, reproduction and embryo development, and/or carbohydrate and lipid metabolism. The genes TTC23L, FBXL20, GHDC, ENSOCUG00000031631, SLC18A1, CD300LG, MC2R, and ENSOCUG00000006264 were particularly relevant, since each one carried a functional mutation that was fixed in one of the rabbit lines and absent in the other line. In the 3MODIFIER LETTER PRIMEUTR region of the MC2R and ENSOCUG00000006264 genes, we detected a novel insertion/deletion (INDEL) variant. Conclusions Our findings provide further evidence in favour of V-E as a measure of animal resilience. Signatures of selection were identified for V-E of LS in genes that have a functional mutation in their transcription units and are mostly implicated in the immune response and stress response pathways. However, the real implications of these genes for V-E and animal resilience will need to be assessed through functional analyses., We are grateful to CEGEN-PRB3-ISCIII for their genotyping service, supported by Grant No PT17/0019 of the PE I+D+i 2013-2016, funded by ISCIII and ERDF. Cristina Casto-Rebollo acknowledges a FPU17/01196 scholarship from the Spanish Ministry of Science, Innovation and Universities. This study was supported by Projects AGL2014-5592, C2-1-P and C2-2-P, and AGL2017-86083, C2-1-P and C2-2-P, funded by the Spanish Ministerio de Ciencia e Innovacion (MIC)-Agencia Estatal de Investigacion (AEI) and the European Regional Development Fund (FEDER).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Changes in platelet count as a marker of myocardial iron uptake after administration of ferric carboxymaltose in patients with heart failure

  • Mollar, Anna
  • Garcia-Conejo, Celia
  • Revuelta-Lopez, Elena
  • Cardells, Ingrid
  • Lopez, Raquel
  • Canto Serrano, Irene Del
  • de la Espriella, Rafael
  • Lopez-Lereu, Maria P.
  • Monmeneu, Jose Vicente
  • Maceira, Alicia
  • Lakhal-Littleton, Samira
  • Almenar, Luis
  • Cases, Aleix
  • Peiro, Marta
  • Bayes Genis, Antonio
[EN] Iron deficiency (ID) treated with ferric carboxymaltose (FCM) previously showed reduced platelet count; however, no studies have evaluated its biological significance in heart failure. In the current study, we aimed to: (a) assess the changes in platelet count at 7 and 30 days post-FCM, and (b) explore its association with non-invasive surrogates of myocardial iron uptake and left systolic function in patients with ID and heart failure with left ventricular ejection fraction < 50% (HFrEF and HFmrEF). This post-hoc analysis of a randomized, double-blind, FCM vs. placebo clinical trial (Myocardial-IRON Trail) involved 45 outpatients with HFrEF and HFmrEF and ID in which the platelet count value was available. Platelet count, cardiac magnetic resonance T1-mapping and 3D-global longitudinal strain (CMR-GLS) were assessed at baseline, 7, and 30 days. Linear regression models were used to evaluate the between-treatment differences and endpoints. The mean (SD) age was 71 +/- 8 years, and 32 (71%) were men. At 30 days, we found a significant reduction in platelet count in those treated with FCM (p-value = 0.027). In those treated with FCM, the greater 30-day decrease in platelets showed lower 30-day changes in T1-mapping (p = 0.024) and CMR-GLS (p = 0.028). After administration of FCM, we found a significant 30-day reduction in platelet count. The greater platelet count reduction was related to lower myocardial iron repletion and a smaller improvement in left ventricular systolic function., This work was supported in part by an unrestricted grant from Vifor Pharma, CIBER Cardiovascular [grant numbers 16/11/00420 and 16/11/00403], Unidad de Investigacion Clinica y Ensayos Clinicos INCLIVA Health Research Institute, Spanish Clinical Research Network (SCReN; PT13/0002/0031 and PT17/0017/0003), cofounded by Fondo Europeo de Desarrollo Regional-Instituto de Salud Carlos III, and Proyectos de Investigacion de la Seccion de Insuficiencia Cardiaca 2017 from the Sociedad Espanola de Cardiologia.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Functional Signatures in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Sex-Based Differences in Transcriptomic Studies

  • Pérez-Díez, Irene
  • Hidalgo, Marta R.
  • Malmierca-Merlo, Pablo
  • Andreu, Zoraida
  • Romera-Giner, Sergio
  • Farràs, Rosa
  • Provencio, Mariano
  • Romero, Atocha
  • García-García, Francisco
  • DE LA IGLESIA VAYÁ, MARIA DE LOS DESAMPARADOS
[EN] While studies have established the existence of differences in the epidemiological and clinical patterns of lung adenocarcinoma between male and female patients, we know relatively little regarding the molecular mechanisms underlying such sex-based differences. In this study, we explore said differences through a meta-analysis of transcriptomic data. We performed a meta-analysis of the functional profiling of nine public datasets that included 1366 samples from Gene Expression Omnibus and The Cancer Genome Atlas databases. Meta-analysis results from data merged, normalized, and corrected for batch effect show an enrichment for Gene Ontology terms and Kyoto Encyclopedia of Genes and Genomes pathways related to the immune response, nucleic acid metabolism, and purinergic signaling. We discovered the overrepresentation of terms associated with the immune response, particularly with the acute inflammatory response, and purinergic signaling in female lung adenocarcinoma patients, which could influence reported clinical differences. Further evaluations of the identified differential biological processes and pathways could lead to the discovery of new biomarkers and therapeutic targets. Our findings also emphasize the relevance of sex-specific analyses in biomedicine, which represents a crucial aspect influencing biological variability in disease., This work was supported by Fondo de Investigación Sanitaria (ISCIII PI15-00209), GV/2020/186, and ISCIII PT17/0009/0015 FEDER.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients

  • Cano, Jordi
  • Zorio, Esther
  • Mazzanti, Andrea
  • Arnau, Miguel Ángel
  • Priori, Silvia G.
  • Trenor Gomis, Beatriz Ana|||0000-0001-9166-6112
  • Saiz Rodríguez, Francisco Javier|||0000-0002-9850-0825
  • Romero Pérez, Lucia|||0000-0003-4605-8630
[EN] The prolongation of the QT interval represents the main feature of the long QT syndrome (LQTS), a life-threatening genetic disease. The heterozygous SCN5A V411M mutation of the human sodium channel leads to a LQTS type 3 with severe proarrhythmic effects due to an increase in the late component of the sodium current (INaL). The two sodium blockers flecainide and ranolazine are equally recommended by the current 2015 ESC guidelines to treat patients with LQTS type 3 and persistently prolonged QT intervals. However, awareness of pro-arrhythmic effects of flecainide in LQTS type 3 patients arose upon the study of the SCN5A E1784K mutation. Regarding SCN5A V411M individuals, flecainide showed good results albeit in a reduced number of patients and no evidence supporting the use of ranolazine has ever been released. Therefore, we ought to compare the effect of ranolazine and flecainide in a SCN5A V411M model using an in-silico modeling and simulation approach. We collected clinical data of four patients. Then, we fitted four Markovian models of the human sodium current (INa) to experimental and clinical data. Two of them correspond to the wild type and the heterozygous SCN5A V411M scenarios, and the other two mimic the effects of flecainide and ranolazine on INa. Next, we inserted them into three isolated cell action potential (AP) models for endocardial, midmyocardial and epicardial cells and in a one-dimensional tissue model. The SCN5A V411M mutation produced a 15.9% APD90 prolongation in the isolated endocardial cell model, which corresponded to a 14.3% of the QT interval prolongation in a one-dimensional strand model, in keeping with clinical observations. Although with different underlying mechanisms, flecainide and ranolazine partially countered this prolongation at the isolated endocardial model by reducing the APD90 by 8.7 and 4.3%, and the QT interval by 7.2 and 3.2%, respectively. While flecainide specifically targeted the mutation-induced increase in peak INaL, ranolazine reduced it during the entire AP. Our simulations also suggest that ranolazine could prevent early afterdepolarizations triggered by the SCN5A V411M mutation during bradycardia, as flecainide. We conclude that ranolazine could be used to treat SCN5A V411M patients, specifically when flecainide is contraindicated., This work was partially supported by Fondo Europeo de Desarrollo Regional (FEDER, "Union Europea, Una forma de hacer Europa") with the Ministerio de Economia y Competitividad (DPI2015-69125-R), Direccion General de Politica Cientifica de la Generalitat Valenciana (PROMETEO/2020/043) and Instituto de Salud Carlos III (La Fe Biobank PT17/0015/0043), as well as by Vicerrectorado de Investigacion, Innovacion y Transferencia de la Universitat Politecnica de Valencia with Ayuda a Primeros Proyectos de Investigacion (PAID-06-18), and by Memorial Nacho Barbera.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Mutant PRPF8 Causes Widespread Splicing Changes in Spliceosome Components in Retinitis Pigmentosa Patient iPSC-Derived RPE Cells

  • Arzalluz-Luque, Ángeles
  • Cabrera, Jose Luis
  • Skottman, Heli
  • Benguria, Alberto
  • Bolinches-Amorós, Arantxa
  • Cuenca, Nicolás
  • Lupo, Vincenzo
  • Dopazo, Ana
  • Delás, Bárbara
  • Carballo, Miguel
  • Pascual, Beatriz
  • Hernán, Imma
  • Erceg, Slaven
  • Lukovic, Dunja
  • Tarazona, Sonia|||0000-0001-5346-1407
[EN] Retinitis pigmentosa (RP) is a rare, progressive disease that affects photoreceptors and retinal pigment epithelial (RPE) cells with blindness as a final outcome. Despite high medical and social impact, there is currently no therapeutic options to slow down the progression of or cure the disease. The development of effective therapies was largely hindered by high genetic heterogeneity, inaccessible disease tissue, and unfaithful model organisms. The fact that components of ubiquitously expressed splicing factors lead to the retina-specific disease is an additional intriguing question. Herein, we sought to correlate the retinal cell-type-specific disease phenotype with the splicing profile shown by a patient with autosomal recessive RP, caused by a mutation in pre-mRNA splicing factor 8 (PRPF8). In order to get insight into the role of PRPF8 in homeostasis and disease, we capitalize on the ability to generate patient-specific RPE cells and reveal differentially expressed genes unique to RPE cells. We found that spliceosomal complex and ribosomal functions are crucial in determining cell-type specificity through differential expression and alternative splicing (AS) and that PRPF8 mutation causes global changes in splice site selection and exon inclusion that particularly affect genes involved in these cellular functions. This finding corroborates the hypothesis that retinal tissue identity is conferred by a specific splicing program and identifies retinal AS events as a framework toward the design of novel therapeutic opportunities., This work was supported by Institute of Health Carlos III/ERDF (European Regional Development Fund), Spain [PI16/00409 (DL), PI20/01119 (DL), CP18/00033 (DL), PI15/00227 (MC), CPII16/00037 (SE), and PI18-00286 (SE)], Platform for Proteomics, Genotyping and Cell Lines; PRB3 of ISCIII (PT17/0019/0024); National Science Foundation GACR 18-04393S and the project "Centre of Reconstructive Neuroscience", registration number CZ.02.1.01/0.0./0.0/15_003/0000419PI15/00227; Spanish Ministry of Economy and Competitiveness grant BES-2016-076994 (AA-L); and Academy of Finland (HS).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer

  • Adam-Artigues, Anna
  • Garrido-Cano, Iris
  • Carbonell-Asins, Juan Antonio
  • Lameirinhas, Ana
  • Simón, Soraya
  • Ortega-Morillo, Belén
  • Martínez, María Teresa
  • Hernando, Cristina
  • Constâncio, Vera
  • Burgues, Octavio
  • Bermejo, Begoña
  • Henrique, Rui
  • Lluch, Ana
  • Jerónimo, Carmen
  • Eroles, Pilar
  • Cejalvo, Juan Miguel
[EN] The early diagnosis of breast cancer is essential to improve patients' survival rate. In this context, microRNAs have been described as potential diagnostic biomarkers for breast cancer. Particularly, circulating microRNAs have a strong value as non-invasive biomarkers. Herein, we assessed the potential of a microRNA signature based on miR-30b-5p and miR-99a-5p levels in plasma as a diagnostic biomarker for breast cancer. This two-microRNA signature was constructed by Principal Component Analysis and its prognostic value was assessed in a discovery cohort and blindly validated in a second cohort from an independent institution. ROC curve analysis and biomarker performance parameter evaluation demonstrated that our proposed signature presents a high value as a non-invasive biomarker for very early detection of breast cancer. In addition, pathway enrichment analysis identified three of the well-known pathways involved in cancer as targets of the two microRNAs., This study was financed by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) and FEDER funds (PI18/01219 to P.E. and CB16/12/00481 to A.Ll.) and from the Research Centre of the Portuguese Oncology Institute of Porto (PI 74-CBEG-CI-IPOP-19-2015 to C.J.). A.A.-A. and A.L. were funded by Asociación Española Contra el Cáncer (PRDVA18013LLUC and PRDVA19016LAME). V.C. was funded by Liga Portuguesa Contra o Cancro/Fundação PT. J.M.C. was funded by Sociedad Española de Oncología Médica (Río Hortega-SEOM). The authors are grateful to INCLIVA Biobank (PT17/0015/0049; B.000768 ISCIII) and Valencian Biobanking Network integrated into the Spanish National Biobanks Network and nursing staff from all institutions for collaboration.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Impact of thermal treatments and simulated gastrointestinal digestion on the alpha-amylase inhibitory activity of different legumes

  • Arnal-Salinas, Milagros|||0000-0002-9301-2478
  • Talens Oliag, Pau|||0000-0001-7318-3336
  • Gallego, Marta
  • Mora, Leticia
[EN] Legumes are excellent sources of proteins that can be hydrolysed to generate antidiabetic peptides, which inhibit carbohydrate digestive enzymes. The degree of protein hydrolysis depends on the thermal treatment applied and how it impacts protein denaturation and thus accessibility to enzymes. In this study, alpha-amylase inhibitory activities of cooked (conventional, pressure, and microwave cooking) and digested (simulated gastrointestinal digestion, GID) green pea, chickpea, and navy beans were evaluated, together with the impact of thermal treatments on peptide profiles after GID. All peptides extracts inhibited alpha-amylase after cooking and GID, and the peptide fraction <3 kDa was responsible for main activity. In green peas and navy beans, microwave cooking showed the highest impact whereas none thermal treatment highlighted in chickpeas. The peptidomics analysis of the fractions <3 kDa identified a total of 205 peptides, 43 of which were found to be potentially bioactive according to in silico analysis. Also quantitative results evidenced differences in the peptide profile between the type of legume and thermal treatment., M.A. gratefully acknowledges the Predoctoral contract (FPU19/02401) from the Spanish Ministry of Science, Innovation and Univer-sities. The proteomic analysis was performed in the proteomics facility of SCSIE University of Valencia that belongs to Proteored, PRB3 and is supported by grant PT17/0019, of the PE I + D + i 2013-2016, funded by ISCIII and ERDF.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Tesis doctoral (DoctoralThesis)

Prediction of the effects of drugs on cardiac activity using computer simulations

  • Cano García, Jordi
[ES] Las enfermedades cardiovasculares siguen siendo la principal causa de muerte en Europa. Las arritmias cardíacas son una causa importante de muerte súbita, pero sus mecanismos son complejos. Esto denota la importancia de su estudio y prevención. La investigación sobre electrofisiología cardíaca ha demostrado que las anomalías eléctricas causadas por mutaciones que afectan a canales cardíacos pueden desencadenar arritmias. Sorprendentemente, se ha descubierto una gran variedad de fármacos proarrítmicos, incluidos aquellos que usamos para prevenirlas. Las indicaciones de uso de fármacos actuales intentaron solucionar este problema diseñando una prueba para identificar aquellos fármacos que podían ser peligrosos basado en el bloqueo de un solo canal iónico. El estudio de las interacciones fármaco-canal ha revelado la existencia no sólo de compuestos que bloquean múltiples canales, sino también una gran complejidad en esas interacciones. Esto podría explicar por qué algunos medicamentos pueden mostrar efectos muy diferentes en la misma enfermedad. Existen dos desafíos importantes con respecto a los efectos de los fármacos en la electrofisiología cardíaca. Por un lado, las empresas y entidades reguladoras están buscando una herramienta de alto rendimiento que mejore la detección del potencial proarrítmico durante el desarrollo de fármacos. Por otro lado, los pacientes con anomalías eléctricas a menudo requieren tratamientos personalizados más seguros. Las simulaciones computacionales contienen un poder sin precedentes para abordar fenómenos biofísicos complejos. Deberían ser de utilidad a la hora de determinar las características que definen tanto los efectos beneficiosos como no deseados de los fármacos mediante la reproducción de datos experimentales y clínicos. En esta tesis doctoral, se han utilizado modelos computacionales y simulaciones para dar respuesta a estos dos desafíos. El estudio de los efectos de los fármacos sobre la actividad cardíaca se dividió en el estudio de su seguridad y de su eficacia, respectivamente. Para dar respuesta al primer desafío, se adoptó un enfoque más amplio y se generó un nuevo biomarcador fácil de usar para la clasificación del potencial proarrítmico de los fármacos utilizando modelos del potencial de acción de células y tejidos cardíacos humanos. Se integró el bloqueo de múltiples canales a través de IC50 y el uso de concentraciones terapéuticas con el fin de mejorar el poder predictivo. Luego, se entrenó el biomarcador cuantificando el potencial proarrítmico de 84 fármacos. Los resultados obtenidos sugieren que el biomarcador podría usarse para probar el potencial proarrítmico de nuevos fármacos. Respecto al segundo desafío, se adoptó un enfoque más específico y se buscó mejorar la terapia de pacientes con anomalías eléctricas cardíacas. Por lo tanto, se creó un modelo detallado de la mutación V411M del canal de sodio, causante del síndrome de QT largo, reproduciendo datos clínicos y experimentales. Se evaluaron los posibles efectos beneficiosos de ranolazina, a la par que se aportó información sobre los mecanismos que impulsan la efectividad de la flecainida. Los resultados obtenidos sugieren que, si bien ambos fármacos mostraron diferentes mecanismos de bloqueo de los canales de sodio, un tratamiento con ranolazina podría ser beneficioso en estos pacientes., [CA] Les malalties cardiovasculars continuen sent la principal causa de mort a Europa. Les arrítmies cardíaques són una causa important de mort sobtada, però els seus mecanismes són complexos. Això denota la importància del seu estudi i prevenció. La investigació sobre electrofisiologia cardíaca ha demostrat que les anomalies elèctriques que afecten a canals cardiacs poden desencadenar arrítmies. Sorprenentment, s'ha descobert una gran varietat de fàrmacs proarrítmics, inclosos aquells que utilitzem per a previndre-les. Les indicacions d'ús de fàrmacs actuals van intentar solucionar aquest problema dissenyant una prova per a identificar aquells fàrmacs que podien ser perillosos basada en el bloqueig d'un sol canal iònic. L'estudi de les interaccions fàrmac-canal ha revelat l'existència no sols de compostos que bloquegen múltiples canals, sinó també una gran complexitat en aquestes interaccions. Això podria explicar per què alguns medicaments poden mostrar efectes molt diferents en la mateixa malaltia. Existeixen dos desafiaments importants respecte als efectes dels fàrmacs en la electrofisiologia cardíaca. D'una banda, les empreses i entitats reguladores estan buscant una eina d'alt rendiment que millore la detecció del potencial proarrítmic durant el desenvolupament de fàrmacs. D'altra banda, els pacients amb anomalies elèctriques sovint requereixen tractaments personalitzats més segurs. Les simulacions computacionals contenen un poder sense precedents per a abordar fenòmens biofísics complexos. Haurien de ser d'utilitat a l'hora de determinar les característiques que defineixen tant els efectes beneficiosos com no desitjats dels fàrmacs mitjançant la reproducció de dades experimentals i clíniques. En aquesta tesi doctoral, s'han utilitzat models computacionals i simulacions per a donar resposta a aquests dos desafiaments. L'estudi dels efectes dels fàrmacs sobre l'activitat cardíaca es va dividir en l'estudi de la seva seguretat i la seva eficacia. Per a donar resposta al primer desafiament, es va adoptar un enfocament més ampli i es va generar un nou biomarcador fàcil d'usar per a la classificació del potencial proarrítmic dels fàrmacs utilitzant models del potencial d'acció de cèl·lules i teixits cardíacs humans. Es va integrar el bloqueig de múltiples canals a través d'IC50 i l'ús de concentracions terapèutiques amb la finalitat de millorar el poder predictiu. Després, es va entrenar el biomarcador quantificant el potencial proarrítmic de 84 fàrmacs. Els resultats obtinguts suggereixen que el biomarcador podria usar-se per a provar el potencial proarrítmic de nous fàrmacs. Respecte al segon desafiament, es va adoptar un enfocament més específic i es va buscar millorar la teràpia de pacients amb anomalies elèctriques cardíaques. Per tant, es va crear un model detallat de la mutació V411M del canal de sodi, causant de la síndrome de QT llarg, reproduint dades clíniques i experimentals. Es van avaluar els possibles efectes beneficiosos de ranolazina, a l'una que es va aportar informació sobre els mecanismes que impulsen l'efectivitat de la flecainida. Els resultats obtinguts suggereixen que, si bé tots dos fàrmacs van mostrar diferents mecanismes de bloqueig dels canals de sodi, un tractament amb ranolazina podria ser beneficiós en aquests pacients., [EN] Cardiovascular disease remains the main cause of death in Europe. Cardiac arrhythmias are an important cause of sudden death, but their mechanisms are complex. This denotes the importance of their study and prevention. Research on cardiac electrophysiology has shown that electrical abnormalities caused by mutations in cardiac channels can trigger arrhythmias. Surprisingly, a wide variety of drugs have also shown proarrhythmic potential, including those that we use to prevent arrhythmia. Current guidelines designed a test to identify dangerous drugs by assessing their blocking power on a single ion channel to address this situation. Study of drug-channel interactions has revealed not only compounds that block multiple channels but also a great complexity in those interactions. This could explain why similar drugs can show vastly different effects in some diseases. There are two important challenges regarding the effects of drugs on cardiac electrophysiology. On the one hand, companies and regulators are in search of a high throughput tool that improves proarrhythmic potential detection during drug development. On the other hand, patients with electrical abnormalities often require safer personalized treatments owing to their condition. Computer simulations provide an unprecedented power to tackle complex biophysical phenomena. They should prove useful determining the characteristics that define the drugs' beneficial and unwanted effects by reproducing experimental and clinical observations. In this PhD thesis, we used computational models and simulations to address the two abovementioned challenges. We split the study of drug effects on the cardiac activity into the study of their safety and efficacy, respectively. For the former, we took a wider approach and generated a new easy-to-use biomarker for proarrhythmic potential classification using cardiac cell and tissue human action potential models. We integrated multiple channel block through IC50s and therapeutic concentrations to improve its predictive power. Then, we quantified the proarrhythmic potential of 84 drugs to train the biomarker. Our results suggest that it could be used to test the proarrhythmic potential of new drugs. For the second challenge, we took a more specific approach and sought to improve the therapy of patients with cardiac electrical abnormalities. Therefore, we created a detailed model for the long QT syndrome-causing V411M mutation of the sodium channel reproducing clinical and experimental data. We tested the potential benefits of ranolazine, while giving insights into the mechanisms that drive flecainide's effectiveness. Our results suggest that while both drugs showed different mechanisms of sodium channel block, ranolazine could prove beneficial in these patients., This PhD thesis was developed within the following projects: Ministerio de Economía y Competitividad and Fondo Europeo de Desarrollo Regional (FEDER) DPI2015-69125-R (MINECO/FEDER, UE): Simulación computacional para la predicción personalizada de los efectos de los fármacos sobre la actividad cardiaca. Dirección General de Política Científica de la Generalitat Valenciana (PROMETEU2016/088): “Modelos computacionales personalizados multiescala para la optimización del diagnóstico y tratamiento de arritmias cardiacas (personalised digital heart). Vicerrectorado de Investigación, Innovación y Transferencia de la Universitat Politècnica de València, Ayuda a Primeros Proyectos de Investigación (PAID-06-18), and by Memorial Nacho Barberá. Instituto de Salud Carlos III (La Fe Biobank PT17/0015/0043).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

  • García-Foncillas, J.
  • Tabernero, J.
  • Ëlez, E.
  • Aranda, E.
  • Benavides, M.
  • Camps-Herrrero, Carlos
  • Lopez, R.
  • Muinelo-Romay, L.
  • Montagut, C.
  • Antón, A.
  • Lopez, G.
  • Diaz-Rubio, E.
  • Rojo, F.
  • Vivancos, A.
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] BACKGROUND: Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laboratories in Spain where this technology is routinely implemented. METHODS: Circulating cell-free DNA from plasma was examined for RAS mutations using the OncoBEAM platform at each hospital laboratory. Results were then compared to those obtained from DNA extracted from tumour tissue from the same patient. RESULTS: The overall percentage agreement between plasma-based and tissue-based RAS mutation testing of the 236 participants was 89% (210/236; kappa, 0.770 (95% CI: 0.689-0.852)). Re-analysis of tissue from all discordant cases by BEAMing revealed two false negative and five false positive tumour tissue RAS results, with a final concordance of 92%. Plasma false negative results were found more frequently in patients with exclusive lung metastatic disease. CONCLUSIONS: In this first prospective real-world RAS mutation performance comparison study, a high overall agreement was observed between results obtained from plasma and tissue samples. Overall, these findings indicate that the plasma-based BEAMing assay is a viable solution for rapid delivery of RAS mutation status to determine mCRC patient eligibility for anti-EGFR therapy., This work was supported by Sysmex Inostics, Inc as well as the AES Programme [Grant Numbers PI15/00934, PT17/0015/0006]. The funders had no involvement in the writing of this manuscript but did review for medical accuracy prior to submission.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Development of Decellularized Oviductal Hydrogels as a Support for Rabbit Embryo Culture

  • Francés-Herrero, Emilio
  • De Miguel-Gómez, Lucía
  • López-Martínez, Sara
  • Campo, Hannes
  • Garcia-Dominguez, Ximo
  • Diretto, Gianfranco
  • Faus, Amparo
  • Cervelló, Irene
  • Vicente Antón, José Salvador|||0000-0003-0481-3802
  • Marco-Jiménez, Francisco|||0000-0002-5226-4118
[EN] The oviducts (fallopian tubes in mammals) function as the site of fertilization and provide necessary support for early embryonic development, mainly via embryonic exposure to the tubal microenvironment. The main objective of this study was to create an oviduct-specific extracellular matrix (oviECM) hydrogel rich in bioactive components that mimics the native environment, thus optimizing the developmental trajectories of cultured embryos. Rabbit oviducts were decellularized through SDS treatment and enzymatic digestion, and the acellular tissue was converted into oviductal pre-gel extracellular matrix (ECM) solutions. Incubation of these solutions at 37 degrees C resulted in stable hydrogels with a fibrous structure based on scanning electron microscopy. Histological staining, DNA quantification and colorimetric assays confirmed that the decellularized tissue and hydrogels contained no cellular or nuclear components but retained important components of the ECM, e.g. hyaluronic acid, glycoproteins and collagens. To evaluate the ability of oviECM hydrogels to maintain early embryonic development, two-cell rabbit embryos were cultured on oviECM-coated surfaces and compared to those cultured with standard techniques. Embryo development was similar in both conditions, with 95.9% and 98% of the embryos reaching the late morula/early blastocyst stage by 48 h under standard culture and oviECM conditions, respectively. Metabolomic analysis of culture media in the presence or absence of embryos, however, revealed that the oviECM coating may include signalling molecules and release compounds beneficial to embryo metabolism., This study was supported by Instituto de Salud Carlos III (PI17/01039-CP19/00149 [Irene Cervello]), Ministry of Economy, Industry and Competitiveness (AGL2017-85162-C2-1-R [Francisco Marco], BES-2015-072429 [Ximo Garcia]), Ministry of Science, Innovation and Universities (FPU18/06327 [Emilio Frances]) and Generalitat Valenciana (PROMETEO/2018/137 [Irene Cervello, Lucia de Miguel], ACIF/2017/118 [Sara Lopez]). The proteomics laboratory is a member of ProteoRed, PRB3, and is supported by grant PT17/0019 of the State Plan I+D+i 2013-2016, funded by Instituto de Salud Carlos III and European Regional Development Fund.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

PaintOmics 3: a web resource for the pathway analysis and visualization of multi-omics data

  • Hernandez-De Diego, Rafael
  • Martínez-Mira, Carlos
  • Balzano-Nogueira, Leandro
  • Furió-Tarí, Pedro
  • Conesa, A.
  • Pappas, G.
  • Tarazona, Sonia|||0000-0001-5346-1407
[EN] The increasing availability of multi-omic platforms poses new challenges to data analysis. Joint visualization of multi-omics data is instrumental in better understanding interconnections across molecular layers and in fully utilizing the multi-omic resources available to make biological discoveries. We present here PaintOmics 3, a web-based resource for the integrated visualization of multiple omic data types onto KEGG pathway diagrams. PaintOmics 3 combines server-end capabilities for data analysis with the potential of modern web resources for data visualization, providing researchers with a powerful framework for interactive exploration of their multi-omics information. Unlike other visualization tools, PaintOmics 3 covers a comprehensive pathway analysis workflow, including automatic feature name/identifier conversion, multi-layered feature matching, pathway enrichment, network analysis, interactive heatmaps, trend charts, and more. It accepts a wide variety of omic types, including transcriptomics, proteomics and metabolomics, as well as region-based approaches such as ATAC-seq or ChIP-seq data. The tool is freely available at www.paintomics.org, European Union Seventh Framework Programme [FP7/2007-2013] under the grant agreement [306000-STATegra]; Marie Curie International Research Staff Exchange Scheme under grant agreement [612583-DEANN]; Spanish MINECO [BIO2012-40244]. INB Grant [PT17/0009/0015 - ISCIII-SGEFI / ERDF]. Funding for open access charge: MINECO [BIO2012-40244].
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

MOSim: bulk and single-cell multilayer regulatory network simulator

  • Monzó, Carolina
  • Martínez-Mira, Carlos
  • Arzalluz-Luque, Ángeles
  • Conesa, Ana
  • Aguerralde-Martin, Maider|||0000-0001-9266-8689
  • Tarazona, Sonia|||0000-0001-5346-1407
[EN] As multi-omics sequencing technologies advance, the need for simulation tools capable of generating realistic and diverse (bulk and single-cell) multi-omics datasets for method testing and benchmarking becomes increasingly important. We present MOSim, an R package that simulates both bulk (via mosim function) and single-cell (via sc_mosim function) multi-omics data. The mosim function generates bulk transcriptomics data (RNA-seq) and additional regulatory omics layers (ATAC-seq, miRNA-seq, ChIP-seq, Methyl-seq, and transcription factors), while sc_mosim simulates single-cell transcriptomics data (scRNA-seq) with scATAC-seq and transcription factors as regulatory layers. The tool supports various experimental designs, including simulation of gene co-expression patterns, biological replicates, and differential expression between conditions. MOSim enables users to generate quantification matrices for each simulated omics data type, capturing the heterogeneity and complexity of bulk and single-cell multi-omics datasets. Furthermore, MOSim provides differentially abundant features within each omics layer and elucidates the active regulatory relationships between regulatory omics and gene expression data at both bulk and single-cell levels. By leveraging MOSim, researchers will be able to generate realistic and customizable bulk and single-cell multi-omics datasets to benchmark and validate analytical methods specifically designed for the integrative analysis of diverse regulatory omics data., This work was supported by the Scientific Foundation of the Spanish Association Against Cancer through the project PERME224336TARA and by Instituto de Salud Carlos III through the project AC22/00058 (co-funded by the European Union as part of the Next Generation EU programme and the Recovery and Resilience Mechanism, MRR), both projects under the frame of ERA PerMed (ERAPERMED2022-141 OVA-PDM). This work also received funding from the FP7 STATegra project (agreement no. 306000), the Spanish MINECO (BIO2012-40244), the Spanish MICIN (PID2020-119537RB-100), the Spanish Bioinformatics Institute support (PT17/0009/0015-ISCIII-SGEFI/ERDF), the Scientific Foundation of the Spanish Association Against Cancer (PERME224336TARA), under the frame of ERA PerMed (ERAPERMED2022-141 OVA-PDM), and the European Union's programme Horizon Europe under a Marie Sk&#322;odowska-Curie grant (101149931).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Role of SALL4 in HER2+Breast Cancer Progression: Regulating PI3K/AKT Pathway

  • Pattanayak, Birlipta
  • Trigo-Lameirinhas, Ana Catarina
  • Torres-Ruiz, Sandra
  • Burgués, Octavio
  • AURA ROVIRA, ANA MARÍA
  • Martínez, Maite
  • Tapia, Marta
  • Zazo, Sandra
  • Albanell, Joan
  • Rojo, Federico
  • Bermejo, Begoña
  • Eroles-Asensio, Pilar
[EN] Treatment for the HER2+ breast cancer subtype is still unsatisfactory, despite breakthroughs in research. The discovery of various new molecular mechanisms of transcription factors may help to make treatment regimens more effective. The transcription factor SALL4 has been related to aggressiveness and resistance therapy in cancer. Its molecular mechanisms and involvement in various signaling pathways are unknown in the HER2+ breast cancer subtype. In this study, we have evaluated the implication of SALL4 in the HER2+ subtype through its expression in patients' samples and gain and loss of function in HER2+ cell lines. We found higher SALL4 expression in breast cancer tissues compared to healthy tissue. Interestingly, high SALL4 expression was associated with disease relapse and poor patient survival. In HER2+ cell lines, transient overexpression of SALL4 modulates PI3K/AKT signaling through regulating PTEN expression and BCL2, which increases cell survival and proliferation while reducing the efficacy of trastuzumab. SALL4 has also been observed to regulate the epithelial-mesenchymal transition and stemness features. SALL4 overexpression significantly reduced the epithelial markers E-cadherin, while it increased the mesenchymal markers beta-catenin, vimentin and fibronectin. Furthermore, it has been also observed an increased expression of MYC, an essential transcription factor for regulating epithelial-mesenchymal transition and/or cancer stem cells. Our study demonstrates, for the first time, the importance of SALL4 in the HER2+ subtype and partial regulation of trastuzumab sensitivity. It provides a viable molecular mechanism-driven therapeutic strategy for an important subset of HER2-overexpressing patients whose malignancies are mediated by SALL4 expression., We thank the patients who have agreed to participate in this study. We want to particularly acknowledge the INCLIVA BioBank (PT17/0015/0049; B.000768 ISCIII//) integrated in the Valencian Biobanking Network and the Spanish National Biobanks Network for its collaboration. We also express our gratitude to associations, individuals, and entities that collaborate with our research in breast cancer.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Tesis de maestría (MasterThesis)

Estudio del estado de metilación del gen de desmoplaquina y su papel en el desarrollo de la miocardiopatía arritmogénica, Study of the methylation status of the desmoplakin gene and its role in the onset of arrhythmogenic cardiomyopathy

  • Lin Wong, Liliane
[ES] La miocardiopatía arritmogénica (MCA) es una enfermedad genética rara (OMIM #107970; ORPHA247) con una prevalencia de entre 1:1000 y 1:5000. Se caracteriza por la sustitución progresiva del miocardio por tejido fibroadiposo y puede debutar directamente con muerte súbita. Se conocen 16 genes cuyas mutaciones pueden ser causantes de MCA, siendo más frecuentes las mutaciones en genes desmosómicos (desmoplaquina-DSP, placofilina-2, desmocolina-2, desmogleína-2 y placoglobina). El patrón de herencia de estos genes es con frecuencia autosómico dominante, tiene una penetrancia incompleta y una expresividad variable. La epigenética modula la producción proteica pero el estudio del tejido clave en la MCA plantea limitaciones éticas en tanto en cuanto supone tener que realizar una biopsia endomiocárdica asumiendo potenciales riesgos de complicaciones. Por ello, decidimos verificar si el frotis bucal (fácilmente accesible, barato y sin riesgos) puede actuar como como espejo de lo que sucede en el corazón. Más concretamente, desde un punto de vista bibliográfico evaluamos si el estado los promotores de los genes causantes de la enfermedad son metilables. De entre ellos seleccionamos el gen DSP para el estudio de su metilación por pirosecuenciación en la muestra disponible en humanos, pues es uno de los que tenemos familias bien caracterizadas en la consulta de Cardiopatías Familiares. Se reclutaron 13 portadores de mutación en DSP sin expresión del fenotipo de MCA, 25 pacientes MCA y 11 familiares sanos. Gracias a la actividad trasplantadora del centro en el que se realizó el trabajo, se reclutaron 7 pacientes con muestra pareada de frotis bucal y miocardio obtenidos al acudir a recibir un trasplante cardíaco por insuficiencia cardíaca terminal, independientemente del diagnóstico de base. Se analizaron 4 regiones del gen que comprendían 14 sitios metilables de una isla CpG y un shore localizada en el promotor del gen. Este estudio se realizó en queratinocitos bucales como biomarcador de fenotipo subrogado de la MCA. Dada la situación de alerta sanitaria quedó pendiente la validación de los resultados downstream mediante la cuantificación del mRNA de DSP en dichas muestras para correlacionar el nivel de metilación y de expresión del gen en cada una de las muestras recogidas., [EN] Arrhythmogenic cardiomyopathy (ACM) is a rare genetic disease (OMIM # 107970; ORPHA247) with a prevalence of between 1:1000 and 1:5000. It is characterized by the progressive replacement of the myocardium by fibrofatty tissue and can debut directly with sudden death. Mutations in 16 genes were identified as the cause of ACM with mutations being more frequent in desmosomal genes (desmoplakin-DSP, placophilin-2, desmocollin-2, desmoglein-2 and plakoglobin). The inheritance pattern of these genes is often autosomal dominant, has incomplete penetrance, and variable expressivity. Epigenetics modulates protein production, but the study of the heart tissue in ACM poses ethical limitations as it involves having to perform an endomyocardial biopsy, assuming potential risks of complications. Therefore, we decided to verify if oral keratinocytes (easily accessible, cheap and without risks) can act as a substitute of what happens in the heart. From a bibliographic point of view, we evaluated whether the state of the promoters of the genes causing the disease are methylable. From among them, we selected the DSP gene for the study of its methylation by pyrosequencing in the sample available in humans, since we have well-characterized families in the Family Heart Disease consultation. 13 DSP mutation carriers without expression of the ACM phenotype, 25 ACM patients and 11 healthy family members were recruited. Thanks to the transplantation activity of the center where the work was carried out, we recruited 7 patients with a paired sample of oral keratinocytes and myocardial tissue, regardless of the underlying diagnosis. 4 regions of the gene were analyzed that comprised 14 methylatable sites of a CpG island and shore located in the gene promoter. This study was carried out in oral keratinocytes as a surrogate phenotype biomarker of ACM. Given the health alert situation, the validation of the downstream results by quantifying the DSP mRNA in said samples are pending to correlate the level of methylation and gene expression in each of the samples collected., Este trabajo fue parcialmente financiado con ayudas de investigación del Instituto de Salud Carlos III, FEDER “Unión Europea”, "Una forma de hacer Europa” [PI18/01582; CIBERCV, Biobanco La Fe PT17/0015/0043] y el Memorial Nacho Barberá.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Chemical Modifications of Globular Proteins Phototriggered by an Endogenous Photosensitizer

  • Reid, Lara O.
  • Dántola, M. Laura
  • Petroselli, Gabriela
  • Erra-Balsells, Rosa
  • Miranda Alonso, Miguel Ángel
  • Thomas, Andrés H.
  • Lhiaubet, Virginie Lyria|||0000-0002-8205-8892
[EN] The main goal of the present work was to investigate the damages photoinduced by pterin (Ptr), an endogenous photosensitizer present in human skin under pathological conditions, on a globular protein such as ubiquitin (Ub). Particular attention has been paid on the formation of covalent adducts between Ptr and the protein that can behave as photoantigen and provoke an immune system response. Here, a multifaceted approach including UV-visible spectrophotometry, fluorescence spectroscopy, electrophoresis, size exclusion chromatography, and mass spectrometry is used to establish the Ub changes triggered by UV-A irradiation in the presence of Ptr. Under anaerobic conditions, the only reaction corresponds to the formation of a covalently bound Ptr-Ub adduct that retains the spectroscopic properties of the free photosensitizer. A more complex scheme is observed in air-equilibrated solutions with the occurrence of three different processes, that is, formation of a Ptr-Ub adduct, dimerization, and fragmentation of the protein., The present work was partially supported by Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET-Grants PIP 112-200901-0304 and PIP 11220120100072CO), Agencia de Promocion Cientifica y Tecnologica (ANPCyT-Grants PICT-2015-1988 and PICT 2016-00130), Universidad Nacional de La Plata (UNLP-Grant X712 and X840), and Universidad de Buenos Aires (UBA-Grant 000110BA). Funding from the Programa CSIC de Cooperacion Cientifica para el Desarrollo (iCOOPLight project ref 20105CD0017) and Spanish government (PGC2018-096684-B-I00) is gratefully acknowledged. The Ultraflex II (Bruker) TOF/TOF mass spectrometer was supported by a grant from ANPCYT, PME2003 No. 125, and the ESI-MS Q Exactive, Thermo Scientific, by a grant from ANPCYT, PME2011-PPL2-0009, CEQUIBIEM, DQB, FCEN, UBA. The proteomic analysis was performed in the proteomics facility of SCSIE University of Valencia. This proteomics laboratory is a member of Proteored, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF. L.O.R. thanks CONICET for doctoral research fellowships. RE-B, G.P., M.L.D., and A.H.T are research members of CONICET.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Proteostatic regulation of MEP and shikimate pathways by redox-activated photosynthesis signaling in plants exposed to small fungal volatiles

  • Ameztoy, Kinia
  • Sánchez-López, Ángela María
  • Muñoz, Francisco José
  • Bahaji, Abdellatif
  • Almagro, Goizeder
  • Baroja-Fernández, Edurne
  • Gámez-Arcas, Samuel
  • De Diego, Nuria
  • Dolezal, Karel
  • Novák, Ondrej
  • Alpízar, Adán
  • Pencik, Ales
  • Pozueta-Romero, Javier
  • RODRIGUEZ-CONCEPCION, Manuel|||0000-0002-1280-2305
[EN] Microorganisms produce volatile compounds (VCs) with molecular masses of less than 300 Da that promote plant growth and photosynthesis. Recently, we have shown that small VCs of less than 45 Da other than CO2 are major determinants of plant responses to fungal volatile emissions. However, the regulatory mechanisms involved in the plants' responses to small microbial VCs remain unclear. In Arabidopsis thaliana plants exposed to small fungal VCs, growth promotion is accompanied by reduction of the thiol redox of Calvin-Benson cycle (CBC) enzymes and changes in the levels of shikimate and 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway-related compounds. We hypothesized that plants' responses to small microbial VCs involve post-translational modulation of enzymes of the MEP and shikimate pathways via mechanisms involving redox-activated photosynthesis signaling. To test this hypothesis, we compared the responses of wild-type (WT) plants and a cfbp1 mutant defective in a redox-regulated isoform of the CBC enzyme fructose-1,6-bisphosphatase to small VCs emitted by the fungal phytopathogen Alternaria alternata. Fungal VC-promoted growth and photosynthesis, as well as metabolic and proteomic changes, were substantially weaker in cfbp1 plants than in WT plants. In WT plants, but not in cfbp1 plants, small fungal VCs reduced the levels of both transcripts and proteins of the stromal Clp protease system and enhanced those of plastidial chaperonins and co-chaperonins. Consistently, small fungal VCs promoted the accumulation of putative Clp protease clients including MEP and shikimate pathway enzymes. clpr1-2 and clpc1 mutants with disrupted plastidial protein homeostasis responded weakly to small fungal VCs, strongly indicating that plant responses to microbial volatile emissions require a finely regulated plastidial protein quality control system. Our findings provide strong evidence that plant responses to fungal VCs involve chloroplast-to-nucleus retrograde signaling of redox-activated photosynthesis leading to proteostatic regulation of the MEP and shikimate pathways., This work was supported by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (Spain) (Grants BIO2016-78747-P, BIO2017-84041-P, BIO2017-90877-REDT, and PID2019-104685GB-100) and the Ministry of Education, Youth and Sport of the Czech Republic and ERDF project "Plants as a tool for sustainable global development" (No. CZ.02.1.01/0.0/0.0/16_019/0000827). Proteomic Unit, National Biotechnology Center was a member of Proteored, PRB3 and was supported by grant PT17/0019 of the PE I + D + i 2013-2016, funded by ISCIII and ERDF. Funding from Generalitat de Catalunya (2017SGR-710) and European Union's Horizon 2020 (EU-H2020) COST Action CA15136 (EuroCaroten) was also acknowledged. We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Classification model based on strain measurements to identify patients with arrhythmogenic cardiomyopathy with left ventricular involvement

  • Vives-Gilabert, Yolanda
  • Zorio, Esther
  • Sanz-Sánchez, Jorge
  • Calvillo-Batllés, Pilar
  • Millet Roig, José|||0000-0002-8879-003X
  • Castells, Francisco|||0000-0001-5044-3545
[EN] Background and objective: A heterogenous expression characterizes arrhythmogenic cardiomyopathy (AC). The evaluation of regional wall movement included in the current Task Force Criteria is only qualitative and restricted to the right ventricle. However, a strain-based approach could precisely quantify myocardial deformation in both ventricles. We aim to define and modelize the strain behavior of the left ventricle in AC patients with left ventricular (LV) involvement by applying algorithms such as Principal Component Analysis (PCA), clustering and naive Bayes (NB) classifiers. Methods: Thirty-six AC patients with LV involvement and twenty-three non-affected family members (controls) were enrolled. Feature-tracking analysis was applied to cine cardiac magnetic resonance imaging to assess strain time series from a 3D approach, to which PCA was applied. A Two-Step clustering algorithm separated the patients' group into clusters according to their level of LV strain impairment. A statistical characterization between controls and the new AC subgroups was done. Finally, a NB classifier was built and new data from a small evolutive dataset was predicted. Results: 60% of AC-LV patients showed mildly affected strain and 40% severely affected strain. Both groups and controls exhibited statistically significant differences, especially when comparing controls and severely affected AC-LV patients. The classification accuracy of the strain NB classifier reached 82.76%. The model performance was as good as to classify the individuals with a 100% sensitivity and specificity for severely impaired strain patients, 85.7% and 81.1% for mildly impaired strain patients, and 69.9% and 91.4% for normal strain, respectively. Even when the severely affected LV-AC group was excluded, LV strain showed a good accuracy to differentiate patients and controls. The prediction of the evolutive dataset revealed a progressive alteration of strain in time. Conclusions: Our LV strain classification model may help to identify AC patients with LV involvement, at least in a setting of a high pretest probability, such as family screening., This work was supported by grants from the "Ministerio de Economia y Competitividad"[DPI2015-70821-R], "Instituto de Salud Carlos III " and FEDER "Union Europea, Una forma de hacer Europa"[PI14/01477, PI15/00748, PI18/01582, CIBERCV] and La Fe Biobank [PT17/0 015/0043].
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Left ventricular myocardial dysfunction in arrhythmogenic cardiomyopathy with left ventricular involvement: A door to improving diagnosis

  • Vives-Gilabert, Yolanda
  • Sanz-Sánchez, Jorge
  • Molina, Pilar
  • Igual, Begoña
  • Calvillo-Batllés, Pilar
  • Domingo, Diana
  • Martínez-Dolz, Luis
  • Zorio, Esther
  • Cebrián Ferriols, Antonio José|||0000-0003-0519-5284
  • Millet Roig, José|||0000-0002-8879-003X
  • Castells, Francisco|||0000-0001-5044-3545
[EN] Background: Diagnostic Task Force Criteria (TFC) for arrhythmogenic cardiomyopathy (AC) exhibit poor performance for left dominant forms. TFC only include right ventricular (RV) dysfunction (akinesia, dyssynchrony, volumes and ejection fraction). Moreover, cardiac magnetic resonance imaging (CMRI) assessment of left ventricular (LV) dyssynchrony has hitherto not been described. Thus, we aimed to comprehensively characterize LVCMRI behavior in AC patients. Methods: Thirty-five AC patients with LV involvement and twenty-three non-affected family members (controls) were enrolled. Feature-tracking analysis was applied to cine CMRI to assess LV ejection fraction (LVEF), LV end-systolic and end-diastolic volume indexes, strain values and dyssynchrony. Regions with more frequent strain and dyssynchrony impairment were also studied. Results: Radial dyssynchrony and LVEF were selected (sensitivities 54.3% and 48.6%, respectively at 100% specificity), with a threshold of 70 ms for radial dyssynchrony and 48.5% for LVEF. 71.4% of patients exceeded these thresholds (31.4% both, 22.9% only dyssynchrony and 17.1% only LVEF). Considering these cut-off values as a novel combined criterion, 30% of patients with 'borderline' or 'possible' AC following 2010 TFC would move to a 'definite' AC diagnosis. Strain was globally impaired whereas dyssynchronous regions were more often apical and located at the inferolateral wall. Conclusions: Mirroring the RV evaluation, we suggest including LVEF and LV dyssynchrony to improve the diagnosis of AC. Two independent mechanisms can be claimed in AC patients with LV involvement: 1) decreased myocardial deformation with global LV affectation and 2) delayed myocardial contraction at localized regions., This work was supported by grants from the "Ministerio de Economia y Competitividad" [DPI2015-70821-R], "Instituto de Salud Carlos III" and FEDER "Union Europea, Una forma de hacer Europa" [RD12/0042/0029, PI14/01477, PI18/01582 and La Fe Biobank PT17/0015/0043].
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Peptidomic profile and alpha-glucosidase inhibitory activity of cooked and gastrointestinal digested legumes

  • Arnal-Salinas, Milagros|||0000-0002-9301-2478
  • Talens Oliag, Pau|||0000-0001-7318-3336
  • Gallego Ibáñez, Marta
  • Mora Soler, Leticia
[EN] Legumes are a good source of bioactive compounds, including peptides with antidiabetic potential. The alpha-glucosidase inhibitory activity of simulated gastrointestinal digested (GID) soybean, chickpea, green pea, and navy bean was determined after using three different household cooking methods (conventional, pressure, and microwave cooking). Samples were analysed by reversed-phase high-performance liquid chromatography (RPHPLC), and the fractions responsible for the alpha-glucosidase inhibitory activity were isolated. Lastly, peptides were identified by mass spectrometry in tandem (MS/MS) and in silico analyses were done to hypothesise potentially bioactive sequences. The results indicated that all legume extracts exert alpha-glucosidase inhibitory activity after thermal treatment and GID. Peptide profiles obtained by RP-HPLC showed the highest generation of peptides after the intestinal digestion phase, with small changes between thermal treatments. Best alpha-glucosidase inhibitory activity was observed in fraction 2 of all gastrointestinal digested samples, with values between 40 % and 62 % inhibition. In soybean, green pea, and navy bean, conventional-cooked samples showed the highest activity, while the pressure-cooked treatment resulted in significantly higher activity in chickpea samples. Finally, 48 peptides were identified by MS/MS and 13 were found as potentially bioactive using in silico tools, expanding previous knowledge on antidiabetic peptides derived from legumes., M.A. gratefully acknowledges the Predoctoral contract (FPU19/02401) from the Spanish Ministry of Science, Innovation and Universities. The proteomic analysis was performed in the proteomics facility of SCSIE University of Valencia that belongs to Proteored, PRB3 and is supported by grant PT17/0019, of the PE I + D + i 2013-2016, funded by ISCIII and ERDF.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC

  • Pulido, I.
  • Garcia-Canaveras, J. C.
  • Rodriguez, M. L.
  • Becker, J. H.
  • Lopez, A.
  • Aupi, M.
  • Aparisi, S.
  • Chulia-Peris, L.
  • Tamayo-Torres, E.
  • Carreres-Rey, C.
  • Alcacer Fernandez-Coronado, J.
  • Benet, M.
  • Montero, S.
  • Mena, S.
  • Sandoval, J.
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] Lung cancer is the deadliest neoplasia worldwide. Despite the availability of targeted therapies like tyrosine kinase inhibitors (TKIs) for EGFR-driven tumours in Non-Small Cell Lung Cancer (NSCLC), drug resistance remains a major factor that dramatically cuts life expectancy. Here we identify how increased expression of nicotinamide N-methyltransferase (NNMT) in TKI-resistant cancer cells diverts nicotinamide to synthesise 1-Methylnicotinamide (1-MNA) and lowers NAD+ levels that generates a druggable nicotinamide phosphoribosyltransferase (NAMPT) metabolic vulnerability. We also report that high blood levels of 1-MNA, the byproduct of NNMT activity, are significantly associated with lower survival rates in EGFR TKI-treated NSCLC patients. Taken together, our findings describe a new and highly specific non-genetic metabolic synthetic lethality for mesenchymal-like tumours, which exposes NAMPT as an in vivo druggable target and establishes 1-MNA as a novel liquid biopsy biomarker to predict and monitor EGFR TKI resistance in NSCLC., This work is supported by the Spanish Ministry of Science, Innovation and Universities (SAF2017-85352 and PID2020-119426RB-I00) and the Domingo Martinez Foundation to J. Carretero; NIH grant CA230778 and DoD CDMRP LCRP HT9425-23-1-0486, HT9425-23-1-0713, and HT9425-23-1-0497 to T. Shimamura; the European Regional Development Fund, the Carlos III Institute of Health of the Spanish Ministry of Science, Innovation and Universities (PI23/01369 and PI20/00580) to A. Lahoz; DoD CDMRP LCRP W81XWH-22-1-0023 to I. Pulido; and the Mansueto Lung Research Fund to Malek Massad. Part of the equipment used in this work was cofunded by the Generalitat Valenciana and the European Regional Development Fund (FEDER of the Comunitat Valenciana 2014-2020) . We gratefully acknowledge the support of the INCLIVA BioBank (PT17/0015/0049; B.000768 ISCIII) as part of the Valencian Biobanking Network and the Spanish National Biobanks Network. We thank Dr. Enrico Benedetti, Dr. Ajay Rana, and the Department of Surgery at the University of Illinois, Chicago, and Dr. Roque Bort from the La Fe Hospital for their help and support.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Short-Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial-IRON Trial

  • del Canto Serrano, Irene
  • Santas, Enrique
  • Cardells, Ingrid
  • Miñana, Gema
  • Palau, Patricia
  • Llàcer, Pau
  • Fácila, Lorenzo
  • López-Vilella, Raquel
  • Almenar, Luis
  • Bodí, Vicent
  • López-Lereu, Maria P.
  • Monmeneu, Jose V.
  • Sanchis, Juan
  • Maceira, Alicia M.
  • Moratal, David|||0000-0002-2825-3646
[EN] BACKGROUND: The mechanisms explaining the clinical benefits of ferric carboximaltose (FCM) in patients with heart failure, reduced or intermediate left ventricular ejection fraction, and iron deficiency remain not fully clarified. The Myocardial-IRON trial showed short-term cardiac magnetic resonance (CMR) changes suggesting myocardial iron repletion following administration of FCM but failed to find a significant increase in left ventricular ejection fraction in the whole sample. Conversely, the strain assessment could evaluate more specifically subtle changes in contractility. In this subanalysis, we aimed to evaluate the effect of FCM on the short-term left and right ventricular CMR feature tracking derived strain. METHODS AND RESULTS: This is a post hoc subanalysis of the double-blind, placebo-controlled, randomized clinical trial that enrolled 53 ambulatory patients with heart failure and left ventricular ejection fraction <50%, and iron deficiency [Myocardial-IRON trial (NCT03398681)]. Three-dimensional left and 2-dimensional right ventricular CMR tracking strain (longitudinal, circumferential, and radial) changes were evaluated before, 7 and 30 days after randomization using linear mixed-effect analysis. The median (interquartile range) age of the sample was 73 years (65-78), and 40 (75.5%) were men. At baseline, there were no significant differences in CMR feature tracking strain parameters across both treatment arms. At 7 days, the only global 3-dimensional left ventricular circumferential strain was significantly higher in the FCM treatment-arm (difference: -1.6%, P=0.001). At 30 days, and compared with placebo, global 3-dimensional left ventricular strain parameters significantly improved in those allocated to FCM treatment-arm [longitudinal (difference: -2.3%, P<0.001), circumferential (difference: -2.5%, P<0.001), and radial (difference: 4.2%, P=0.002)]. Likewise, significant improvements in global right ventricular strain parameters were found in the active arm at 30 days (longitudinal [difference: -3.3%, P=0.010], circumferential [difference: -4.5%, P<0.001], and radial [difference: 4.5%, P=0.027]). CONCLUSIONS: In patients with stable heart failure, left ventricular ejection fraction <50%, and iron deficiency, treatment with FCM was associated with short-term improvements in left and right ventricular function assessed by CMR feature tracking derived strain parameters., This work was supported in part by an unrestricted grant from Vifor Pharma, CIBER Cardiovascular [grant numbers 16/11/00420 and 16/11/00403], Unidad de Investigacion Clinica y Ensayos Clinicos INCLIVA Health Research Institute, Spanish Clinical Research Network (SCReN; PT13/0002/0031 and PT17/0017/0003), cofounded by Fondo Europeo de Desarrollo Regional-Instituto de Salud Carlos III, and Proyectos de Investigacion de la Seccion de Insuficiencia Cardiaca 2017 from Sociedad Espanola de Cardiologia.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Metabolomic study for the identification of symptomatic carotid plaque biomarkers

  • Botello-Marabotto, Marina Dolores
  • Plana Andani, Emma
  • Medina, Pilar
  • Miralles, Manuel
  • Martínez-Bisbal, M.Carmen|||0000-0002-8526-4413
  • Bernardos Bau, Andrea|||0000-0002-3842-5771
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Carotid artery stenosis is mainly produced due to the progressive accumulation of atherosclerotic plaque in the vascular wall. The atherosclerotic plaque is characterized by the accumulation of lipids, low density proteins, expression of chemokines and adhesion molecules, and migration of monocytes and lymphocytes into the plaque. Its rupture can produce stroke, but embolic propensity depends principally on the composition and vulnerability of plaque rather than the severity of stenosis. It is important, then, to ascertain which patients with carotid artery stenosis have a greater risk of developing neurological symptomatology. Here, we present a metabolomic study by using nuclear magnetic resonance (NMR) spectroscopy in atheroma plaque and serum samples from patients with recently symptomatic and asymptomatic carotid stenosis to search for metabolites that could be used as biomarkers associated with plaque vulnerability and subsequent risk of rupture. Thirty-eight atheromatous plaque samples (24 asymptomatic patients and 14 symptomatic) and 70 serum samples (43 asymptomatic and 27 symptomatic) were studied by NMR spectroscopy. The data were analysed using multivariate statistics (PLS-DA) to determine a model to discriminate between symptomatic and asymptomatic samples (atheroma plaques and sera). The calculated PLS-DA models showed a 100 % sensitivity and a 96.6 % specificity for the cross validation to discriminate between symptomatic and asymptomatic plaques, and 88.37% sensitivity and 77.78 % specificity when serum samples were analysed. According to the results of our multivariate and univariate analysis, the most discriminative metabolites for plaque vulnerability were threonine in serum samples, and glutamate in plaque samples. Also, an analysis of the main metabolic pathways involved in plaque vulnerability revealed that D-glutamine and D-glutamate metabolism, and phenylalanine, tyrosine, and tryptophan biosynthesis were the most affected pathways in plaque and serum, respectively., M. Botello-Marabotto acknowledges Generalitat Valenciana and the Spanish Government for her PhD grants ACIF/2020 and FPU 2020, respectively. Andrea Bernardos acknowledges her "Beatriz Galindo" contract from the MCIN (BG20/00020). This project has received the following funding: Instituto de Salud Carlos III (ISCIII) (PI20/01171 and PI20/00075) co-funded by the European Union (ERDF, "A way to make Europe") , project PID2021-126304OB-C41 and PID2021-128141OB-C22 funded by MCIN/AEI/10.13039/501100011033/and by European Regional Development Fund - A way of doing Europe and Generalitat Valenciana (project CIPROM/2021/007). La Fe Biobank (Hospital Universitario y Politecnico La Fe) is acknowledged for the storage and management of tissue samples (PT17/0015/0043). CIBER -Consorcio Centro de Investigacion Biomedica en Red- (CB07/01/2012), Ministerio de Ciencia e Innovacion and U26 NMR: Biomedical Applications II platform from Nanbiosis (Research Infrastructures & Services of CIBER-BBN) are also gratefully acknowledged.
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells

  • Kobayashi-Ishihara, Mie
  • Frazão Smutná, Katarína
  • Alonso, Florencia E.
  • Argilaguet, Jordi
  • Esteve-Codina, Anna
  • Geiger, Kerstin
  • Genescà, Meritxell
  • Grau-Expósito, Judith
  • Duran-Castells, Clara
  • Rogenmoser, Selina
  • Böttcher, René
  • Jungfleisch, Jennifer
  • Oliva, Baldomero
  • Martinez, Javier P.
  • Li, Manqing
  • David, Michael
  • Yamagishi, Makoto
  • Ruiz-Riol, Marta
  • Brander, Christian
  • Tsunetsugu-Yokota, Yasuko
  • Buzon, Maria J.
  • Díez, Juana
  • Meyerhans, Andreas
Latency is a major barrier towards virus elimination in HIV-1-infected individuals. Yet, the mechanisms that contribute to the maintenance of HIV-1 latency are incompletely understood. Here we describe the Schlafen 12 protein (SLFN12) as an HIV-1 restriction factor that establishes a post-transcriptional block in HIV-1-infected cells and thereby inhibits HIV-1 replication and virus reactivation from latently infected cells. The inhibitory activity is dependent on the HIV-1 codon usage and on the SLFN12 RNase active sites. Within HIV-1-infected individuals, SLFN12 expression in PBMCs correlated with HIV-1 plasma viral loads and proviral loads suggesting a link with the general activation of the immune system. Using an RNA FISH-Flow HIV-1 reactivation assay, we demonstrate that SLFN12 expression is enriched in infected cells positive for HIV-1 transcripts but negative for HIV-1 proteins. Thus, codon-usage dependent translation inhibition of HIV-1 proteins participates in HIV-1 latency and can restrict the amount of virus release after latency reversal., We thank Drs Yingying Li, Feng Gao and Beatrice H. Hahn for providing codon-optimized HIV-1 Gag expression vector, Drs James Hoxie and Susan Zolla-Pazner for supplying anti-Nef and -p24 antibodies, respectively through the NIH AIDS reagent program. We also thank Dr Song Gao for providing SLFN13-tRNA structure information, and Dr Maria-Eugenia Gas Lopez and Dr Ester Gea-Mallorquí for advise. This work was supported by following grants: M.K.I., JSPS Oversea Research Fellowship and Takeda Science Foundation; A.E.C., PT17/0009/0019 (ISCIII/MINECO and FEDER); M.J.B., RTI2018-101082-B-I00 and PID2021-123321OB-I00 [MINECO/FEDER]), and the Miguel Servet program by ISCIII (CP17/00179 and CPII22/00005); C.B., M.R.R., C.D.C., European Union’s Horizon 2020 research and innovation program under grant agreement 681137-EAVI2020 and NIH grant P01-AI131568; J.D., the Spanish Ministry of Science and Innovation (PID2019106959RB-I00/AEI/10.13039/501100011033); A.M., the Spanish Ministry of Science and Innovation (PID2019-106323RB-I00 AEI//10.13039/501100011033) and the institutional “María de Maeztu” Programme for Units of Excellence in R&D (CEX2018-000792-M)., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides

  • Gualdrón-López, Melisa
  • Ayllon-Hermida, Alberto
  • Cortes-Serra, Núria
  • Resa-Infante, Patricia
  • Bech-Serra, Joan Josep
  • Aparici-Herraiz, Iris
  • Nicolau-Fernandez, Marc
  • Erkizia, Itziar
  • Gutierrez-Chamorro, Lucia
  • Marfil, Silvia
  • Pradenas, Edwards
  • Ávila Nieto, Carlos
  • Cucurull, Bernat
  • Montaner-Tarbés, Sergio
  • Muelas, Magdalena
  • Sotil, Ruth
  • Ballana, Ester
  • Urrea, Victor
  • Fraile, Lorenzo
  • Montoya, Maria
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Fernandez-Becerra, Carmen
  • de La Torre, Carolina
  • Pinazo, Maria-Jesus
  • Martinez-Picado, Javier
  • del Portillo, Hernando A.
Extracellular vesicles (EVs) released by virus-infected cells have the potential to encapsulate viral peptides, a characteristic that could facilitate vaccine development. Furthermore, plasma-derived EVs may elucidate pathological changes occurring in distal tissues during viral infections. We hypothesized that molecular characterization of EVs isolated from COVID-19 patients would reveal peptides suitable for vaccine development. Blood samples were collected from three cohorts: severe COVID-19 patients (G1), mild/asymptomatic cases (G2), and SARS-CoV-2-negative healthcare workers (G3). Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). Clinical data analysis revealed elevated inflammatory markers in G1. Notably, non-vaccinated individuals in G1 exhibited increased levels of neutralizing antibodies at m8, suggesting prolonged exposure to viral antigens. Proteomic profiling of EVs was performed using three distinct methods: immunocapture (targeting CD9), ganglioside-capture (utilizing Siglec-1) and size-exclusion chromatography (SEC). Contrary to our hypothesis, this analysis failed to identify viral peptides. These findings were subsequently validated through Western blot analysis targeting the RBD of the SARS-CoV-2 Spike protein’s and comparative studies using samples from experimentally infected Syrian hamsters. Furthermore, analysis of the EV cargo revealed a diverse molecular profile, including components involved in the regulation of viral replication, systemic inflammation, antigen presentation, and stress responses. These findings underscore the potential significance of EVs in the pathogenesis and progression of COVID-19., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The proteomics of EVs isolated by CD9 was performed at the proteomics facility of Utrecht (Netherlands) as part of an EPIC-XS grant (0000205) to CT and HP. The proteomics analyses of EVs isolated by SEC were performed in the IJC Proteomic unit, which is part of the of Proteored, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF”. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). We thank Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real time PCR system. JM-P was supported by the Spanish Ministry of Science,Innovation and Universities (grants PID2022-139271OB-I00 and CB21/13/00063, Spain), and Fundació La Marató de TV3 (grant 202120-30-31-32, Spain). Funded in part by the European Union. The PCR-4-ALL and UNDINE projects have received funding under the Horizon Europe research and innovation programme (grant agreement No 101095606 and No 101057100 respectively). CF-B and HP acknowledge support from the Spanish Ministry of Science and Innovation (MICINN) (PID2022- 142908OB-I00) and support from the grant CEX2023-0001290-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. This research is part of the ISGlobal’s Program on the Molecular Mechanisms of Malaria which is partially supported by the Fundación Ramón Areces. We also acknowledged the internal funding from IrsiCaixa through the crowdfunding initiative YoMeCorono (JM-P) and ISGlobal (HP) to initiate these studies., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Cross-protection against African swine fever virus upon intranasal vaccination is associated with an adaptive-innate immune crosstalk

  • Bosch Camós, Laia
  • Alonso, Uxía
  • Esteve-Codina, Anna
  • Chang, Chia-Yu
  • Martín-Mur, Beatriz
  • Accensi, Francesc
  • Muñoz, Marta
  • Navas, María J.
  • Dabad, Marc
  • Vidal, Enric
  • Pina-Pedrero, Sonia
  • Pleguezuelos, Patricia
  • Caratù, Ginevra
  • Salas, María L.
  • Liu, Lihong
  • Bataklieva, Stanimira
  • Gavrilov, Boris
  • Rodriguez, Fernando
  • Argilaguet, Jordi
African swine fever virus (ASFV) is causing a worldwide pandemic affecting the porcine industry and leading to important global economic consequences. The virus causes a highly lethal hemorrhagic disease in wild boars and domestic pigs. Lack of effective vaccines hampers the control of virus spread, thus increasing the pressure on the scientific community for urgent solutions. However, knowledge on the immune components associated with protection is very limited. Here we characterized the in vitro recall response induced by immune cells from pigs intranasally vaccinated with the BA71ΔCD2 deletion mutant virus. Vaccination conferred dose-dependent cross-protection associated with both ASFV-specific antibodies and IFNγ-secreting cells. Importantly, bulk and single-cell transcriptomics of blood and lymph node cells from vaccinated pigs revealed a positive feedback from adaptive to innate immunity. Indeed, activation of Th1 and cytotoxic T cells was concomitant with a rapid IFNγ-dependent triggering of an inflammatory response characterized by TNF-producing macrophages, as well as CXCL10-expressing lymphocytes and cross-presenting dendritic cells. Altogether, this study provides a detailed phenotypic characterization of the immune cell subsets involved in cross-protection against ASFV, and highlights key functional immune mechanisms to be considered for the development of an effective ASF vaccine., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Developmental RNA-Seq transcriptomics of haploid germ cells and spermatozoa uncovers novel pathways associated with teleost spermiogenesis

  • Castro-Arnau, Júlia
  • Chauvigné, François
  • Gómez-Garrido, Jessica
  • Esteve-Codina, Anna
  • Dabad, Marc
  • Alioto, Tyler
  • Finn, Roderick Nigel
  • Cerdà, Joan
In non-mammalian vertebrates, the molecular mechanisms involved in the transformation of haploid germ cells (HGCs) into spermatozoa (spermiogenesis) are largely unknown. Here, we investigated this process in the marine teleost gilthead seabream (Sparus aurata) through the examination of the changes in the transcriptome between cell-sorted HGCs and ejaculated sperm (SPZEJ). Samples were collected under strict quality controls employing immunofluorescence microscopy as well as by determining the sperm motion kinematic parameters by computer-assisted sperm analysis. Deep sequencing by RNA-seq identified a total of 7286 differentially expressed genes (DEGs) (p-value < 0.01) between both cell types, of which nearly half were upregulated in SPZEJ compared to HCGs. In addition, approximately 9000 long non-coding RNAs (lncRNAs) were found, of which 56% were accumulated or emerged de novo in SPZEJ. The upregulated transcripts are involved in transcriptional and translational regulation, chromatin and cytoskeleton organization, metabolic processes such as glycolysis and oxidative phosphorylation, and also include a number of ion and water channels, exchangers, transporters and receptors. Pathway analysis conducted on DEGs identified 37 different signaling pathways enriched in SPZEJ, including 13 receptor pathways, from which the most predominant correspond to the chemokine and cytokine, gonadotropin-releasing hormone receptor and platelet derived growth factor signaling pathways. Our data provide new insight into the mRNA and lncRNA cargos of teleost spermatozoa and uncover the possible involvement of novel endocrine mechanisms during the differentiation and maturation of spermatozoa., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Differential kinetics of splenic CD169+ macrophage death is one underlying cause of virus infection fate regulation

  • Casella, Valentina
  • Domenjo-Vila, Eva
  • Esteve-Codina, Anna
  • Pedragosa, Mireia
  • Cebollada Rica, Paula
  • Vidal, Enric
  • de la Rubia, Ivan
  • López-Rodríguez, Cristina
  • Bocharov, Gennady
  • Argilaguet, Jordi
  • Meyerhans, Andreas
Acute infection and chronic infection are the two most common fates of pathogenic virus infections. While several factors that contribute to these fates are described, the critical control points and the mechanisms that underlie infection fate regulation are incompletely understood. Using the acute and chronic lymphocytic choriomeningitis virus (LCMV) infection model of mice, we find that the early dynamic pattern of the IFN-I response is a differentiating trait between both infection fates. Acute-infected mice generate a 2-wave IFN-I response while chronic-infected mice generate only a 1-wave response. The underlying cause is a temporal difference in CD8 T cell-mediated killing of splenic marginal zone CD169+ macrophages. It occurs later in acute infection and thus enables CD169+ marginal zone macrophages to produce the 2nd IFN-I wave. This is required for subsequent immune events including induction of inflammatory macrophages, generation of effector CD8+ T cells and virus clearance. Importantly, these benefits come at a cost for the host in the form of spleen fibrosis. Due to an earlier marginal zone destruction, these ordered immune events are deregulated in chronic infection. Our findings demonstrate the critical importance of kinetically wellcoordinated sequential immune events for acute infection control and highlights that it may come at a cost for the host organism., We thank the Flow Cytometry and Genomic Core Facilities (Universitat Pompeu Fabra) and the Advanced Light Microscopy Unit (ALMU-CRG) for excellent technical support, Monica Perez (CReSA-IRTA-UAB) for helping with the histology samples and Hector Huerga Encabo (Immunology Unit, Universitat Pompeu Fabra) for fruitful discussions and ideas. We further thank Dr. Kenji Kohno and Dr. Masato Tanaka for allowing us to use their CD169-DTR transgenic mice which we obtained through Dr. Andres Hidalgo. The graphical abstract was created using BioRender.com platform. This work was supported by grants from the Spanish Ministry of Science and Innovation grant No. PID2019-106323RB-I00 AEI//10.13039/501100011033 and PID2022-141395OB-I00, the “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000792-M), the Russian Science Foundation grant No. 23-11-00116 and the AEC funded by ISCIII /MINECO (PT17/0009/0019) and co-funded by FEDER., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Global analysis of the association between pig muscle fatty acid composition and gene expression using RNA-Seq

  • Valdés-Hernández, Jesús
  • Ramayo-Caldas, Yuliaxis
  • Passols, Magí
  • Sebastià, Cristina
  • Criado-Mesas, Lourdes
  • Crespo-Piazuelo, Daniel
  • Esteve-Codina, Anna
  • Castelló, Anna
  • Sánchez, Armand
  • Folch, Josep M.
Fatty acids (FAs) play an essential role as mediators of cell signaling and signal transduction, affecting metabolic homeostasis and determining meat quality in pigs. However, FAs are transformed by the action of several genes, such as those encoding desaturases and elongases of FAs in lipogenic tissues. The aim of the current work was to identify candidate genes, biological processes, and pathways involved in the modulation of intramuscular FA profile from longissimus dorsi muscle. FA profile by gas chromatography of methyl esters and gene expression by RNA-Seq were determined in 129 Iberian × Duroc backcrossed pigs. An association analysis between the muscle transcriptome and its FA profile was performed, followed by a concordance and functional analysis. Overall, a list of well-known (e.g., PLIN1, LEP, ELOVL6, SC5D, NCOA2, ACSL1, MDH1, LPL, LGALS12, TFRC, GOT1, and FBP1) and novel (e.g., TRARG1, TANK, ENSSSCG00000011196, and ENSSSCG00000038429) candidate genes was identified, either in association with specific or several FA traits. Likewise, several of these genes belong to biological processes and pathways linked to energy, lipid, and carbohydrate metabolism, which seem determinants in the modulation of FA compositions. This study can contribute to elucidate the complex relationship between gene expression and FA profile in pig muscle., info:eu-repo/semantics/publishedVersion
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Metatax: metataxonomics with a Compi-based pipeline for precision medicine

  • Graña Castro, Osvaldo
  • López Fernández, Hugo
  • Nogueira Rodríguez, Alba
  • Fernández Riverola, Florentino
  • Al-Shahrour, Fátima
  • González Peña, Daniel
The human body immune system, metabolism and homeostasis are affected by microbes. Dysbiosis occurs when the homeostatic equilibrium is disrupted due to an alteration in the normal microbiota of the intestine. Dysbiosis can cause cancer, and also affect a patient’s ability to respond to treatment. Metataxonomics seeks to identify the bacteria present in a biological sample, based on the sequencing of the 16S rRNA genetic marker. Precision medicine attempts to find relationships between the microbiota and the risk of acquiring cancer, and design new therapies targeting bacteria. Flexible and portable bioinformatic pipelines are necessary to be able to bring metataxonomics to the clinical field, which allow groups of biological samples to be classified according to their diversity in the microbiota. With this aim we implemented Metatax, a new pipeline to analyze biological samples based on 16S rRNA gene sequencing. The results obtained with our pipeline should complement those obtained by sequencing a patient's DNA and RNA, in addition to clinical data, to improve knowledge of the possible reasons for a disease or a worse response to treatment., Instituto de Salud Carlos III | Ref. PT17/0009/0011, Xunta de Galicia | Ref. ED481B 2016/068-0, Xunta de Galicia | Ref. ED481A-2019/299, Xunta de Galicia | Ref. ED431C2018/55
RUA. Repositorio Institucional de la Universidad de Alicante
Publication Otros (Other)

Fibroblast Growth Factor 23 and Outcomes in Acute Heart Failure

  • Martí-Martínez, Arancha
  • Nuñez, Julio
  • López-Escribano, Herminio
  • de la Espriella, Rafael
  • Santas, Enrique
  • Rodríguez Borja, Enrique
  • Miró, Òscar
  • Llorens, Pere
  • Alquézar-Arbé, Aitor
  • Herrero-Puente, Pablo
  • Llorens, Pere|||/items/757956aa-c39c-4e15-850b-e5bf9ed72f94
Worsening heart failure (WHF) is a complex clinical syndrome associated with a high risk of mortality and further decompensations, characterized by fluid overload and upregulated inflammatory and fibrotic processes linked to organ dysfunction. Fibroblast growth factor 23 (FGF23) is an emerging proxy of fibrosis and may interact to influence long-term outcomes in WHF patients. This study evaluated the association between FGF23 levels and long-term outcomes in patients with WHF evaluated in the emergency department (ED). A total of 635 patients from the EAHFE registry, enrolled during 2007, 2009, and 2011, were prospectively included. FGF23 was measured in the first blood sample obtained at ED presentation. During a median follow-up of 380 days (interquartile range: 126 to 456), all-cause mortality occurred in 216 patients (34.0%), while 351 patients (55.3%) experienced the composite endpoint of death/WHF ED reconsultation and 295 (46.5%) experienced death/HF hospitalization. Event rates increased progressively across FGF23 levels. Patients with FGF23 above the median (48.4 pg/mL) displayed higher rates (per 100 patient-years) of all-cause mortality (49 vs. 31, p = 0.003), death/WHF ED reconsultation (93 vs. 65, p = 0.003), and death/HF hospitalization (77 vs. 56, p = 0.043). In continuous analyses, each doubling of FGF23 remained significantly associated with an increased risk of all three outcomes after multivariable adjustment. These associations were consistent across clinically relevant subgroups, including those defined by age, sex, and kidney function, supporting the potential prognostic value of FGF23 within this cohort, although external validation is warranted.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Integrative metabolic pathway analysis reveals novel therapeutic targets in osteoarthritis

  • Rocha Loureda, Beatriz
  • Cillero-Pastor, B.
  • Eijkel, Gert
  • Calamia, Valentina
  • Fernández-Puente, Patricia
  • Paine, Martin R.L.
  • Ruiz-Romero, Cristina
  • Heeren, Ron M.A.
  • Blanco García, Francisco J
Data availability: The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (https://www.ebi.ac.uk/pride/archive/projects/PXD012879) with the dataset identifier PXD012879 and the project name of MSCs OA SILAC Mass spectrometry imaging, [Abstract] In osteoarthritis (OA), impairment of cartilage regeneration can be related to a defective chondrogenic differentiation of mesenchymal stromal cells (MSCs). Therefore, understanding the proteomic- and metabolomic-associated molecular events during the chondrogenesis of MSCs could provide alternative targets for therapeutic intervention. Here, a SILAC-based proteomic analysis identified 43 proteins related with metabolic pathways whose abundance was significantly altered during the chondrogenesis of OA human bone marrow MSCs (hBMSCs). Then, the level and distribution of metabolites was analyzed in these cells and healthy controls by matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI), leading to the recognition of characteristic metabolomic profiles at the early stages of differentiation. Finally, integrative pathway analysis showed that UDP-glucuronic acid synthesis and amino sugar metabolism were downregulated in OA hBMSCs during chondrogenesis compared with healthy cells. Alterations in these metabolic pathways may disturb the production of hyaluronic acid (HA) and other relevant cartilage extracellular matrix (ECM) components. This work provides a novel integrative insight into the molecular alterations of osteoarthritic MSCs and potential therapeutic targets for OA drug development through the enhancement of chondrogenesis., This work has been funded by Fondo Investigación Sanitaria-Spain (grant numbers PI14/01707, PI16/02124, PI17/00404, DTS17/00200, CIBER-CB06/01/0040 and RETIC-RIER-RD12/0009/0018), a part of the National Plan for Scientific Program Development and Technological Innovation 2013–2016, funded by the ISCIII-General Subdirection of Assessment and Promotion of Research - European Regional Development Fund (FEDER) “A way of making Europe.” The Proteomics Unit of GIR belongs to ProteoRed, PRB2- ISCIII (grant number PT17/0019/0014). B.R. is supported by Xunta de Galicia (IN606B-2016/004). The research was partially performed within the M4I research program, financially supported by the Dutch Province of Limburg as part of the “LINK” program, Xunta de Galicia; IN606B-2016/004, https://www.ebi.ac.uk/pride/archive/projects/PXD012879
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Targeted phospholipidomic analysis of synovial fluid as a tool for osteoarthritis deep phenotyping

  • Rocha Loureda, Beatriz
  • Illiano, Anna
  • Calamia, Valentina
  • Pinto, Gabriella
  • Amoresano, Angela
  • Ruiz-Romero, Cristina
  • Blanco García, Francisco J
[Abstract] Objective. The aim of this study was to carry out a targeted phospholipidomic analysis on synovial fluid (SF) from patients with different grades of osteoarthritis (OA) and controls, in order to search for specific phospholipid profiles that may be useful for the deep phenotyping of this disease. Design. Multiple reaction monitoring-mass spectrometry (MRM/MS) was applied to explore the potential phospholipidomic differences in the SF of knee OA patients (n ​= ​15) (subclassified into early- and late-stage OA) and non-OA controls (n ​= ​4). Multivariate statistical analyses conducted by partial least squares discriminant analysis (PLS-DA) and hierarchical clustering analysis (HCA) were performed to identify significantly altered phospholipids in OA, characterize phospholipidomic profiles associated with the radiographic stage of the disease and describe potential endotypes at early stages. Results. Significant discrimination of phospholipid profiles between non-OA controls and the early- and late-stage OA groups were found by PLS-DA and HCA. Compared to SF from non-OA controls, OA patients showed higher levels of most quantified phospholipid species, including phosphatidylcholines (PC), phosphatidylserines and phosphatidylinositols. Furthermore, several PC species showed significant differences in abundance between the two OA subgroups and were negatively correlated with cartilage damage. Finally, two distinct endotypes of early-stage OA were identified based on the phospholipidomic profile of SF. Conclusions. Our data provides a novel insight into the phospholipid profiles of OA synovial fluid, revealing specific alterations associated with the radiographic stage of the disease. This targeted phospholipidomic profiling also facilitated the characterization of two different OA endotypes at early stages of the disease., This work is supported by grants from Fondo Investigación Sanitaria-Spain (PI16/02124, PI17/00404, PI19/01206, PI20/00793 and RETIC-RIER-RD16/0012/0002), integrated in the National Plan for Scientific Program, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of Research - European Regional Development Fund (FEDER) “A way of making Europe”. This study is also supported by AE CICA-INIBIC (ED431E 2018/03) and grants IN607A 2017/11, IN607A 2021/7 and IN607D 2020/10 from Axencia Galega de Innovacion - Xunta de Galicia. The Biomedical Research Networking Center (CIBER) is an initiative from Instituto de Salud Carlos III (ISCIII). The Proteomics Unit of GIR belongs to ProteoRed, PRB3- ISCIII (PT17/0019/0014), Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN607A 2017/11, Xunta de Galicia; IN607A 2021/7, Xunta de Galicia; IN607D 2020/10
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Identification of a distinct lipidomic profile in the osteoarthritic synovial membrane by mass spectrometry imaging

  • Rocha Loureda, Beatriz
  • Cillero-Pastor, B.
  • Ruiz-Romero, Cristina
  • Paine, Martin R.L.
  • Cañete, Juan D.
  • Heeren, Ron M.A.
  • Blanco García, Francisco J
[Abstract] Objective: Synovial inflammation is one of the most characteristic events in different types of arthritis, including Osteoarthritis (OA). Emerging evidence also suggests the involvement of lipids in the regulation of inflammatory processes. The aim of this study was to elucidate the heterogeneity and spatial distribution of lipids in the OA synovial membrane and explore their putative involvement in inflammation. Method: The abundance and distribution of lipids were examined in human synovial membranes. To this end, histological cuts from this tissue were analysed by matrix-assisted laser desorption ionization - mass spectrometry imaging (MALDI-MSI). The lipidomic profile of OA synovium was characterized and compared with healthy and other forms of inflammatory arthropathies as Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) using principal component analysis and discriminant analysis methods. Lipid identification was undertaken by tandem MS analyses and database queries. Results: Our results reveal differential and characteristic lipidomic profiles between OA and control samples. Specifically, we unveiled that OA synovium presents elevated levels of phosphatidylcholines, fatty acids and lysophosphatidic acids and lower levels of lysophosphatidylcholines compared to control tissues. The spatial distribution of particular glycerophospholipids was also correlated with hypertrophic, inflamed or vascularized synovial areas. Compared with other inflammatory arthritis, the OA tissue showed lower amounts of phosphatidylethanolamine-based plasmalogens. Conclusions: This study provides a novel insight into the lipid profiles of synovial membrane and differences in abundance between OA and control tissues. The lipidomic alterations improves understanding of the pathogenic mechanisms of OA and may be important for its diagnosis., This work is supported by grants from Fondo Investigación Sanitaria-Spain (PI16/02124, PI17/00404 PI19/01206 and RETIC-RIER-RD16/0012/0002), integrated in the National Plan for Scientific Program, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of Research – European Regional Development Fund (FEDER) “A way of making Europe”. This study is also supported by AE CICA-INIBIC (ED431E 2018/03) and grants IN607A2017/11 and IN607D2020/10 from Xunta de Galicia. The Biomedical Research Networking Center (CIBER) is an initiative from Instituto de Salud Carlos III (ISCIII). The Proteomics Unit of GIR belongs to ProteoRed, PRB3- ISCIII (PT17/0019/0014). B.R. has been supported by Xunta de Galicia (IN606B-2016/004). The research was partially performed within the M4I research program, financially supported by the Dutch Province of Limburg as part of the “LINK” program, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN607A2017/11, Xunta de Galicia; IN607D2020/10, Xunta de Galicia; IN606B-2016/004
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

mtDNA haplogroup A enhances the effect of obesity on the risk of knee OA in a mexican population

  • Ramos-Louro, Paula
  • Arellano Pérez Vertti, Rubén Daniel
  • López-Reyes, Alberto
  • Martínez-Nava, Gabriela Angélica
  • Espinosa, Rolando
  • Pineda, Carlos
  • González Galarza, Faviel Francisco
  • Argüello Astorga, Rafael
  • Aguilar Muñiz, Lizette Sarai
  • Hernández Terán, Fernando
  • Parra Torres, Nancy Marbella
  • Durán-Sotuela, Alejandro
  • Fernández-Moreno, Mercedes
  • Balboa-Barreiro, Vanesa
  • Blanco García, Francisco J
  • Rego-Pérez, I.
[Abstract] To evaluate the influence of mitochondrial DNA haplogroups on the risk of knee OA in terms of their interaction with obesity, in a population from Mexico. Samples were obtained from (n = 353) knee OA patients (KL grade ≥ I) and (n = 364) healthy controls (KL grade = 0) from Mexico city and Torreon (Mexico). Both Caucasian and Amerindian mtDNA haplogroups were assigned by single base extension assay. A set of clinical and demographic variables, including obesity status, were considered to perform appropriate statistical approaches, including chi-square contingency tables, regression models and interaction analyses. To ensure the robustness of the predictive model, a statistical cross-validation strategy of B = 1000 iterations was used. All the analyses were performed using boot, GmAMisc and epiR package from R software v4.0.2 and SPSS software v24. The frequency distribution of the mtDNA haplogroups between OA patients and healthy controls for obese and non-obese groups showed the haplogroup A as significantly over-represented in knee OA patients within the obese group (OR 2.23; 95% CI 1.22-4.05; p-value = 0.008). The subsequent logistic regression analysis, including as covariate the interaction between obesity and mtDNA haplogroup A, supported the significant association of this interaction (OR 2.57; 95% CI 1.24-5.32; p-value = 0.011). The statistical cross-validation strategy confirmed the robustness of the regression model. The data presented here indicate a link between obesity in knee OA patients and mtDNA haplogroup A., This work is supported by Grants from Fondo de Investigación Sanitaria (PI17/00210, PI16/02124, PI20/00614, RETIC-RIER-RD16/0012/0002 and PRB3-ISCIII-PT17/0019/0014) integrated in the National Plan for Scientific Program, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of Research-European Regional Development Fund (FEDER) “A way of making Europe” and Grant IN607A2017/11 from Xunta de Galicia. The authors further acknowledge AE CICA-INIBIC (ED431E 2018/03) for financial support. IRP is supported by Contrato Miguel Servet-II Fondo de Investigación Sanitaria (CPII17/00026) and AD-S is supported by Grant IN606A-2018/023 from Xunta de Galicia, Spain. The Biomedical Research Networking Center (CIBER) is an initiative from Instituto de Salud Carlos III (ISCIII), Xunta de Galicia; IN607A2017/11, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN606A-2018/023
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

A clinical model including protein biomarkers predicts radiographic knee osteoarthritis: a prospective study using data from the Osteoarthritis Initiative

  • Lourido Salas, Lucía María
  • Balboa-Barreiro, Vanesa
  • Ruiz-Romero, Cristina
  • Rego-Pérez, I.
  • Camacho Encina, María
  • Paz González, Rocío
  • Calamia, Valentina
  • Oreiro Villar, Natividad
  • Nilsson, Peter
  • Blanco García, Francisco J
The Osteoarthritis Initiative (OAI) is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Pfizer, Inc.; Novartis Pharmaceuticals Corporation; Merck Research Laboratories; and GlaxoSmithKline. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This work has been supported by grants from Fondo Investigación Sanitaria (PI16/02124, PI17/00404, PI19/01206, DTS17/00200, CIBER-CB06/01/0040 and RETIC-RIER-RD16/0012/0002), integrated in the National Plan for Scientific Program, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of Research-European Regional Development Fund (FEDER) “A way of making Europe”. This study has been also supported by grants IN607A2017/11, IN607D2020/10 and AE CICA-INIBIC (ED431E 2018/03) from Xunta de Galicia. The Proteomics Unit of GIR belongs to ProteoRed, PRB3- ISCIII (PT17/0019/0014). L.L. is supported by Xunta de Galicia (IN606B-2016/2005) and Contrato Sara Borrell (CD19/00229) Fondo de Investigación Sanitaria, ISCIII. I.R.P. is supported by Contrato Miguel Servet-II Fondo de Investigación Sanitaria (CPII17/00026). This work was also supported by the KTH Center for Applied Precision Medicine funded by the Ehrling Persson foundation, as well as the Human Protein Atlas project funded by Knut and Alice Wallenberg Foundation, Xunta de Galicia; IN607A2017/11, Xunta de Galicia; IN607D2020/10, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN606B-2016/2005
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

First autochthonous transmission of West Nile virus (WNV) lineage 2 to humans in Spain

  • Lara, Maria
  • Casimiro-Soriguer, Carlos S.
  • Pedrosa-Corral, Irene
  • Gómez-Camarasa, Cristina
  • Lorusso, Nicola
  • Navarro-Marí, José M.
  • Dopazo, Joaquin
  • Perez-Florido, Javier
  • Sanbonmatsu-Gámez, Sara
ata is available in the European Nucleotide Archive (ENA) database under the project identifier PRJEB43037, sample accession ERS22985467, West Nile Virus (WNV) lineage 2, primarily endemic to parts of Africa and Europe, has recently emerged as a public health concern in new geographic regions. In 2024, the first autochthonous human case of neuroinvasive disease caused by WNV lineage 2 was identified in Andalusia, Southern Spain. Molecular testing and whole-genome sequencing confirmed WNV lineage 2 as the causative agent. Phylogenetic analysis revealed a close relationship with strains circulating in Central Europe, distinct from previous WNV lineage 2 detections in Spain. Concurrently, WNV lineage 2 RNA was detected in an imperial eagle near the case location, suggesting local viral circulation. This case marks a significant shift in WNV epidemiology in Spain, where lineage 1 has historically been dominant. The findings underscore the expanding range of WNV lineage 2 and the necessity for enhanced vector surveillance, genomic monitoring, and strengthened One Health strategies to mitigate future outbreaks and protect public health., This research was funded by grants PT17/0009/0006 from the ISCIII, co-funded by the European Regional Development Fund (ERDF) as well as H2020 “ELIXIR-EXCELERATE fast-track ELIXIR implementation and drive early user exploitation across the life sciences” (GA 676559). We thank the Laboratorio Central de Veterinaria, Algete-Madrid for sharing with us the partial sequence of the WNV isolated from an imperial eagle in the same region and date than the virus studied here., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Effectiveness of oral step-down therapy and early oral switch for bloodstream infections caused by Enterobacterales: A post hoc emulation trial of the SIMPLIFY trial

  • Rando, Emanuele
  • Delgado-Valverde, Mercedes
  • Goikoetxea-Aguirre, Josune
  • Guio Carrión, Laura
  • Blanco-Vidal, María José
  • Barrios Andrés, José Luis
  • Pérez-Rodríguez, María Teresa
  • Martínez-Lamas, Lucía
  • Arnaiz de Las Revillas, Francisco
  • Armiñanzas, Carlos
  • Ruiz de Alegría, Carlos
  • Jiménez-Aguilar, Patricia
  • Martínez-Rubio, María del Carmen
  • Sáez-Béjar, Carmen
  • Cuevas, Carmen de las
  • Martín-Aspas, Andrés
  • Galán, Fátima
  • Yuste, José Ramón
  • Leiva-León, José
  • Bou, Germán
  • Capón González, Patricia
  • Boix-Palop, Lucía
  • Xercavins-Valls, Mariona
  • Goenaga Sánchez, Miguel Ángel
  • Anza, Diego Vicente
  • Castón, Juan José
  • Recio Rufián, Manuel
  • Merino, Esperanza
  • Rodríguez, Juan Carlos
  • Loeches, Belén
  • Rosso-Fernández, Clara
  • Bravo-Ferrer, José María
  • Retamar-Gentil, Pilar
  • Rodríguez-Baño, Jesús
  • López-Cortés, Luis Eduardo
[Objectives] We investigated the effectiveness of early oral switch for treating Enterobacterales bloodstream infection (BSI) by performing a post hoc emulation trial of the SIMPLIFY trial., [Methods] We conducted a post hoc analysis of a randomized controlled trial. We specified the target trial characteristics selecting patients who achieved clinical stability on day 5. We categorized patients into those who switched on day 5 and those who continued intravenously. The primary outcome was clinical cure at the test of cure. We set a propensity score for being switched on day 5 to reduce confounding. We ran simple, not-propensity-adjusted, and propensity-adjusted logistic regression models to ascertain the association of switch on day 5 with clinical cure., [Results] Among 303 patients who achieved clinical stability on day 5, 110 (36.3%) were switched orally on day 5, and 193 (63.7%) were kept intravenously. We detected no difference in clinical cure between those switched on day 5 and those continued intravenously (risk ratios 1.04, 95% confidence intervals [CI] 0.98-1.10). Propensity-adjusted analysis did not show an association between day 5 switch and clinical cure (OR 2.10, 95% CI 0.96-7.41)., [Conclusion] Oral step-down therapy on day 5 was not associated with worse clinical cure for Enterobacterales BSI., The study was funded by the Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; 0002; 0003; 0005; 0007; 0008; 0009; 0011; 0012; 0015); Spanish Clinical Research and Clinical Trials Platform, (SCReN, PT13/0002/0010 and PT17/0017/0012, and PI15/00439), co‐financed by European Union; European Development Regional Fund “A way to achieve Europe,” Operative Program Intelligence Growth 2014‐2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Tesis doctoral (DoctoralThesis)

Papel de las cadherinas RGD en metástasis y búsqueda de nuevos biomarcadores pronósticos en cáncer colorrectal

  • Robles Sebastián, Javier
Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Biología. Fecha de Lectura: 21-02-2024, [EN] Cancer is one of the major public health problems worldwide. Specifically, metastasis is responsible for more than 90% of cancer-related deaths. This Doctoral Thesis focused on the study of three types of cancer: colorectal cancer (CRC), ovarian cancer, and kidney cancer. In all of these, metastasis plays a crucial role in the patient's prognosis, as the spread of the primary tumor leads to a drastic decrease in survival. Therefore, it is of vital importance to identify new targets and develop new therapies that can inhibit metastasis. Additionally, in the case of CRC, there is an added difficulty due to its molecular and clinical heterogeneity, which complicates clinical decision-making and the selection of optimal treatment, especially in stages II and III. Hence, there is a need to develop new prognostic tools to assess the risk associated with each tumor for more personalized precision medicine. The objectives of the Doctoral Thesis focused on i) establishing the role of cadherin-6 (CDH6) and cadherin-17 (CDH17) in various tumor metastases, and ii) developing new prognostic tools in CRC. Previous studies on CDH17 in CRC and VE-cadherin in breast cancer and melanoma have shown that cadherins with an RGD motif (RGD cadherins) are potential therapeutic targets useful for exerting an antimetastatic effect due to their association with integrin α2β1. In this Doctoral Thesis, the relevance of CDH6 was first studied in ovarian and kidney cancer, where it is overexpressed. Cell lines with different levels of CDH6 expression and integrins αIIbβ3 and α2β1 were used for this purpose. It was demonstrated that CDH6 can bind and activate both integrins. In αIIbβ3-positive cells, CDH6 preferably binds to this integrin, but in αIIbβ3-negative lines, it can also associate with α2β1. Furthermore, a cross-interaction or crosstalk between both integrins was observed, where the activation of αIIbβ3 is a prerequisite for the activation of α2β1. The interaction of CDH6 with these integrins leads to an increase in prometastatic cellular capabilities such as proliferation, adhesion, migration, and invasion, which can be blocked with monoclonal antibodies or inhibitors of integrin αIIbβ3. On the other hand, the relevance of CDH17 in CRC metastasis was analyzed by stable silencing in the KM12SM and SW620 cell lines. It was demonstrated that the loss of CDH17 expression leads to a decrease in the LGR5 receptor and Wnt/β-catenin pathway activation. This results in a decrease in proliferative capacity and stem cell characteristics in tumor cells. The silencing of CDH17 also caused alterations in the epithelial-mesenchymal transition and the molecular basis of the circadian rhythm. Finally, it was observed that both CDH17 and E-cadherin can translocate to the nucleus. Secondly, to address the issue of CRC heterogeneity, a prognostic signature based on a panel of six biomarkers was developed from a proteomic analysis comparing the secretome of highly and poorly metastatic cell lines. This signature, called SEC6 and composed of the genes BMP1, CD109, IGFBP3, LTBP1, NPC2, and PSAP, proved effective in segregating stage II and III patients into high and low-risk categories. Patients classified as high-risk showed worse prognosis, a higher risk of relapse, and a poorer response to basic chemotherapy. Moreover, SEC6 also showed prognostic potential in other digestive cancers such as stomach, pancreas, and liver cancer. Finally, in collaboration with EMBL-EBI, another approach based on the reuse of proteomic data was conducted. Despite the generation and deposition of a large amount of proteomic data from CRC samples in public repositories over the years, this information has not been as widely used as transcriptomic data. This is mainly due to the difficulty in integrating data and the lower annotation of samples in repositories. In this Doctoral Thesis, a meta-study was conducted, including public datasets containing solid and liquid biopsy samples. This allowed the development of a protein expression map in CRC samples, enabling the comparison of protein expression between healthy tissue and tumor, evaluating its association with prognosis, and examining potential detection in liquid biopsies. This meta-study was applied in the validation and discovery of biomarkers, confirming the potential of SEC6 at the protein level and identifying five new potentially detectable prognostic biomarkers in serum (CD14, MRC2, PPIA, PRDX1, and TXNDC5). In conclusion, this Doctoral Thesis addresses two areas of great interest in cancer research: the inhibition of metastasis and the discovery of new prognostic biomarkers. Regarding metastasis, the potential of CDH6 as an antimetastatic target in ovarian and kidney cancer was demonstrated. Furthermore, the key involvement of CDH17 in hepatic metastasis of CRC was reinforced. In the field of biomarkers, the prognostic signature SEC6 was developed and validated, and a metastudy using proteomic datasets contributed to the discovery and validation of biomarkers, [ES] El cáncer es uno de los mayores problemas de salud pública en el mundo. Concretamente, la metástasis es causante de más del 90% de los fallecimientos debido a cáncer. En esta Tesis Doctoral se estudiaron tres tipos de cáncer: cáncer colorrectal (CCR), cáncer de ovario y cáncer de riñón. En todos ellos, la metástasis juega un papel trascendental en el pronóstico del paciente ya que la diseminación del tumor primario conlleva un descenso drástico de la supervivencia. Eso hace de vital importancia la identificación de nuevas dianas y el desarrollo de nuevas terapias que puedan inhibir la metástasis. Además, en el caso particular de CCR, existe una dificultad añadida debido a su gran heterogeneidad molecular y clínica, que dificulta la toma de decisiones clínicas y la selección del tratamiento óptimo, especialmente en los estadios II y III. Por ello, es necesario desarrollar nuevas herramientas pronósticas que permitan evaluar el riesgo asociado a cada tumor para aplicar una medicina de precisión más personalizada. Los objetivos de la Tesis Doctoral se centraron en i) establecer el papel de cadherina-6 (CDH6) y cadherina-17 (CDH17) en diversas metástasis tumorales y ii) desarrollar nuevas herramientas de pronóstico en CCR. Estudios previos centrados en CDH17 en CCR y en VE-cadherina en cáncer de mama y melanoma han demostrado que las cadherinas que presentan un motivo RGD (cadherinas RGD) son potenciales dianas terapeúticas de utilidad para ejercer un efecto antimetastásico debido a su asociación con la integrina α2β1. En esta Tesis Doctoral se estudió en primer lugar la relevancia de CDH6 en cáncer de ovario y cáncer de riñón, donde se encuentra sobreexpresada. Para ello, se emplearon líneas celulares con distintos niveles de expresión de CDH6 e integrinas αIIbβ3 y α2β1. Se demostró que CDH6 es capaz de unirse y activar ambas integrinas. En las células αIIbβ3 positivas, CDH6 se une preferentemente a esta integrina, pero en líneas αIIbβ3 negativas también puede asociarse con α2β1. Además, se observó una interacción cruzada o crosstalk entre ambas integrinas, de forma que la activación de αIIbβ3 es un prerrequisito para la activación de α2β1. La interacción de CDH6 con estas integrinas provoca un aumento de capacidades celulares prometástasicas como proliferación, adhesión, migración e invasión, las cuales pueden ser bloqueadas con anticuerpos monoclonales o inhibidores de la integrina αIIbβ3. Por otro lado, se analizó la relevancia de CDH17 en la metástasis de CCR mediante el silenciamiento estable en las líneas celulares KM12SM y SW620. Se demostró que la pérdida de expresión de CDH17 provoca un descenso del receptor LGR5 y de la activación de la vía Wnt/βcatenina. Esto desemboca en un descenso de la capacidad proliferativa y de las características de célula madre en las células tumorales. El silenciamiento de CDH17 también provocó una alteración en la transición epitelio-mesénquima y en las bases moleculares del ritmo circadiano. Finalmente, se observó que CDH17, y también E-cadherina, pueden translocarse al núcleo. En segundo lugar, para abordar el problema de la heterogeneidad del CCR, se desarrolló una firma pronóstica basada en un panel de seis biomarcadores identificados a partir de un análisis proteómico en el que se comparó el secretoma de líneas celulares alta y pobremente metastásicas. Esta firma, denominada SEC6 y compuesta por los genes BMP1, CD109, IGFBP3, LTBP1, NPC2 y PSAP, demostró ser efectiva para segregar los pacientes de estadios II y III en alto y bajo riesgo, de forma que los pacientes clasificados como pacientes de alto riesgo mostraron un peor pronóstico, un mayor riesgo de recaída y una peor respuesta a quimioterapia básica. Además, SEC6 también mostró potencial pronóstico en otros cánceres digestivos como cáncer de estómago, de páncreas y de hígado. Por último, en colaboración con el EMBL-EBI, se llevó a cabo otra aproximación basada en la reutilización de datos de proteómica. Aunque a lo largo de los años se han generado y depositado en repositorios públicos una gran cantidad de datos de proteómica obtenidos a partir de muestras de CCR, esta información no ha sido tan utilizada como en el caso de transcriptómica. Esto es principalmente debido a la dificultad en la integración de los datos y a la menor anotación de las muestras en los repositorios. En esta Tesis Doctoral, se realizó un metaestudio incluyendo datasets públicos que contenían muestras de biopsias sólidas y biopsias líquidas. Esto permitió desarrollar un mapa de expresión proteica en muestras de CCR que permite comparar la expresión proteica entre tejido sano y tumor, evaluar la asociación con pronóstico y examinar una potencial detección en biopsias líquidas. Este metaestudio se aplicó en la validación y descubrimiento de biomarcadores, confirmando el potencial de SEC6 a nivel de proteína e identificando cinco nuevos biomarcadores pronósticos potencialmente detectables en suero (CD14, MRC2, PPIA, PRDX1 y TXNDC5). En conclusión, en esta Tesis Doctoral se abordan dos áreas de gran interés en el estudio del cáncer: la inhibición de la metástasis y el descubrimiento de nuevos biomarcadores pronósticos. En lo respectivo a la metástasis, se demostró el potencial de CDH6 como diana antimetastásica en cáncer de ovario y de riñón. Además, se reforzó la evidencia de la implicación clave de CDH17 en metástasis hepática de CCR. En el campo de los biomarcadores, se desarrolló y validó la firma pronóstica SEC6 y se realizó un metaestudio a partir de datasets públicos de proteómica con aplicación en el descubrimiento y validación de biomarcadores., Esta Tesis doctoral fue financiada por los proyectos RTI2018-095055-B-100 y PID2021-122227OB-I00 del MICYT, así como el doctorado industrial IND2019/BMD-17153 de la Comunidad de Madrid y la plataforma PRB3 (ISCIII-SGEFI/FEDER-PT17/0019/0008) del ISCIII., Peer reviewed, Modelo experimental alternativo-NAM, in silico, in vitro - Tipos celulares - líneas inmortalizadas humanas
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

The outer-membrane protein MafA of Neisseria meningitidis constitutes a novel protein secretion pathway specific for the fratricide protein MafB

  • Arenas, J.
  • Catón, L.
  • van den Hoeven, T.
  • de Maat, V.
  • Cruz Herrero, J.
  • Tommassen, J.
MafB proteins are toxins secreted by Neisseria spp. which are involved in interbacterial competition. Their secretion mechanism has so far not been elucidated. Each strain can produce several MafB variants. On the chromosome, the mafB genes are localized on genomic islands also containing mafA genes. MafA proteins have a role in virulence with reported activities in adhesion and transcytosis of pathogenic Neisseria, a priori unrelated to MafB activities. In this study, we investigated the possible involvement of MafA in the transport of MafB across the outer membrane of Neisseria meningitidis. In wild-type strains, proteolytic fragments of MafB proteins were detected in the extracellular medium. In the absence of MafA, secretion was abrogated, and, in the case of MafBI, full-length and truncated polypeptides were detected inside the cells and inside outer-membrane vesicles. MafBI secretion required its cognate MafA, whereas MafBIII could use any MafA. Heterologous expression in Escherichia coli showed that MafBIII is transported to a cell-surface-exposed, i.e. protease-accessible, location in a MafA-dependent way. MafA itself was found to be localized to the outer membrane, forming large oligomeric complexes. As homologs were found in diverse bacteria, the Maf system represents a new protein secretion system in Gram-negative bacteria.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

  • Conde, E.
  • Hernandez, S.
  • Martinez, R.
  • Angulo, B.
  • De Castro, J.
  • Collazo-Lorduy, A.
  • Jimenez, B.
  • Muriel, A.
  • Mate, J.L.
  • Moran, T.
  • Aranda, I.
  • Massuti, B.
  • Rojo, F.
  • Domine, M.
  • Sansano, I.
  • Garcia, F.
  • Felip, E.
  • Mancheño, N.
  • Juan, O.
  • Sanz, J.
  • Gonzalez-Larriba, J.L.
  • Atienza-Cuevas, L.
  • Arriola-Arellano, E.
  • Abdulkader, I.
  • Garcia-Gonzalez, J.
  • Camacho, C.
  • Rodriguez-Abreu, D.
  • Teixido, C.
  • Reguart, N.
  • Gonzalez-Piñeiro, A.
  • Lazaro-Quintela, M.
  • Lozano, M.D.
  • Gurpide, A.
  • Gomez-Roman, J.
  • Lopez-Brea, M.
  • Pijuan, L.
  • Salido, M.
  • Arriola, E.
  • Company, A.
  • Insa, A.
  • Esteban-Rodriguez, I.
  • Saiz, M.
  • Azkona, E.
  • Alvarez, R.
  • Artal, A.
  • Plaza, M.L.
  • Aguiar, D.
  • Enguita, A.B.
  • Benito, A.
  • Paz-Ares, L.
  • Garrido, P.
  • Lopez-Rios, F.
Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. We have evaluated a novel anti-ROS1 IHC antibody (SP384) in a large multicenter series to obtain real-world data. Methods: A total of 43 ROS1 FISH–positive and 193 ROS1 FISH–negative NSCLC samples were studied. All specimens were screened by using two antibodies (clone D4D6 from Cell Signaling Technology and clone SP384 from Ventana Medical Systems), and the different interpretation criteria were compared with break-apart FISH (Vysis). FISH-positive samples were also analyzed with next-generation sequencing (Oncomine Dx Target Test Panel, Thermo Fisher Scientific). Results: An H-score of 150 or higher or the presence of at least 70% of tumor cells with an intensity of staining of 2+ or higher by the SP384 clone was the optimal cutoff value (both with 93% sensitivity and 100% specificity). The D4D6 clone showed similar results, with an H-score of at least 100 (91% sensitivity and 100% specificity). ROS1 expression in normal lung was more frequent with use of the SP384 clone (p < 0.0001). The ezrin gene (EZR)-ROS1 variant was associated with membranous staining and an isolated green signal FISH pattern (p = 0.001 and p = 0.017, respectively). Conclusions: The new SP384 ROS1 IHC clone showed excellent sensitivity without compromising specificity, so it is another excellent analytical option for the proposed testing algorithm.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

ANGPTL3 gene variants in subjects with familial combined hyperlipidemia

  • Bea, A.M.
  • Franco-Marín, E.
  • Marco-Benedí, V.
  • Jarauta, E.
  • Gracia-Rubio, I.
  • Cenarro, A.
  • Civeira, F.
  • Lamiquiz-Moneo, I.
Angiopoietin-like 3 (ANGPTL3) plays an important role in lipid metabolism in humans. Loss-of-function variants in ANGPTL3 cause a monogenic disease named familial combined hypolipidemia. However, the potential contribution of ANGPTL3 gene in subjects with familial combined hyperlipidemia (FCHL) has not been studied. For that reason, the aim of this work was to investigate the potential contribution of ANGPTL3 in the aetiology of FCHL by identifying gain-of-function (GOF) genetic variants in the ANGPTL3 gene in FCHL subjects. ANGPTL3 gene was sequenced in 162 unrelated subjects with severe FCHL and 165 normolipemic controls. Pathogenicity of genetic variants was predicted with PredictSNP2 and FruitFly. Frequency of identified variants in FCHL was compared with that of normolipemic controls and that described in the 1000 Genomes Project. No GOF mutations in ANGPTL3 were present in subjects with FCHL. Four variants were identified in FCHL subjects, showing a different frequency from that observed in normolipemic controls: c.607-109T>C, c.607-47_607-46delGT, c.835+41C>A and c.*52_*60del. This last variant, c.*52_*60del, is a microRNA associated sequence in the 3'UTR of ANGPTL3, and it was present 2.7 times more frequently in normolipemic controls than in FCHL subjects. Our research shows that no GOF mutations in ANGPTL3 were found in a large group of unrelated subjects with FCHL.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Comprehensive and systematic characterization of multi-functionalized cisplatin nano-conjugate: from the chemistry and proteomic biocompatibility to the animal model

  • Hernández, Ángela-Patricia
  • Micaelo, Ania
  • Piñol, Rafael
  • García-Vaquero, Marina L.
  • Aramayona, José J.
  • Criado, Julio J.
  • Rodriguez, Emilio
  • Sánchez-Gallego, José Ignacio
  • Landeira-Viñuela, Alicia
  • Juanes-Velasco, Pablo
  • Díez, Paula
  • Góngora, Rafael
  • Jara-Acevedo, Ricardo
  • Orfao, Alberto
  • Miana-Mena, Javier
  • Muñoz, María Jesús
  • Villanueva, Sergio
  • Millán, Ángel
  • Fuentes, Manuel
Background Nowadays, nanoparticles (NPs) have evolved as multifunctional systems combining different custom anchorages which opens a wide range of applications in biomedical research. Thus, their pharmacological involvements require more comprehensive analysis and novel nanodrugs should be characterized by both chemically and biological point of view. Within the wide variety of biocompatible nanosystems, iron oxide nanoparticles (IONPs) present mostly of the required features which make them suitable for multifunctional NPs with many biopharmaceutical applications. Results Cisplatin-IONPs and different functionalization stages have been broadly evaluated. The potential application of these nanodrugs in onco-therapies has been assessed by studying in vitro biocompatibility (interactions with environment) by proteomics characterization the determination of protein corona in different proximal fluids (human plasma, rabbit plasma and fetal bovine serum),. Moreover, protein labeling and LC–MS/MS analysis provided more than 4000 proteins de novo synthetized as consequence of the nanodrugs presence defending cell signaling in different tumor cell types (data available via ProteomeXchanges with identified PXD026615). Further in vivo studies have provided a more integrative view of the biopharmaceutical perspectives of IONPs. Conclusions Pharmacological proteomic profile different behavior between species and different affinity of protein coating layers (soft and hard corona). Also, intracellular signaling exposed differences between tumor cell lines studied. First approaches in animal model reveal the potential of theses NPs as drug delivery vehicles and confirm cisplatin compounds as strengthened antitumoral agents.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Enhancement of tumor cell immunogenicity and antitumor properties derived from platinum-conjugated iron nanoparticles

  • Hernández, Ángela-Patricia
  • Iglesias-Anciones, Laura
  • Vaquero-González, José Javier
  • Piñol, Rafael
  • Criado, Julio J.
  • Rodriguez, Emilio
  • Juanes-Velasco, Pablo
  • García-Vaquero, Marina L.
  • Arias-Hidalgo, Carlota
  • Orfao, Alberto
  • Millán, Ángel
  • Fuentes, Manuel
From chemistry design to clinical application, several approaches have been developed to overcome platinum drawbacks in antitumoral therapies. An in-depth understanding of intracellular signaling may hold the key to the relationship of both conventional drugs and nanoparticles. Within these strategies, first, nanotechnology has become an essential tool in oncotherapy, improving biopharmaceutical properties and providing new immunomodulatory profiles to conventional drugs mediated by activation of endoplasmic reticulum (ER) stress. Secondly, functional proteomics techniques based on microarrays have proven to be a successful method for high throughput screening of proteins and profiling of biomolecule mechanisms of action. Here, we conducted a systematic characterization of the antitumor profile of a platinum compound conjugated with iron oxide nanoparticles (IONPs). As a result of the nano-conjugation, cytotoxic and proteomics profiles revealed a significant improvement in the antitumor properties of the starting material, providing selectivity in certain tumor cell lines tested. Moreover, cell death patterns associated with immunogenic cell death (ICD) response have also been identified when ER signaling pathways have been triggered. The evaluation in several tumor cell lines and the analysis by functional proteomics techniques have shown novel perspectives on the design of new cisplatin-derived conjugates, the high value of IONPs as drug delivery systems and ICD as a rewarding approach for targeted oncotherapy and onco-immunotherapies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Endoplasmic Reticulum Protein TXNDC5 Interacts with PRDX6 and HSPA9 to Regulate Glutathione Metabolism and Lipid Peroxidation in the Hepatic AML12 Cell Line

  • Bidooki, Seyed Hesamoddin
  • Sánchez-Marco, Javier
  • Martínez-Beamonte, Roberto
  • Herrero-Continente, Tania
  • Navarro, María A.
  • Rodríguez-Yoldi, María J.
  • Osada, Jesús
Non-alcoholic fatty liver disease or steatosis is an accumulation of fat in the liver. Increased amounts of non-esterified fatty acids, calcium deficiency, or insulin resistance may disturb endoplasmic reticulum (ER) homeostasis, which leads to the abnormal accumulation of misfolded proteins, activating the unfolded protein response. The ER is the primary location site for chaperones like thioredoxin domain-containing 5 (TXNDC5). Glutathione participates in cellular oxidative stress, and its interaction with TXNDC5 in the ER may decrease the disulfide bonds of this protein. In addition, glutathione is utilized by glutathione peroxidases to inactivate oxidized lipids. To characterize proteins interacting with TXNDC5, immunoprecipitation and liquid chromatography–mass spectrometry were used. Lipid peroxidation, reduced glutathione, inducible phospholipase A2 (iPLA2) and hepatic transcriptome were assessed in the AML12 and TXNDC5-deficient AML12 cell lines. The results showed that HSPA9 and PRDX6 interact with TXNDC5 in AML12 cells. In addition, TXNDC5 deficiency reduced the protein levels of PRDX6 and HSPA9 in AML12. Moreover, lipid peroxidation, glutathione and iPLA2 activities were significantly decreased in TXNDC5-deficient cells, and to find the cause of the PRDX6 protein reduction, proteasome suppression revealed no considerable effect on it. Finally, hepatic transcripts connected to PRDX6 and HSPA9 indicated an increase in the Dnaja3, Mfn2 and Prdx5 and a decrease in Npm1, Oplah, Gstp3, Gstm6, Gstt1, Serpina1a, Serpina1b, Serpina3m, Hsp90aa1 and Rps14 mRNA levels in AML12 KO cells. In conclusion, the lipid peroxidation system and glutathione mechanism in AML12 cells may be disrupted by the absence of TXNDC5, a novel protein–protein interacting partner of PRDX6 and HSPA9.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

ATAD3C regulates ATAD3A assembly and function in the mitochondrial membrane

  • Gaudó, Paula
  • de Tomás-Mateo, Elena
  • Garrido-Pérez, Nuria
  • Santana, Alfredo
  • Ruiz-Pesini, Eduardo
  • Montoya, Julio
  • Bayona-Bafaluy, Pilar
Mitochondrial ATAD3A is an ATPase Associated with diverse cellular Activities (AAA) domain containing enzyme, involved in the structural organization of the inner mitochondrial membrane and of increasing importance in childhood disease. In humans, two ATAD3A paralogs arose by gene duplication during evolution: ATAD3B and ATAD3C. Here we investigate the cellular activities of the ATAD3C paralog that has been considered a pseudogene. We detected unique ATAD3C peptides in HEK 293T cells, with expression similar to that in human tissues, and showed that it is an integral membrane protein that exposes its carboxy-terminus to the intermembrane space. Overexpression of ATAD3C, but not of ATAD3A, in fibroblasts caused a decrease in cell proliferation and oxygen consumption rate, and an increase of cellular ROS. This was due to the incorporation of ATAD3C monomers in ATAD3A complex in the mitochondrial membrane reducing its size. Consistent with a negative regulation of ATAD3A function in mitochondrial membrane organization, ATAD3C expression led to increased accumulation of respiratory chain dimeric CIII in the inner membrane, to the detriment to that assembled in respiratory supercomplexes. Our results demonstrate a negative dominant role of the ATAD3C paralog with implications for mitochondrial OXPHOS function and suggest that its expression regulates ATAD3A in the cell.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Familial Colorectal Cancer and Genetic Susceptibility: Colorectal Risk Variants in First-Degree Relatives of Patients With Colorectal Cancer

  • Gargallo-Puyuelo, C.J.
  • Lanas, Á.
  • Carrera-Lasfuentes, P.
  • Ferrández, Á.
  • Quintero, E.
  • Carrillo, M.
  • Alonso-Abreu, I.
  • García-González, M.A.
INTRODUCTION: Epidemiological studies estimate that having a first-degree relative (FDR) with colorectal cancer (CRC) increases 2-fold to 3-fold the risk of developing the disease. Because FDRs of CRC patients are more likely to co-inherit CRC risk variants, we aimed to evaluate potential differences in genotype distribution of single nucleotide polymorphisms (SNPs) related to CRC risk between FDRs of patients with nonsyndromic CRC (cases) and individuals with no family history of CRC (controls). METHODS: We designed a case-control study comprising 750 cases and 750 Spanish Caucasian controls matched by sex, age, and histological findings after colonoscopy. Genomic DNA from all participants was genotyped for 88 SNPs associated with CRC risk using the MassArray (Sequenom) platform. RESULTS: Ten of the 88 SNPs analyzed revealed significant associations (P < 0.05) with a family history of CRC in our population. The most robust associations were found for the rs17094983G>A SNP in the long noncoding RNA LINC01500 (odds ratio = 0.72; 95% confidence interval: 0.58-0.88, log-additive model), and the rs11255841T>A SNP in the long noncoding RNA LINC00709 (odds ratio = 2.04; 95% confidence interval: 1.19-3.51, dominant model). Of interest, the observed associations were in the same direction than those reported for CRC risk. DISCUSSION: FDRs of CRC patients show significant differences in genotype distribution of SNPs related to CRC risk as compared to individuals with no family history of CRC. Genotyping of CRC risk variants in FDRs of CRC patients may help to identify subjects at risk that would benefit from stricter surveillance and CRC screening programs.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Antibiotic use and outcome in patients with negative blood cultures, a new target population for antimicrobial stewardship interventions: a prospective multicentre cohort (NO-BACT)

  • Girón Ortega, J.A.
  • Fernández Guerrero, R.
  • Montes de Oca Arjona, M.
  • Sánchez Galán, F.
  • Pellejero Sagastizábal, G.
  • Morte Romea, E.
  • De Cueto, M.
  • Beltrán García, M.
  • Palacios Baena, Z.
  • Jiménez Jorge, S.
  • Rodríguez Baño, J.
  • Retamar Gentil, P.
Objectives: To evaluate the appropriateness of antimicrobial treatment and the risk factors for mortality in patients with negative blood cultures (BC), in order to evaluate whether this population would be a suitable target for antimicrobial stewardship (AMS) interventions. Methods: A multicentre prospective cohort study of patients with negative BC in three Spanish hospitals between October 2018 and July 2019 was performed. The main endpoints were the appropriateness of antimicrobial treatment (evaluated by two investigators according to local guidelines) and 30-day mortality. Cox-regression was performed to estimate the association between variables and 30-day mortality. Results: Of 1011 patients in whom BC was obtained, these were negative in 803 (79%) and were included; 30-day mortality was 9% (70 patients); antibiotic treatment was considered inappropriate in 299 (40%) of 747 patients evaluated at day 2, and in 266 (46%) of 573 at day 5–7. The variables independently associated with increased risk of 30-day mortality were higher age (HR 1.05; 95% CI 1.03–1.07), neoplasia (HR 2.73; 95% CI 1.64–4.56), antibiotic treatment in the 48 h prior to BC extraction (HR 2.06; 95% CI 1.23–3.43) and insufficient antibiotic coverage at day 2 after BC obtainment (HR 2.35; 95% CI 1.39–4.00). Urinary, catheter and biliary sources of infection were associated with lower risk (HR 0.40; 95% CI 0.20–0.81). Conclusions: Antimicrobial treatment is frequently inappropriate among patients with negative BC; insufficient antibiotic coverage at day 2 was associated with mortality. These results suggest that patients with negative BC are a suitable population for AS interventions. Summary: Antimicrobial treatment in patients with negative blood culture was frequently inappropriate, and inappropriate coverage at day 2 was associated with increased risk of death. These data support the consideration of this population as a potential target for antimicrobial stewardship interventions.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Sequencing and functional characterization of SCARB1 variants in subjects with extreme HDL cholesterol levels

  • Gracia-Rubio, Irene
  • Benito-Vicente, Asier
  • Lamiquiz-Moneo, Itziar
  • Bea, Ana María
  • Marco-Benedí, Victoria
  • Cabrera-Antón, Endika
  • Martín, César
  • Civeira, Fernando
  • Cenarro, Ana
BACKGROUND Rare variants in SCARB1, which encodes the high-density lipoprotein (HDL) receptor scavenger receptor class B type 1 (SR-B1), are hypothesized to drive unexplained extreme levels of plasma HDL cholesterol (HDL-C). OBJECTIVE We sequenced and phenotypically correlated SCARB1 by analyzing individuals with extreme HDL-C levels and characterizing the functional consequences of rare identified variants. METHODS SCARB1 was Sanger-sequenced in 96 unrelated participants with extreme HDL-C levels. Clinical, biochemical, and anthropometric data were compared between groups. Bioinformatic tools were used to predict the functional impact of all detected variants. Familial analyses of predicted damaging in silico or not previously described variants was assessed, and HDL uptake was quantified by flow cytometry in HEK293 cells expressing rare SCARB1 variants showing a suggestive pattern of familial segregation. RESULTS Compared with the high-HDL-C group, low-HDL-C subjects exhibited lower low-density lipoprotein cholesterol and total cholesterol but higher triglycerides, higher body mass index, and a greater frequency of atherosclerotic cardiovascular disease events. Twenty-five SCARB1 variants were identified; 4 of them, c.-177G>T, p.(Thr118Ser), c.843-982G>A and p.(Thr378Met), were predicted to be deleterious. The missense changes p.(Thr118Ser) and p.(Thr378Met) showed a suggestive pattern of segregation with high HDL-C in available pedigrees. Cells expressing p.(Thr378Met) SCARB1 variant showed a reduction in HDL uptake vs wild-type. CONCLUSION Rare predicted damaging in silico variant in SCARB1, p.(Thr378Met), impairs SR-B1-mediated HDL uptake and associates with high HDL-C levels, highlighting SCARB1 as a candidate gene for genetic screening in dyslipidemic patients.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Antimicrobial therapy among hospitalized older adults with suspected infection and negative blood cultures

  • Pellejero-Sagastizabal, Galadriel
  • Morte-Romea, Elena
  • Girón Ortega, José Antonio
  • Paño-Pardo, José Ramón
  • Fernández Guerrero, Raquel
  • Guerrero, Francisca
  • Montes de Oca, Montserrat
  • Jiménez-Jorge, Silvia
  • Palacios-Baena, Zaira R.
  • Rodríguez-Baño, Jesús
  • Retamar-Gentil, Pilar
  • Montes de Oca Arjona, Montserrat
  • Galán Sánchez, Fátima
  • Rodríguez Mateos, María Eugenia
  • Girón-González, José Antonio
  • Martín Aspas, Andrés
  • Sánchez Tembleque, Claudio
  • Guerrero Sánchez, Francisca María
  • Morte-Romea, Elena
  • Pellejero-Sagastizabal, Galadriel
  • Luque Gómez, Pilar
  • Paño-Pardo, José Ramón
  • Sierra, José Luis
  • Letona Gimenez, Santiago
  • Palacián, Pilar
  • Rodriguez, Nora Mariela
  • Arenere Mendoza, Mercedes
  • Allende Bandrés, Maria Ángeles
  • Fresquet Molina, Raquel
  • Navarro Pardo, Irene
  • Girón Ortega, José Antonio
  • Fernández Guerero, Raquel
  • Retamar-Gentil, Pilar
  • Palacios-Baena, Zaira
  • de Cueto, Marina
  • Beltrán García, Margarita
  • Cantón Bulnes, María Luisa
  • Suarti, Lorenzo Roberto
  • Rodríguez-Baño, Jesús
Background Managing infections in older adults is challenging due to their unique characteristics, which often drives empirical antimicrobial use, increasing risks of adverse outcomes and antimicrobial resistance (AMR). Data on antimicrobial adequacy in older patients with suspected infection but negative blood cultures (BC) remain scarce, despite this being a common clinical scenario. Methods In this multicenter prospective cohort study (NO-BACT project) across three Spanish hospitals (2018–2019), we compared antimicrobial therapy adequacy between older adults (≥ 85 years) and younger patients with suspected infections and negative BC. Antimicrobial stewardship (AMS) experts evaluated treatment adequacy at days 2 and 5–7 using standardized guideline-based criteria. We assessed predictors of adequacy using logistic regression and examined clinical outcomes including 30-day mortality and length of hospital stay (LOS). Results Among 799 enrolled patients, 90 (11.3%) were older adults. While initial antimicrobial adequacy was comparable between groups at Day 2 (59.8% vs. 60.1%), older adults were significantly less likely to receive adequate treatment by Days 5–7 (adjusted OR 0.46, 95% CI 0.25–0.82, p = 0.009). The main drivers of inadequacy were excess antimicrobial spectrum (84.2%) and inappropriate route of administration (48.7%). Older adults demonstrated higher 30-day mortality (16.7% vs. 7.8%; p = 0.009) despite shorter LOS (8 vs. 10 days, p = 0.006), though treatment adequacy was not associated with mortality. Conclusions In older patients with negative BC, antimicrobial therapy shows high rates of inadequacy that worsen over time, primarily due to delayed de-escalation and prolonged intravenous therapy. These findings identify a clear target for AMS interventions focusing on timely treatment optimization.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Role of POLE and POLD1 in familial cancer

  • Mur, Pilar
  • García-Mulero, Sandra
  • Vidal, August
  • Balmaña Gelpí, Judith
  • Pineda, Marta
  • del Valle, Jesús
  • Magraner-Pardo, Lorena
Domini de l'exonucleasa; Càncer colorectal hereditari; Fenotip ultramutat, Dominio exonucleasa; Cáncer colorrectal hereditario; Fenotipo ultramutado, Exonuclease domain; Hereditary colorectal cancer; Ultramutated phenotype, Purpose Germline pathogenic variants in the exonuclease domain (ED) of polymerases POLE and POLD1 predispose to adenomatous polyps, colorectal cancer (CRC), endometrial tumors, and other malignancies, and exhibit increased mutation rate and highly specific associated mutational signatures. The tumor spectrum and prevalence of POLE and POLD1 variants in hereditary cancer are evaluated in this study. Methods POLE and POLD1 were sequenced in 2813 unrelated probands referred for genetic counseling (2309 hereditary cancer patients subjected to a multigene panel, and 504 patients selected based on phenotypic characteristics). Cosegregation and case–control studies, yeast-based functional assays, and tumor mutational analyses were performed for variant interpretation. Results Twelve ED missense variants, 6 loss-of-function, and 23 outside-ED predicted-deleterious missense variants, all with population allele frequencies <1%, were identified. One ED variant (POLE p.Met294Arg) was classified as likely pathogenic, four as likely benign, and seven as variants of unknown significance. The most commonly associated tumor types were colorectal, endometrial and ovarian cancers. Loss-of-function and outside-ED variants are likely not pathogenic for this syndrome. Conclusions Polymerase proofreading–associated syndrome constitutes 0.1–0.4% of familial cancer cases, reaching 0.3–0.7% when only CRC and polyposis are considered. ED variant interpretation is challenging and should include multiple pieces of evidence., We thank Gemma Aiza, Mireia Menéndez, Sara González, and Xavier Muñoz for support, and Biobanc HUB-ICO-IDIBELL, integrated in the Spanish Platform Biobanks Network and funded by Instituto de Salud Carlos III (PT17/0015/0024) and Xarxa Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya. This work was funded by the Spanish Ministry of Science and Innovation, cofunded by FEDER funds (SAF2016-80888-R, SAF2015-68016-R, Severo Ochoa SVP-2014-068895 contract [L.M.-P.]); Instituto de Salud Carlos III (PI16/00563, PI16/00588, PI14/00613, PI19/00553, CIBERONC CB16/12/00234, CIBERESP, Sara Borrell contract [P.M.]); Government of Catalonia [AGAUR 2017SGR1282, CERCA Program]; and Fundación Olga Torres. This study was facilitated by COST Action CA17118, supported by COST (European Cooperation in Science and Technology).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Differential kinetics of splenic CD169+ macrophage death is one underlying cause of virus infection fate regulation

  • Casella, Valentina
  • Domenjo-Vila, Eva
  • Esteve-Codina, Anna
  • Pedragosa, Mireia
  • Cebollada Rica, Paula
  • Vidal, Enric
  • de la Rubia, Ivan
  • López-Rodríguez, Cristina
  • Bocharov, Gennady
  • Argilaguet, Jordi
  • Meyerhans, Andreas
Acute infection and chronic infection are the two most common fates of pathogenic virus infections. While several factors that contribute to these fates are described, the critical control points and the mechanisms that underlie infection fate regulation are incompletely understood. Using the acute and chronic lymphocytic choriomeningitis virus (LCMV) infection model of mice, we find that the early dynamic pattern of the IFN-I response is a differentiating trait between both infection fates. Acute-infected mice generate a 2-wave IFN-I response while chronic-infected mice generate only a 1-wave response. The underlying cause is a temporal difference in CD8 T cell-mediated killing of splenic marginal zone CD169+ macrophages. It occurs later in acute infection and thus enables CD169+ marginal zone macrophages to produce the 2nd IFN-I wave. This is required for subsequent immune events including induction of inflammatory macrophages, generation of effector CD8+ T cells and virus clearance. Importantly, these benefits come at a cost for the host in the form of spleen fibrosis. Due to an earlier marginal zone destruction, these ordered immune events are deregulated in chronic infection. Our findings demonstrate the critical importance of kinetically wellcoordinated sequential immune events for acute infection control and highlights that it may come at a cost for the host organism., We thank the Flow Cytometry and Genomic Core Facilities (Universitat Pompeu Fabra) and the Advanced Light Microscopy Unit (ALMU-CRG) for excellent technical support, Monica Perez (CReSA-IRTA-UAB) for helping with the histology samples and Hector Huerga Encabo (Immunology Unit, Universitat Pompeu Fabra) for fruitful discussions and ideas. We further thank Dr. Kenji Kohno and Dr. Masato Tanaka for allowing us to use their CD169-DTR transgenic mice which we obtained through Dr. Andres Hidalgo. The graphical abstract was created using BioRender.com platform. This work was supported by grants from the Spanish Ministry of Science and Innovation grant No. PID2019-106323RB-I00 AEI//10.13039/501100011033 and PID2022-141395OB-I00, the “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000792-M), the Russian Science Foundation grant No. 23-11-00116 and the AEC funded by ISCIII /MINECO (PT17/0009/0019) and co-funded by FEDER., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides

  • Gualdrón-López, Melisa
  • Ayllon-Hermida, Alberto
  • Cortes-Serra, Núria
  • Resa-Infante, Patricia
  • Bech-Serra, Joan Josep
  • Aparici-Herraiz, Iris
  • Nicolau-Fernandez, Marc
  • Erkizia, Itziar
  • Gutierrez-Chamorro, Lucia
  • Marfil, Silvia
  • Pradenas, Edwards
  • Ávila Nieto, Carlos
  • Cucurull, Bernat
  • Montaner-Tarbés, Sergio
  • Muelas, Magdalena
  • Sotil, Ruth
  • Ballana, Ester
  • Urrea, Victor
  • Fraile, Lorenzo
  • Montoya, Maria
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Fernandez-Becerra, Carmen
  • de La Torre, Carolina
  • Pinazo, Maria-Jesus
  • Martinez-Picado, Javier
  • del Portillo, Hernando A.
Extracellular vesicles (EVs) released by virus-infected cells have the potential to encapsulate viral peptides, a characteristic that could facilitate vaccine development. Furthermore, plasma-derived EVs may elucidate pathological changes occurring in distal tissues during viral infections. We hypothesized that molecular characterization of EVs isolated from COVID-19 patients would reveal peptides suitable for vaccine development. Blood samples were collected from three cohorts: severe COVID-19 patients (G1), mild/asymptomatic cases (G2), and SARS-CoV-2-negative healthcare workers (G3). Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). Clinical data analysis revealed elevated inflammatory markers in G1. Notably, non-vaccinated individuals in G1 exhibited increased levels of neutralizing antibodies at m8, suggesting prolonged exposure to viral antigens. Proteomic profiling of EVs was performed using three distinct methods: immunocapture (targeting CD9), ganglioside-capture (utilizing Siglec-1) and size-exclusion chromatography (SEC). Contrary to our hypothesis, this analysis failed to identify viral peptides. These findings were subsequently validated through Western blot analysis targeting the RBD of the SARS-CoV-2 Spike protein’s and comparative studies using samples from experimentally infected Syrian hamsters. Furthermore, analysis of the EV cargo revealed a diverse molecular profile, including components involved in the regulation of viral replication, systemic inflammation, antigen presentation, and stress responses. These findings underscore the potential significance of EVs in the pathogenesis and progression of COVID-19., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The proteomics of EVs isolated by CD9 was performed at the proteomics facility of Utrecht (Netherlands) as part of an EPIC-XS grant (0000205) to CT and HP. The proteomics analyses of EVs isolated by SEC were performed in the IJC Proteomic unit, which is part of the of Proteored, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF”. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). We thank Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real time PCR system. JM-P was supported by the Spanish Ministry of Science,Innovation and Universities (grants PID2022-139271OB-I00 and CB21/13/00063, Spain), and Fundació La Marató de TV3 (grant 202120-30-31-32, Spain). Funded in part by the European Union. The PCR-4-ALL and UNDINE projects have received funding under the Horizon Europe research and innovation programme (grant agreement No 101095606 and No 101057100 respectively). CF-B and HP acknowledge support from the Spanish Ministry of Science and Innovation (MICINN) (PID2022- 142908OB-I00) and support from the grant CEX2023-0001290-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. This research is part of the ISGlobal’s Program on the Molecular Mechanisms of Malaria which is partially supported by the Fundación Ramón Areces. We also acknowledged the internal funding from IrsiCaixa through the crowdfunding initiative YoMeCorono (JM-P) and ISGlobal (HP) to initiate these studies., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells

  • Kobayashi-Ishihara, Mie
  • Frazão Smutná, Katarína
  • Alonso, Florencia E.
  • Argilaguet, Jordi
  • Esteve-Codina, Anna
  • Geiger, Kerstin
  • Genescà, Meritxell
  • Grau-Expósito, Judith
  • Duran-Castells, Clara
  • Rogenmoser, Selina
  • Böttcher, René
  • Jungfleisch, Jennifer
  • Oliva, Baldomero
  • Martinez, Javier P.
  • Li, Manqing
  • David, Michael
  • Yamagishi, Makoto
  • Ruiz-Riol, Marta
  • Brander, Christian
  • Tsunetsugu-Yokota, Yasuko
  • Buzon, Maria J.
  • Díez, Juana
  • Meyerhans, Andreas
Latency is a major barrier towards virus elimination in HIV-1-infected individuals. Yet, the mechanisms that contribute to the maintenance of HIV-1 latency are incompletely understood. Here we describe the Schlafen 12 protein (SLFN12) as an HIV-1 restriction factor that establishes a post-transcriptional block in HIV-1-infected cells and thereby inhibits HIV-1 replication and virus reactivation from latently infected cells. The inhibitory activity is dependent on the HIV-1 codon usage and on the SLFN12 RNase active sites. Within HIV-1-infected individuals, SLFN12 expression in PBMCs correlated with HIV-1 plasma viral loads and proviral loads suggesting a link with the general activation of the immune system. Using an RNA FISH-Flow HIV-1 reactivation assay, we demonstrate that SLFN12 expression is enriched in infected cells positive for HIV-1 transcripts but negative for HIV-1 proteins. Thus, codon-usage dependent translation inhibition of HIV-1 proteins participates in HIV-1 latency and can restrict the amount of virus release after latency reversal., We thank Drs Yingying Li, Feng Gao and Beatrice H. Hahn for providing codon-optimized HIV-1 Gag expression vector, Drs James Hoxie and Susan Zolla-Pazner for supplying anti-Nef and -p24 antibodies, respectively through the NIH AIDS reagent program. We also thank Dr Song Gao for providing SLFN13-tRNA structure information, and Dr Maria-Eugenia Gas Lopez and Dr Ester Gea-Mallorquí for advise. This work was supported by following grants: M.K.I., JSPS Oversea Research Fellowship and Takeda Science Foundation; A.E.C., PT17/0009/0019 (ISCIII/MINECO and FEDER); M.J.B., RTI2018-101082-B-I00 and PID2021-123321OB-I00 [MINECO/FEDER]), and the Miguel Servet program by ISCIII (CP17/00179 and CPII22/00005); C.B., M.R.R., C.D.C., European Union’s Horizon 2020 research and innovation program under grant agreement 681137-EAVI2020 and NIH grant P01-AI131568; J.D., the Spanish Ministry of Science and Innovation (PID2019106959RB-I00/AEI/10.13039/501100011033); A.M., the Spanish Ministry of Science and Innovation (PID2019-106323RB-I00 AEI//10.13039/501100011033) and the institutional “María de Maeztu” Programme for Units of Excellence in R&D (CEX2018-000792-M)., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Developmental RNA-Seq transcriptomics of haploid germ cells and spermatozoa uncovers novel pathways associated with teleost spermiogenesis

  • Castro-Arnau, Júlia
  • Chauvigné, François
  • Gómez-Garrido, Jessica
  • Esteve-Codina, Anna
  • Dabad, Marc
  • Alioto, Tyler
  • Finn, Roderick Nigel
  • Cerdà, Joan
In non-mammalian vertebrates, the molecular mechanisms involved in the transformation of haploid germ cells (HGCs) into spermatozoa (spermiogenesis) are largely unknown. Here, we investigated this process in the marine teleost gilthead seabream (Sparus aurata) through the examination of the changes in the transcriptome between cell-sorted HGCs and ejaculated sperm (SPZEJ). Samples were collected under strict quality controls employing immunofluorescence microscopy as well as by determining the sperm motion kinematic parameters by computer-assisted sperm analysis. Deep sequencing by RNA-seq identified a total of 7286 differentially expressed genes (DEGs) (p-value < 0.01) between both cell types, of which nearly half were upregulated in SPZEJ compared to HCGs. In addition, approximately 9000 long non-coding RNAs (lncRNAs) were found, of which 56% were accumulated or emerged de novo in SPZEJ. The upregulated transcripts are involved in transcriptional and translational regulation, chromatin and cytoskeleton organization, metabolic processes such as glycolysis and oxidative phosphorylation, and also include a number of ion and water channels, exchangers, transporters and receptors. Pathway analysis conducted on DEGs identified 37 different signaling pathways enriched in SPZEJ, including 13 receptor pathways, from which the most predominant correspond to the chemokine and cytokine, gonadotropin-releasing hormone receptor and platelet derived growth factor signaling pathways. Our data provide new insight into the mRNA and lncRNA cargos of teleost spermatozoa and uncover the possible involvement of novel endocrine mechanisms during the differentiation and maturation of spermatozoa., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Efficacy of tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial

  • Augustin Recio, Salvador
  • Prió, Alba
  • Sellarès-Nadal, Júlia
  • Espinosa-Pereiro, Juan
  • Burgos, Joaquin
  • Falcó, Vicenç
  • Guillen-Del-Castillo, Alfredo
  • Bañares, Juan
  • Martínez-Valle, Fernando
  • Kirkegaard, Cristina
  • SÁNCHEZ-MONTALVÁ, ADRIÁN
Acute respiratory distress syndrome; COVID-19; Interleukin-6, Síndrome de dificultat respiratòria aguda; COVID-19; Interleucina-6, Síndrome de dificultad respiratoria aguda; COVID-19; Interleucina-6, Background The objective of this clinical trial is to evaluate the efficacy and safety of IL-6 driven personalized treatment strategy with tocilizumab in patients with severe COVID-19 pneumonia. Trial design Randomized, controlled, open-label, single-center trial of a tocilizumab treatment strategy in adult patients hospitalized with severe COVID-19 pneumonia and IL-6 serum levels > 40 pg/mL. Methods Patients were randomized 1:1 to receive standard of care (SOC) or SOC plus one dose of tocilizumab. The primary outcome was death or need for invasive mechanical ventilation (IMV) within 28 days after randomization. Secondary outcomes included ICU admission, days on IMV and hospital stay. A meta-analysis of clinical trials to evaluate the effect of tocilizumab on mortality and need of IMV in patients with COVID-19 pneumonia was performed. Results Sixty-two patients were included: 30 in the SOC arm and 32 in the standard-treatment plus tocilizumab arm. The primary outcome occurred in 12.9% in the tocilizumab arm and 32.3% in the SOC arm(p = 0.068). There was a trend towards fewer days on IMV (7.5 vs 19.5 days, p = 0.073) and a shorter hospital stay (4 vs 8 days, p = 0.134) in the tocilizumab group. No serious adverse events were reported. The meta-analysis revealed a RR for death or IMV of 0.83 (95% CI: 0.77–0.89) in patients receiving tocilizumab, compared to patients receiving SOC. Conclusion Tocilizumab could be effective to prevent death or IMV in patients with severe COVID-19 pneumonia and high IL-6 serum levels. Safety profile of tocilizumab does not arise major concern in patients with severe COVID19., Open Access Funding provided by Universitat Autonoma de Barcelona. This study received support of “Plataforma ISCIII de Soporte para la Investigación Clínica—SCReN (Spanish Clinical Research Network)” which is funded by ISCIII through the project sPT17/0017/0030 and PT20/00078, which are both integrated in the “Plan Estatal de I + D + I 2013–2016 y 2017–2020” and co-funded by the “ Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa””. ASM was supported by the Instituto de Salud Carlos III (Juan Rodés postdoctoral fellowship grant number JR18/00022) during the study period. JSN and JEP are supported by the Instituto de Salud Carlos III (Rio Hortega predoctoral grant numbers CM22/00262 and CM22/00246).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation

  • Calvo Lozano, Olalla
  • Sierra Montoya, Miquel
  • Soler, Maria
  • Estevez, M. Carmen
  • Chiscano Camon, Luis Silvestre
  • Ruiz Sanmartin, Adolfo
  • Ruiz Rodriguez, Juan Carlos
  • Ferrer Roca, Ricard
  • Gonzalez Lopez, Juan Jose
  • Esperalba Esquerra, Juliana
  • Fernandez Naval, Candela
COVID-19; Biosensor plasmónico; Serología, COVID-19; Biosensor plasmònic; Serologia, COVID-19; Plasmonic biosensor; Serology, Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL–1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment., ICN2 and UVE acknowledge financial support from H2020 Research and Innovation Programme of the European Commission (H202-SC1-PHE-Coronavirus-2020, CONVAT Project, No. 101003544). The ICN2 is funded by the CERCA program/Generalitat de Catalunya and supported by the Severo Ochoa Centres of Excellence program funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). ICN2 group is very grateful to EPI Industries (Barcelona, Spain) for its kind donation supporting our research in COVID-19. O.C.-L. acknowledges the economic support from the Spanish Ministry of Science and Innovation and the Spanish Research Agency and the European Social Fund (ESF) (ref. BES-2017-080527) linked to the TEC 2016-78515-R project Predict. A part of the work was supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the EU Horizon 2020 (grant agreement No. 871029). A.T. and L.F.-B. acknowledge financial support from GENCAT-DGRIS COVID. We are indebted to all the patients who accepted to participate contributing to science advancement. We are indebted to the HCB-IDIBAPS Biobank for the human samples and data procurement and to the Fundació Glòria Soler for its support to the COVIDBANK collection. We thank the IDIBAPS Biobank for its valuable contribution to sample processing and storage. The authors acknowledge the EU Horizon 2020 Program under grant agreement no. 644956 (RAIS project) for funding the Hospital Vall d’Hebron Biobank. The VHIR-HUVH is supported by Plan Nacional de I + D + i 2013-2016 and ISCIII-Ministerio de Ciencia e Innovación, and Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003)─cofinanced by European Development Regional Fund “A way to achieve Europe,” Operative program Intelligent Growth 2014. Part of the samples and data from patients included in this study were provided by the Vall d’Hebron University Hospital Biobank (PT17/0015/0047), integrated in the Spanish National Biobanks Network, and they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. The authors kindly appreciate the generous donation of samples and clinical data of the donors of the Sepsis Bank of HUVH Biobank and COVID-19 patients attended at HUVH.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Sex and gender differences and biases in artificial intelligence for biomedicine and healthcare

  • Cirillo, Davide
  • Catuara Solarz, Silvina
  • Morey, Czuee
  • Guney, Emre
  • Subirats, Laia
  • Mellino, Simona
  • Gigante, Annalisa
  • Valencia, Alfonso
  • Rementeria, María José
  • Santuccione Chadha, Antonella
  • Mavridis, Nikolaos
Precision Medicine implies a deep understanding of inter-individual differences in health and disease that are due to genetic and environmental factors. To acquire such understanding there is a need for the implementation of different types of technologies based on artificial intelligence (AI) that enable the identification of biomedically relevant patterns, facilitating progress towards individually tailored preventative and therapeutic interventions. Despite the significant scientific advances achieved so far, most of the currently used biomedical AI technologies do not account for bias detection. Furthermore, the design of the majority of algorithms ignore the sex and gender dimension and its contribution to health and disease differences among individuals. Failure in accounting for these differences will generate sub-optimal results and produce mistakes as well as discriminatory outcomes. In this review we examine the current sex and gender gaps in a subset of biomedical technologies used in relation to Precision Medicine. In addition, we provide recommendations to optimize their utilization to improve the global health and disease landscape and decrease inequalities., This work is written on behalf of the Women’s Brain Project (WBP) (www.womensbrainproject.com/), an international organization advocating for women’s brain and mental health through scientific research, debate and public engagement. The authors would like to gratefully acknowledge Maria Teresa Ferretti and Nicoletta Iacobacci (WBP) for the scientific advice and insightful discussions; Roberto Confalonieri (Alpha Health) for reviewing the manuscript; the Bioinfo4Women programme of Barcelona Supercomputing Center (BSC) for the support. This work has been supported by the Spanish Government (SEV 2015–0493) and grant PT17/0009/0001, of the Acción Estratégica en Salud 2013–2016 of the Programa Estatal de Investigación Orientada a los Retos de la Sociedad, funded by the Instituto de Salud Carlos III (ISCIII) and European Regional Development Fund (ERDF). EG has received funding from the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement No 116030 (TransQST), which is supported by the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA)., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Effect of Probiotics on Preterm Birth Rates in Pregnant Women After a Threatened Preterm Birth Episode (The PROPEV Trial)

  • Miserachs Sala, Marta
  • Puerto Tamayo , Linda Grace
  • Garrido-Giménez, Carmen
  • Soler, Zaida
  • Dalmau Artal, Marta
  • Casellas de Miguel, Alba
  • Carreras, Elena
  • Goya, Maria
  • del Barco Martínez, Ester
  • González Molano, Leidy Alejandra
  • VARGAS BUJÁN, MIREIA
  • Chaysavanh, Manichanh
Microbiota; Preterm birth; Probiotics, Microbiota; Parto prematuro; Probióticos, Microbiota; Part prematur; Probiòtics, Introduction: Preterm birth is the leading cause of perinatal mortality worldwide, with prevalence rates showing little reduction. Although mortality rates have decreased, morbidity rates remain concerningly high. In recent years, there has been a surge in studies examining the etiology, risk factors, and management of preterm birth. The use of vaginal probiotics in pregnant women at risk of preterm birth has garnered attention as a potential approach for improving perinatal outcomes and modulating the vaginal microbiota. However, the efficacy of this intervention remains unclear. Therefore, this study explored the impact of vaginal probiotics on perinatal outcomes and vaginal microbiota composition in pregnant women at risk of preterm birth. Materials and Methods: This was a randomized, prospective, longitudinal, double-blind, placebo-controlled, multicentric trial conducted across seven maternities in Spain from October 2017 to August 2022 in pregnant women at risk of preterm birth. Participants were randomly assigned to receive vaginal probiotics containing four lactobacilli strains or a placebo. The primary outcome was to explore a potential correlation between probiotic use among pregnant women at risk of preterm birth and the actual rate of preterm birth before 37 gestational weeks. Secondary outcomes included an evaluation of preterm birth rates, neonatal morbidity, the vaginal microbiota, and changes in the vaginal microbiota after receiving probiotics. Other secondary outcomes were identifying vaginal microbiota patterns associated with preterm birth and exploring potential therapeutic mechanisms involving probiotics. Trial registration: Clinicaltrials.gov, identifier: NCT03689166. Results: A total of 200 participants were included. Of those, birth data were obtained for 181 women. Demographics were similar between both groups. An analysis of perinatal outcomes found no significant differences in preterm birth rates, prematurity rates, gestational weeks at delivery, neonatal complications, time to birth, or latency time to delivery. Microbiota analysis showed no significant differences in vaginal microbiota changes between groups. No serious or unexpected adverse reactions were reported. Conclusions: There were no statistically significant differences for spontaneous preterm birth between pregnant women receiving probiotics and pregnant women receiving the placebo., This work was supported by the Spanish Clinical Research Network (SCReN), which is funded by the ISCIII-General Subdirectorate for Evaluation and Promotion of Research through projects PT17/0017/0030 and PT20/00078. Both projects were integrated into the 2013–2016 National Plan for Scientific and Technical Research and Innovation and co-financed by the European Regional Development Fund (ERDF), “A way of making Europe”. This work was also supported by Project FIS PI 19/00287 (Maria Goya as a principal investigator), which was funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. Laboratorios Ordesa S.L funded the PROPEV study. L.-A.G.M. was supported by Instituto de Salud Carlos III/FEDER (PI20/00130).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Global analysis of the association between pig muscle fatty acid composition and gene expression using RNA-Seq

  • Valdés-Hernández, Jesús
  • Ramayo-Caldas, Yuliaxis
  • Passols, Magí
  • Sebastià, Cristina
  • Criado-Mesas, Lourdes
  • Crespo-Piazuelo, Daniel
  • Esteve-Codina, Anna
  • Castelló, Anna
  • Sánchez, Armand
  • Folch, Josep M.
Fatty acids (FAs) play an essential role as mediators of cell signaling and signal transduction, affecting metabolic homeostasis and determining meat quality in pigs. However, FAs are transformed by the action of several genes, such as those encoding desaturases and elongases of FAs in lipogenic tissues. The aim of the current work was to identify candidate genes, biological processes, and pathways involved in the modulation of intramuscular FA profile from longissimus dorsi muscle. FA profile by gas chromatography of methyl esters and gene expression by RNA-Seq were determined in 129 Iberian × Duroc backcrossed pigs. An association analysis between the muscle transcriptome and its FA profile was performed, followed by a concordance and functional analysis. Overall, a list of well-known (e.g., PLIN1, LEP, ELOVL6, SC5D, NCOA2, ACSL1, MDH1, LPL, LGALS12, TFRC, GOT1, and FBP1) and novel (e.g., TRARG1, TANK, ENSSSCG00000011196, and ENSSSCG00000038429) candidate genes was identified, either in association with specific or several FA traits. Likewise, several of these genes belong to biological processes and pathways linked to energy, lipid, and carbohydrate metabolism, which seem determinants in the modulation of FA compositions. This study can contribute to elucidate the complex relationship between gene expression and FA profile in pig muscle., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cross-protection against African swine fever virus upon intranasal vaccination is associated with an adaptive-innate immune crosstalk

  • Bosch Camós, Laia
  • Alonso, Uxía
  • Esteve-Codina, Anna
  • Chang, Chia-Yu
  • Martín-Mur, Beatriz
  • Accensi, Francesc
  • Muñoz, Marta
  • Navas, María J.
  • Dabad, Marc
  • Vidal, Enric
  • Pina-Pedrero, Sonia
  • Pleguezuelos, Patricia
  • Caratù, Ginevra
  • Salas, María L.
  • Liu, Lihong
  • Bataklieva, Stanimira
  • Gavrilov, Boris
  • Rodriguez, Fernando
  • Argilaguet, Jordi
African swine fever virus (ASFV) is causing a worldwide pandemic affecting the porcine industry and leading to important global economic consequences. The virus causes a highly lethal hemorrhagic disease in wild boars and domestic pigs. Lack of effective vaccines hampers the control of virus spread, thus increasing the pressure on the scientific community for urgent solutions. However, knowledge on the immune components associated with protection is very limited. Here we characterized the in vitro recall response induced by immune cells from pigs intranasally vaccinated with the BA71ΔCD2 deletion mutant virus. Vaccination conferred dose-dependent cross-protection associated with both ASFV-specific antibodies and IFNγ-secreting cells. Importantly, bulk and single-cell transcriptomics of blood and lymph node cells from vaccinated pigs revealed a positive feedback from adaptive to innate immunity. Indeed, activation of Th1 and cytotoxic T cells was concomitant with a rapid IFNγ-dependent triggering of an inflammatory response characterized by TNF-producing macrophages, as well as CXCL10-expressing lymphocytes and cross-presenting dendritic cells. Altogether, this study provides a detailed phenotypic characterization of the immune cell subsets involved in cross-protection against ASFV, and highlights key functional immune mechanisms to be considered for the development of an effective ASF vaccine., info:eu-repo/semantics/publishedVersion
Docta Complutense
Publication Artículo científico (JournalArticle)

Candida albicans Hyphal Extracellular Vesicles Are Different from Yeast Ones, Carrying an Active Proteasome Complex and Showing a Different Role in Host Immune Response

  • Gil, Concha
  • Monteoliva Díaz, Lucía
  • Guillermo Calvo
  • Esther redondo
  • Mercedes Pardo
  • Maria Luisa Hernéz
Candida albicans is the principal causative agent of lethal fungal infections, predominantly in immunocompromised hosts. Extracellular vesicles (EVs) have been described as crucial in the interaction of microorganisms with their host. Since the yeast-to-hypha transition is an important virulence trait with great impact in invasive candidiasis (IC), we have addressed the characterization of EVs secreted by hyphal cells (HEVs) from C. albicans, comparing them to yeast EVs (YEVs). YEVs comprised a larger population of bigger EVs with mainly cell wall proteins, while HEVs were smaller, in general, and had a much higher protein diversity. YEVs were able to rescue the sensitivity of a cell wall mutant against calcofluor white, presumably due to the larger amount of cell wall proteins they contained. On the other hand, HEVs also contained many cytoplasmic proteins related to protein metabolism and intracellular protein transport and the endosomal sorting complexes required for transport (ESCRT) pathway related to exosome biogenesis, pointing to an intracellular origin of HEVs. Interestingly, an active 20S proteasome complex was secreted exclusively in HEVs. Moreover, HEVs contained a greater number of virulence-related proteins. As for their immunogenic role, both types of EV presented immune reactivity with human sera from patients suffering invasive candidiasis; however, under our conditions, only HEVs showed a cytotoxic effect on human macrophages and could elicit the release of tumor necrosis factor alpha (TNF-α) by these macrophages. IMPORTANCE This first analysis of HEVs of C. albicans has shown clear differences between them and the YEVs of C. albicans, showing their relevance and possible use in the discovery of new diagnostic markers and treatment targets against C. albicans infections. The data obtained point to different mechanisms of biogenesis of YEVs and HEVs, as well as different involvements in cell biology and host interaction. YEVs played a more relevant role in cell wall maintenance, while HEVs were more closely related to virulence, as they had greater effects on human immune cells. Importantly, an active 20S proteosome complex was described as a fungal-EV cargo. A deeper study of its role and those of many other proteins exclusively detected in HEVs and involved in different relevant biological processes of this fungus could open up interesting new areas of research in the battle against C. albicans.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effectiveness of antitussives, anticholinergics or honey versus usual care in adults with uncomplicated acute bronchitis, a study protocol of an open randomised clinical trial in primary care

  • Cots, Josep María
  • Moragas, Ana
  • García Sangenís, Ana|||0000-0002-6689-6466
  • Morros, Rosa|||0000-0001-6752-8748
  • Gomez-Lumbreras, Ainhoa|||0000-0002-3916-0402
  • Ouchi, Dan|||0000-0002-8630-152X
  • Monfà, Ramon|||0000-0002-1324-3971
  • Pera, Helena|||0000-0003-3593-819X
  • Pujol Nuez, Jesús|||0000-0002-9946-4547
  • Bayona, Carolina
  • Poza Abad, Mariam de la|||0000-0001-5993-1596
  • Llor, Carl|||0000-0001-6644-717X
Introduction Despite the frequent use of therapies in acute bronchitis, the evidence of their benefit is lacking, since only a few clinical trials have been published, with low sample sizes, poor methodological quality and mainly in children. The objective of this study is to compare the effectiveness of three symptomatic therapies (dextromethorphan, ipratropium or honey) associated with usual care and the usual care in adults with acute bronchitis. Methods and analysis This will be a multicentre, pragmatic, parallel group, open randomised trial. Patients aged 18 or over with uncomplicated acute bronchitis, with cough for less than 3 weeks as the main symptom, scoring ≥4 in either daytime or nocturnal cough on a 7-point Likert scale, will be randomised to one of the following four groups: usual care, dextromethorphan 30 mg three times a day, ipratropium bromide inhaler 20 μg two puffs three times a day or honey 30 mg (a spoonful) three times a day, all taken for up to 14 days. The exclusion criteria will be pneumonia, criteria for hospital admission, pregnancy or lactation, concomitant pulmonary disease, associated significant comorbidity, allergy, intolerance or contraindication to any of the study drugs or admitted to a long-term residence. Sample: 668 patients. The primary outcome will be the number of days with moderate-to-severe cough. All patients will be given a paper-based symptom diary to be self-administered. A second visit will be scheduled at day 2 or 3 for assessing evolution, with two more visits at days 15 and 29 for clinical assessment, evaluation of adverse effects, re-attendance and complications. Patients still with symptoms at day 29 will be called 6 weeks after the baseline visit. Ethics and dissemination The study has been approved by the Ethical Board of IDIAP Jordi Gol (reference number: AC18/002). The findings of this trial will be disseminated through research conferences and peer-review journals. Trial registration number NCT03738917; Pre-results.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY), An open-label, randomised, non-inferiority clinical trial

  • Páez-Vega, Aurora
  • Cantisan, Sara
  • Vaquero, José Manuel|||0000-0002-3923-3245
  • Vidal, Elisa
  • Luque-Pineda, Antonio
  • Lobo-Acosta, María Ángeles|||0000-0002-8587-7201
  • Pérez, Ana Belén|||0000-0001-9655-817X
  • Alonso-Moralejo, Rodrigo|||0000-0002-7833-5084
  • Iturbe, David|||0000-0002-5241-266X
  • Monforte, Víctor|||0000-0002-2918-7679
  • Otero-González, Isabel|||0000-0003-4718-7477
  • Pastor, Amparo
  • Ussetti, Piedad|||0000-0002-3439-5536
  • Torre-Cisneros, J.|||0000-0003-1529-6302
Introduction Prolonged use of antivirals to prevent the development of cytomegalovirus (CMV) disease in lung transplant patients has been shown to have significant side effects, for which alternatives are being sought to reduce their use. The monitoring of cell immunity against CMV could be an alternative as it has shown to be useful in identifying transplant patients at low risk of infection, who could benefit from shorter prophylaxis. The aim of the CYTOCOR study is to demonstrate that the combination of a reduced prophylaxis strategy with subsequent CMV-specific immunological monitoring would allow CMV infection to be controlled in lung transplant patients as effectively as the usual strategy (prophylaxis followed by pre-emptive therapy), while reducing the side effects of antivirals due to the shorter duration of prophylaxis. Methods and analysis Phase III randomised, open, multicentre, parallel, non-inferiority clinical trial to study the efficacy and safety of the combination of a prophylaxis strategy up to month +3 post-transplant followed by immuno-guided prophylaxis using the QuantiFERON-CMV technique up to month +12 post-transplant to prevent CMV disease in CMV-seropositive lung transplant recipients. This strategy will be compared with a combination of a usual prophylaxis strategy up to month +6 post-transplant followed by pre-emptive therapy up to month +12. To study the incidence of CMV disease, patients will be followed up to 18 months post-transplantation. A total of 150 patients are expected to be recruited for the study. Ethics and public dissemination The clinical trial has been approved by the Research Ethics Committees and authorised by the Spanish Agency of Medicines and Medical Devices (AEMPS). If the hypothesis of this clinical trial is verified, the dissemination of the results could change clinical practice by increasing knowledge about the safety and efficacy of discontinuing valganciclovir prophylaxis in lung transplant recipients. Trial registration number NCT03699254.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer's disease cerebrospinal fluid

  • Lleó, Alberto|||0000-0002-2568-5478
  • Núñez-Llaves, Raúl|||0000-0002-6702-4774
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Chiva, Cristina
  • Balateu Paños, Daniel
  • Colom-Cadena, Martí|||0000-0002-8514-4534
  • Gómez, Gemma
  • Muñoz, Laia|||0000-0003-0578-3094
  • Querol-Vilaseca, Marta|||0000-0002-8589-1636
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Tainta, Mikel|||0000-0003-0624-1211
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Spires Jones, Tara
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • Martínez Lage, Pablo
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Bayés, Àlex|||0000-0002-5265-6306
  • Belbin, Olivia|||0000-0002-6109-6371
A biomarker of synapse loss, an early event in Alzheimer's disease (AD) pathophysiology that precedes neuronal death and symptom onset, would be a much-needed prognostic biomarker. With direct access to the brain interstitial fluid, the cerebrospinal fluid (CSF) is a potential source of synapse-derived proteins. In this study, we aimed to identify and validate novel CSF biomarkers of synapse loss in AD. Discovery: Combining shotgun proteomics of the CSF with an exhaustive search of the literature and public databases, we identified 251 synaptic proteins, from which we selected 22 for further study. Verification: Twelve proteins were discarded because of poor detection by Selected Reaction Monitoring (SRM). We confirmed the specific expression of 9 of the remaining proteins (Calsyntenin-1, GluR2, GluR4, Neurexin-2A, Neurexin-3A, Neuroligin-2, Syntaxin-1B, Thy-1, Vamp-2) at the human synapse using Array Tomography microscopy and biochemical fractionation methods. Exploration: Using SRM, we monitored these 9 synaptic proteins (20 peptides) in a cohort of CSF from cognitively normal controls and subjects in the pre-clinical and clinical AD stages (n 80). Compared with controls, peptides from 8 proteins were elevated 1.3 to 1.6-fold (p < 0.04) in prodromal AD patients. Validation: Elevated levels of a GluR4 peptide at the prodromal stage were replicated (1.3-fold, p 0.04) in an independent cohort (n 60). Moreover, 7 proteins were reduced at preclinical stage 1 (0.6 to 0.8-fold, p < 0.04), a finding that was replicated (0.7 to 0.8-fold, p < 0.05) for 6 proteins in a third cohort (n 38). In a cross-cohort meta-analysis, 6 synaptic proteins (Calsyn-tenin-1, GluR4, Neurexin-2A, Neurexin-3A, Syntaxin-1B and Thy-1) were reduced 0.8-fold (p < 0.05) in preclinical AD, changes that precede clinical symptoms and CSF markers of neurodegeneration. Therefore, these proteins could have clinical value for assessing disease progression, especially in preclinical stages of AD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015

  • Jiménez De Ory, S.
  • Ramos Amador, José Tomás
  • Fortuny Guasch, Claudia
  • González-Tomé, María Isabel
  • Mellado Peña, María José|||0000-0003-2251-9666
  • Moreno Pérez, David|||0000-0002-7017-4095
  • Gavilán, C.
  • Menasalvas, A. I.
  • Piqueras, Ana Isabel
  • Frick, Marie Antoinette|||0000-0002-2553-5090
  • Muñoz-Fernández, M. A.
  • Navarro, Maria Luisa
Background There are not enough nationwide studies on perinatal HIV transmission in connection with a combination of antiretroviral treatments in Spain. Our objectives were to study sociodemographic changes and trends in the rates of HIV diagnoses and perinatal transmission in Spain from 1997 to 2015. Methods A retrospective study using data from Spanish Paediatric HIV Network (CoRISpe) and Spanish Minimum Basic Data Set (MDBS) was performed. HIV- diagnosed children between 1997 and 2015 were selected. Sociodemographic, clinical and immunovirological data of HIV-infected children and their mothers were studied in four calendar periods (P1: 1997-2000; P2: 2001-2005; P3: 2006-2010; P4: 2011-2015). Rates of perinatal HIV diagnoses and transmission from 1997 to 2015 were calculated. Results A total of 532 HIV-infected children were included in this study. Of these children, 406 were Spanish (76.3%) and 126 immigrants (23.7%). A decrease in the number of HIV diagnoses, 203 (38.2%) children in the first (P1), 149 (28%) in the second (P2), 130 (24.4%) in the third (P3) and 50 (9.4%) in the fourth (P4) calendar periods was studied. The same decrease in the Spanish HIV-infected children (P1, 174 (46.6%), P2, 115 (30.8%), P3, 65 (17.4%) and P4, 19 (5.1%)) was monitored. However, an increase in the number of HIV diagnoses by sexual contact (P1: 0%; P2: 1.3%; P3: 4.6%; P4: 16%) was observed. The rates of new perinatal HIV diagnoses and perinatal transmission in Spanish children decreased from 0.167 to 0.005 per 100,000 inhabitants and 11.4% to 0.4% between 1997 and 2015, respectively. Conclusions A decline of perinatal HIV diagnoses and transmission was observed. However, an increase of teen-agers HIV diagnoses with sexual infection was studied. Public awareness campaigns directed to teen-agers are advisable to prevent HIV infection by sexual contact.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma, the ROSING Study

  • Conde, Esther
  • Hernández, Susana
  • Martinez, Rebeca
  • Angulo, Bárbara
  • Castro, Javier de|||0000-0002-3622-6306
  • Collazo-Lorduy, Ana
  • Jiménez-Munarriz, Beatriz Carolina
  • Muriel, Alfonso|||0000-0002-4805-4011
  • Mate Sanz, Jose Luís|||0000-0002-4829-3426
  • Morán, Teresa
  • Aranda, Ignacio
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • Rojo, Federico|||0000-0001-9989-0290
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Sansano, Irene|||0000-0003-0188-5210
  • Garcia, Felip
  • Felip, Enriqueta|||0000-0002-7620-0098
  • Mancheño, Nuria
  • Juan, Óscar|||0000-0002-7772-9030
  • Sanz, Julián
  • González Larriba, José Luis|||0000-0003-2631-0309
  • Atienza-Cuevas, Lidia
  • Arriola-Arellano, Esperanza
  • Abdulkader, Ihab
  • Garcia-Gonzalez, Jorge
  • Camacho, Carmen
  • Rodríguez-Abreu, Delvys|||0000-0003-0506-1366
  • Teixidó, Cristina|||0000-0002-7226-6567
  • Reguart, Noemi|||0000-0001-8190-499X
  • Gonzalez-Piñeiro, Ana
  • Lázaro, Martín|||0000-0002-0657-4713
  • Lozano, María Dolores
  • Gurpide, Alfonso
  • Gómez-Román, Javier
  • Lopez-Brea, M.
  • Pijuan, Lara|||0000-0002-9978-6933
  • Salido, Marta|||0000-0001-9988-5977
  • Arriola, Edurne|||0000-0001-8960-7519
  • Company, Amparo
  • Insa, Amelia|||0000-0002-3438-6170
  • Esteban Rodríguez, Isabel|||0000-0003-1576-7215
  • Saiz, Mónica
  • Azkona, Eider
  • Álvarez, Ramiro|||0000-0002-8053-7232
  • Artal, Ángel
  • Plaza, María Luz
  • Aguiar de Sousa, Diana|||0000-0002-6702-7924
  • Enguita, Ana Belén
  • Benito, Amparo
  • Paz-Ares, Luis|||0000-0002-3327-3246
  • Garrido, Pilar|||0000-0002-5899-6125
  • Lopez-Rios, Fernando
Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. We have evaluated a novel anti-ROS1 IHC antibody (SP384) in a large multicenter series to obtain real-world data. Methods: A total of 43 ROS1 FISH-positive and 193 ROS1 FISH-negative NSCLC samples were studied. All specimens were screened by using two antibodies (clone D4D6 from Cell Signaling Technology and clone SP384 from Ventana Medical Systems), and the different interpretation criteria were compared with break-apart FISH (Vysis). FISH-positive samples were also analyzed with next-generation sequencing (Oncomine Dx Target Test Panel, Thermo Fisher Scientific). Results: An H-score of 150 or higher or the presence of at least 70% of tumor cells with an intensity of staining of 2+ or higher by the SP384 clone was the optimal cutoff value (both with 93% sensitivity and 100% specificity). The D4D6 clone showed similar results, with an H-score of at least 100 (91% sensitivity and 100% specificity). ROS1 expression in normal lung was more frequent with use of the SP384 clone (p < 0.0001). The ezrin gene (EZR)-ROS1 variant was associated with membranous staining and an isolated green signal FISH pattern (p = 0.001 and p = 0.017, respectively). Conclusions: The new SP384 ROS1 IHC clone showed excellent sensitivity without compromising specificity, so it is another excellent analytical option for the proposed testing algorithm.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increased plasma levels of galectin-1 in pancreatic cancer, potential use as biomarker

  • Martínez Bosch, Neus|||0000-0003-3596-0039
  • Barranco, Luis E.
  • Orozco, Carlos A.
  • Moreno Martínez-Losa, Mireia|||0000-0002-4365-4341
  • Visa, Laura|||0000-0002-3409-8857
  • Iglesias, Mar|||0000-0002-2274-4671
  • Oldfield, Lucy
  • Neoptolemos, John P.|||0000-0002-6201-7399
  • Greenhalf, William
  • Earl, Julie
  • Carrato, Alfredo|||0000-0001-7749-8140
  • Costello, Eithne
  • Navarro, Pilar|||0000-0003-4314-4584
Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that currently improves prognosis. Here we analyzed whether the detection of circulating galectin-1 (Gal-1), a soluble carbohydrate-binding protein overexpressed in PDA tissue samples, can be used as a biomarker for PDA. Gal-1 levels were determined by ELISA in plasma from healthy controls and patients diagnosed with PDA, using three independent cohorts. Patients with chronic pancreatitis (CP) were also included in the study to analyze the potential of Gal-1 to discriminate between cancer and inflammatory process. Plasma Gal-1 levels were significantly increased in patients with PDA as compared to controls in all three cohorts. Gal-1 sensitivity and specificity values were similar to that of the CA19-9 biomarker (the only FDA-approved blood test biomarker for PDA), and the combination of Gal-1 and CA19-9 significantly improved their individual discriminatory powers. Moreover, high levels of Gal-1 were associated with lower survival in patients with non-resected tumors. Collectively, our data indicate a strong potential of using circulating Gal-1 levels as a biomarker for detection and prognostics of patients with PDA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mitochondrial Proteome of Affected Glutamatergic Neurons in a Mouse Model of Leigh Syndrome

  • Gella, Alejandro|||0000-0002-3983-1392
  • Prada Dacasa, Patricia|||0000-0003-0689-9072
  • Carrascal Pérez, Montserrat|||0000-0002-0205-2176
  • Urpi, Andrea|||0000-0002-2437-7094
  • González Torres, Melania|||0000-0002-9755-8160
  • Abian, Joaquin|||0000-0003-2823-5429
  • Sanz Iglesias, Elisenda|||0000-0002-7932-8556
  • Quintana Romero, Albert|||0000-0003-1674-7160
Defects in mitochondrial function lead to severe neuromuscular orphan pathologies known as mitochondrial disease. Among them, Leigh Syndrome is the most common pediatric presentation, characterized by symmetrical brain lesions, hypotonia, motor and respiratory deficits, and premature death. Mitochondrial diseases are characterized by a marked anatomical and cellular specificity. However, the molecular determinants for this susceptibility are currently unknown, hindering the efforts to find an effective treatment. Due to the complex crosstalk between mitochondria and their supporting cell, strategies to assess the underlying alterations in affected cell types in the context of mitochondrial dysfunction are critical. Here, we developed a novel virus-based tool, the AAV-mitoTag viral vector, to isolate mitochondria from genetically defined cell types. Expression of the AAV-mitoTag in the glutamatergic vestibular neurons of a mouse model of Leigh Syndrome lacking the complex I subunit Ndufs4 allowed us to assess the proteome and acetylome of a subset of susceptible neurons in a well characterized model recapitulating the human disease. Our results show a marked reduction of complex I N-module subunit abundance and an increase in the levels of the assembly factor NDUFA2. Transiently associated non-mitochondrial proteins such as PKCδ, and the complement subcomponent C1Q were also increased in Ndufs4 -deficient mitochondria. Furthermore, lack of Ndufs4 induced ATP synthase complex and pyruvate dehydrogenase (PDH) subunit hyperacetylation, leading to decreased PDH activity. We provide novel insight on the pathways involved in mitochondrial disease, which could underlie potential therapeutic approaches for these pathologies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Extreme differences between human germline and tumor mutation densities are driven by ancestral human-specific deviations

  • Heredia-Genestar, José María|||0000-0002-7970-5016
  • Marquès i Bonet, Tomàs|||0000-0002-5597-3075
  • Juan, David|||0000-0003-1912-9667
  • Navarro, Arcadi|||0000-0003-2162-8246
Mutations do not accumulate uniformly across the genome. Human germline and tumor mutation density correlate poorly, and each is associated with different genomic features. Here, we use non-human great ape (NHGA) germlines to determine human germline- and tumor-specific deviations from an ancestral-like great ape genome-wide mutational landscape. Strikingly, we find that the distribution of mutation densities in tumors presents a stronger correlation with NHGA than with human germlines. This effect is driven by human-specific differences in the distribution of mutations at non-CpG sites. We propose that ancestral human demographic events, together with the human-specific mutation slowdown, disrupted the human genome-wide distribution of mutation densities. Tumors partially recover this distribution by accumulating preneoplastic-like somatic mutations. Our results highlight the potential utility of using NHGA population data, rather than human controls, to establish the expected mutational background of healthy somatic cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis

  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Pérez-Acevedo, Ana Pilar|||0000-0001-5647-4529
  • Pacifici, Roberta
  • Mannocchi, Giulio
  • Gottardi, Massimo
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Martín, Soraya|||0009-0008-3761-9217
  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Pichini, Simona
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
Inhalation by vaporization is a useful application mode for medical cannabis. In this study, we present the disposition of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors, and their metabolites in serum, oral fluid, and urine together with the acute pharmacological effects in 14 healthy individuals treated with vaporized medical cannabis. THC and CBD peaked firstly in serum and then in oral fluid, with higher concentrations in the first biological matrices and consequent higher area under the curve AUCs. Acidic precursors Δ-9-tetrahydrocannabinolic acid A (THCA) and cannabidiolic acid (CBDA) showed a similar time course profile but lower concentrations due to the fact that vaporization partly decarboxylated these compounds. All THC and CBD metabolites showed a later onset with respect to the parent compounds in the absorption phase and a slower decrease to baseline. In agreement with serum kinetics, THC-COOH-GLUC and 7-COOH-CBD were the significantly most excreted THC and CBD metabolites. The administration of vaporized medical cannabis induced prototypical effects associated with the administration of cannabis or THC in humans, with a kinetic trend overlapping that of parent compounds and metabolites in serum. The pharmacokinetics of cannabinoids, their precursors, and their metabolites in biological fluids of individuals treated with vaporized medical cannabis preparations showed a high interindividual variability as in the case of oral medical cannabis decoction and oil. Inhaled medical cannabis was absorbed into the organism earlier than decoction and oil. Cannabinoids reached higher systemic concentrations, also due to the fact that the acid precursors decarboxylated to parent cannabinoids at high temperatures, and consequently, the physiological and subjective effects occurred earlier and resulted with higher intensity. No serious adverse effects were observed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SirT7 auto-ADP-ribosylation regulates glucose starvation response through mH2A1

  • Simonet, Nicolas G.|||0000-0001-9921-7645
  • Thackray, Joshua K.|||0000-0003-2828-452X
  • Vazquez Prat, Berta Nieves|||0000-0002-8164-3926
  • Ianni, Alessandro|||0000-0001-7398-589X
  • Espinosa-Alcantud, María Dolores|||0000-0002-1126-2458
  • Morales-Sanfrutos, J.
  • Hurtado-Bagès, Sarah|||0000-0002-6588-0876
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Buschbeck, Marcus|||0000-0002-3218-4567
  • Tischfield, J.
  • De La Torre Gómez, Gisela Carolina|||0000-0001-9363-291X
  • Esteller, M.|||0000-0003-4490-6093
  • Braun, Thomas|||0000-0002-6165-4804
  • Olivella, Mireia|||0000-0002-6035-3399
  • Serrano, L.
  • Vaquero, Alejandro|||0000-0002-8735-4156
Sirtuins are key players of metabolic stress response. Originally described as deacetylases, some sirtuins also exhibit poorly understood mono-adenosine 5'-diphosphate (ADP)-ribosyltransferase (mADPRT) activity. We report that the deacetylase SirT7 is a dual sirtuin, as it also features auto-mADPRT activity. SirT7 mADPRT occurs at a previously undefined active site, and its abrogation alters SirT7 chromatin distribution. We identify an epigenetic pathway by which ADP-ribosyl-SirT7 is recognized by the ADP-ribose reader mH2A1.1 under glucose starvation, inducing SirT7 relocalization to intergenic regions. SirT7 promotes mH2A1 enrichment in a subset of nearby genes, many of them involved in second messenger signaling, resulting in their specific up- or down-regulation. The expression profile of these genes under calorie restriction is consistently abrogated in SirT7-deficient mice, resulting in impaired activation of autophagy. Our work provides a novel perspective on sirtuin duality and suggests a role for SirT7/mH2A1.1 axis in glucose homeostasis and aging.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Predictors of Metachronous Risk Polyps After Index Colonoscopy

  • Carot, Laura|||0000-0001-6507-9571
  • Navarro Viu, Gemma|||0000-0001-7906-5437
  • Naranjo-Hans, Dolores|||0000-0002-4089-047X
  • Iglesias, Mar|||0000-0002-2274-4671
  • Dalmases, Alba
  • Fernández Ibarrondo, Lierni|||0000-0003-2612-0484
  • Seoane, Agustín|||0000-0001-8023-4445
  • Buron, Andrea|||0000-0003-3590-1303
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Bessa Caserras, Xavier|||0000-0003-4680-1228
  • Andreu, Montserrat|||0000-0003-4286-1098
  • Alvarez-Urturi, Cristina|||0000-0002-7305-9973
We included patients with high-risk lesions (HRLs), defined as advanced adenoma (AA), large serrated polyps (SPs), and multiplicity (≥3 of any adenomas/SPs). Data on age, sex, cardiovascular risk factors, pharmacological treatment, and the histological characteristics in each individual, and mutations in genes involved in the most advanced index polyp, were collected. Parameters independently associated with a metachronous HRL diagnosis were evaluated through univariate and multivariate analyses. The results are reported as odds ratios and 95% confidence intervals along with P values. A total of 537 cases (median age: 60.7 years; 66% male) were included. Dyslipidemia and smoking correlated with metachronous HRLs. Multivariate logistic regression analysis showed that the presence of multiplicity with ≥3 polyps on the index colonoscopy was significantly associated with metachronous HRL, AA, proximal AA, and ≥3 polyps at 3 years. In addition, independent predictors of metachronous proximal AA were increasing age, female sex, and the loss of expression of the MLH1 protein. Multiplicity was a strong predictor of HRLs at 3 years, although the inclusion of other clinical variables (age, sex, smoking status, and dyslipidemia) improves surveillance recommendations. Without these risk factors, the surveillance could be extended to 5 years; we propose examining the somatic expression of MHL1 in all patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey

  • Hüls, Anke|||0000-0002-6005-417X
  • Costa, Alberto C. S.
  • Dierssen, Mara|||0000-0003-0853-6865
  • Baksh, Asaad|||0000-0001-6596-2145
  • Bargagna, Stefania
  • Baumer, Nicole
  • Brandão, Ana Claudia
  • Carfi, Angelo|||0000-0002-9837-7003
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Chicoine, Brian|||0000-0002-1520-3893
  • Ghosh, Sujay
  • Lakhanpaul, Monica
  • Manso, Coral
  • Mayer, Miguel-Angel
  • Ortega, Maria del Carmen
  • de Asua, Diego Real
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Russell, Lauren Ashley
  • Sgandurra, Giuseppina
  • Valentini, Diletta
  • Sherman, Stephanie L.
  • Strydom, Andre
Health conditions, immune dysfunction, and premature aging associated with trisomy 21 (Down syndrome, DS) may impact the clinical course of COVID-19. The T21RS COVID-19 Initiative launched an international survey for clinicians or caregivers on patients with COVID-19 and DS. Data collected between April and October 2020 (N=1046) were analysed and compared with the UK ISARIC4C survey of hospitalized COVID-19 patients with and without DS. The mean age of COVID-19 patients with DS in the T21RS survey was 29 years (SD = 18). Similar to the general population, the most frequent signs and symptoms of COVID-19 were fever, cough, and shortness of breath. Joint/muscle pain and vomiting or nausea were less frequent (p < 0.01), whereas altered consciousness/confusion were more frequent (p < 0.01). Risk factors for hospitalization and mortality were similar to the general population with the addition of congenital heart defects as a risk factor for hospitalization. Mortality rates showed a rapid increase from age 40 and were higher in patients with DS (T21RS DS versus non-DS patients: risk ratio (RR) = 3.5 (95%-CI=2.6;4.4), ISARIC4C DS versus non-DS patients: RR = 2.9 (95%-CI=2.1;3.8)) even after adjusting for known risk factors for COVID-19 mortality. Leading signs/symptoms of COVID-19 and risk factors for severe disease course are similar to the general population. However, individuals with DS present significantly higher rates of medical complications and mortality, especially from age 40. Down Syndrome Affiliates in Action, DSMIG-USA, GiGi's Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, NDSS, National Task Group on Intellectual Disabilities and Dementia Practices.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cannabis Use Induces Distinctive Proteomic Alterations in Olfactory Neuroepithelial Cells of Schizophrenia Patients

  • Barrera-Conde, Marta|||0000-0002-0106-0000
  • Ausin, Karina|||0000-0003-4914-9466
  • Lachén-Montes, Mercedes
  • Fernández-Irigoyen, Joaquín|||0000-0001-5072-4099
  • Galindo, Liliana|||0000-0002-2396-4772
  • Cuenca-Royo, Aida|||0000-0001-8551-5457
  • Fernández-Avilés, Cristina|||0000-0002-1029-9216
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Santamaría, Enrique
  • Robledo, Patricia
A close epidemiological link has been reported between cannabis use and schizophrenia (SCZ). However, biochemical markers in living humans related to the impact of cannabis in this disease are still missing. Olfactory neuroepithelium (ON) cells express neural features and offer a unique advantage to study biomarkers of psychiatric diseases. The aim of our study was to find exclusively deregulated proteins in ON cells of SCZ patients with and without a history of cannabis use. Thus, we compared the proteomic profiles of SCZ non-cannabis users (SCZ/nc) and SCZ cannabis users (SCZ/c) with control subjects non-cannabis users (C/nc) and control cannabis users (C/c). The results revealed that the main cascades affected in SCZ/nc were cell cycle, DNA replication, signal transduction and protein localization. Conversely, cannabis use in SCZ patients induced specific alterations in metabolism of RNA and metabolism of proteins. The levels of targeted proteins in each population were then correlated with cognitive performance and clinical scores. In SCZ/c, the expression levels of 2 proteins involved in the metabolism of RNA (MTREX and ZNF326) correlated with several cognitive markers and clinical signs. Moreover, use duration of cannabis negatively correlated with ZNF326 expression. These findings indicate that RNA-related proteins might be relevant to understand the influence of cannabis use on SCZ.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia

  • Jiménez, Isabel|||0000-0002-5144-861X
  • Tazón-Vega, Bárbara|||0000-0003-4513-5104
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Nieto Sáchica, Juan Camilo|||0000-0002-3400-1488
  • Bobillo, Sabela|||0000-0001-7381-680X
  • Palacio-García, Carles|||0000-0002-9085-3327
  • Carabia, Júlia
  • Valdés-Mas, Rafael
  • Munuera, Magdalena
  • Puigdefàbregas, Lluís
  • Parra, Genís
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Franco-Jarava, Clara|||0000-0002-9788-189X
  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Terol, María José
  • García-Marco, José Antonio
  • Crespo, Marta|||0000-0002-7732-7808
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
Mechanisms driving the progression of chronic lymphocytic leukemia (CLL) from its early stages are not fully understood. The acquisition of molecular changes at the time of progression has been observed in a small fraction of patients, suggesting that CLL progression is not mainly driven by dynamic clonal evolution. In order to shed light on mechanisms that lead to CLL progression, we investigated longitudinal changes in both the genetic and immunological scenarios. We performed genetic and immunological longitudinal analysis using paired primary samples from untreated CLL patients that underwent clinical progression (sampling at diagnosis and progression) and from patients with stable disease (sampling at diagnosis and at long-term asymptomatic follow-up). Molecular analysis showed limited and non-recurrent molecular changes at progression, indicating that clonal evolution is not the main driver of clinical progression. Our analysis of the immune kinetics found an increasingly dysfunctional CD8 + T cell compartment in progressing patients that was not observed in those patients that remained asymptomatic. Specifically, terminally exhausted effector CD8 + T cells (T-bet dim/- Eomes hi PD1 hi) accumulated, while the the co-expression of inhibitory receptors (PD1, CD244 and CD160) increased, along with an altered gene expression profile in T cells only in those patients that progressed. In addition, malignant cells from patients at clinical progression showed enhanced capacity to induce exhaustion-related markers in CD8 + T cells ex vivo mainly through a mechanism dependent on soluble factors including IL-10. Altogether, we demonstrate that the interaction with the immune microenvironment plays a key role in clinical progression in CLL, thereby providing a rationale for the use of early immunotherapeutic intervention. The online version contains supplementary material available at 10.1186/s40364-021-00290-z.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenomic profiling of primate lymphoblastoid cell lines reveals the evolutionary patterns of epigenetic activities in gene regulatory architectures

  • García Perez, Raquel|||0000-0002-2573-6984
  • Esteller-Cucala, Paula|||0000-0003-3048-4280
  • Mas, Glòria
  • Lobón, Irene|||0000-0003-1170-9915
  • Di Carlo, Valerio|||0000-0002-5099-0685
  • Riera, Meritxell
  • Kuhlwilm, Martin|||0000-0002-0115-1797
  • Navarro, Arcadi|||0000-0003-2162-8246
  • Blancher, Antoine|||0000-0002-6763-0539
  • Di Croce, Luciano|||0000-0003-3488-6228
  • Gomez-Skarmeta, José Luis
  • Juan, David|||0000-0003-1912-9667
  • Marquès i Bonet, Tomàs|||0000-0002-5597-3075
Changes in the epigenetic regulation of gene expression have a central role in evolution. Here, we extensively profiled a panel of human, chimpanzee, gorilla, orangutan, and macaque lymphoblastoid cell lines (LCLs), using ChIP-seq for five histone marks, ATAC-seq and RNA-seq, further complemented with whole genome sequencing (WGS) and whole genome bisulfite sequencing (WGBS). We annotated regulatory elements (RE) and integrated chromatin contact maps to define gene regulatory architectures, creating the largest catalog of RE in primates to date. We report that epigenetic conservation and its correlation with sequence conservation in primates depends on the activity state of the regulatory element. Our gene regulatory architectures reveal the coordination of different types of components and highlight the role of promoters and intragenic enhancers (gE) in the regulation of gene expression. We observe that most regulatory changes occur in weakly active gE. Remarkably, novel human-specific gE with weak activities are enriched in human-specific nucleotide changes. These elements appear in genes with signals of positive selection and human acceleration, tissue-specific expression, and particular functional enrichments, suggesting that the regulatory evolution of these genes may have contributed to human adaptation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Mediterranean Diet is Associated with an Improved Quality of Life in Adults with Type 1 Diabetes

  • Granado-Casas, Minerva|||0000-0003-3447-5728
  • Martín, Mariona
  • Martinez-Alonso, Montserrat|||0000-0003-1504-8552
  • Alcubierre, Nuria|||0000-0001-6245-3599
  • Hernández García, Marta|||0000-0003-1237-298X
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Mauricio, Didac|||0000-0002-2868-0250
This study aimed to assess the potential association between dietary patterns (i.e., the Mediterranean Diet (MedDiet) and healthy eating) and patient-reported quality of life (QoL) and treatment satisfaction (TS) in adults with type 1 diabetes (T1D). A food frequency questionnaire, the Audit of Diabetes-Dependent Quality of Life (ADDQoL-19), and the Diabetes Treatment Satisfaction Questionnaire-status version (DTSQ-s) were administered via personal interviews to 258 participants with T1D. Multivariable analysis showed that a moderate or high adherence to the MedDiet was associated with greater diabetes-specific QoL (β = 0.32, 95% CI = 0.03; 0.61; p = 0.029). None of the dietary quality indexes (i.e., the alternate Mediterranean Diet Score (aMED) and the alternate Healthy Eating Index (aHEI)) were associated with the overall TS. However, the aHEI was positively associated with the specific items of TS "convenience" and "flexibility" (β = 0.03, 95% CI = 0.00; 0.06; p = 0.042 and β = 0.04; 95% CI = 0.01; 0.06; p = 0.011, respectively). On the other hand, the aHEI was negatively associated with the dimension "recommend to others" (β = -0.5, 95% CI = -0.99; -0.02; p = 0.042). In conclusion, a moderate and high adherence to the MedDiet was associated with greater QoL. Although neither aMED nor aHEI were associated with the overall TS, some specific items were positively (i.e., "convenience", "flexibility") or negatively ("recommend to others") related to the aHEI. Further research is needed to assess how to improve medical nutrition therapy and its impact on patient-reported outcomes in people with T1D.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

ITGB3-mediated uptake of small extracellular vesicles facilitates intercellular communication in breast cancer cells

  • Fuentes Varela, Pedro|||0000-0001-8471-0197
  • Sesé, Marta|||0000-0003-1473-4833
  • Guijarro, Pedro J.
  • Emperador, Marta|||0000-0002-8538-4319
  • Sánchez-Redondo, Sara
  • Peinado, Héctor|||0000-0002-4256-3413
  • Hümmer, Stefan|||0000-0002-8184-3872
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
Metastasis, the spread of malignant cells from a primary tumour to distant sites, causes 90% of cancer-related deaths. The integrin ITGB3 has been previously described to play an essential role in breast cancer metastasis, but the precise mechanisms remain undefined. We have now uncovered essential and thus far unknown roles of ITGB3 in vesicle uptake. The functional requirement for ITGB3 derives from its interactions with heparan sulfate proteoglycans (HSPGs) and the process of integrin endocytosis, allowing the capture of extracellular vesicles and their endocytosis-mediated internalization. Key for the function of ITGB3 is the interaction and activation of focal adhesion kinase (FAK), which is required for endocytosis of these vesicles. Thus, ITGB3 has a central role in intracellular communication via extracellular vesicles, proposed to be critical for cancer metastasis. The integrin ITGB3 has been described to play an essential role in breast cancer metastasis, but the precise mechanisms remain undefined. Here the authors describe thus far unknown roles of ITGB3 in the uptake of extracellular vesicles, required for colony growth of breast cancer cells
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Synergism interaction between genetic polymorphisms in drug metabolizing enzymes and NSAIDs on upper gastrointestinal haemorrhage, a multicenter case-control study

  • Mallah, Narmeen
  • Zapata-Cachafeiro, Maruxa
  • Aguirre, Carmelo
  • Ibarra-García, Eguzkiñe
  • Palacios-Zabalza, Itziar
  • Macías-García, Fernando
  • Piñeiro-Lamas, María
  • Ibáñez, Luisa|||0000-0002-1175-0574
  • Vidal Guitart, Xavier|||0000-0001-6705-4298
  • Vendrell Bosch, Lourdes
  • Martin-Arias, Luis
  • Sáinz-Gil, María
  • Velasco-González, Verónica|||0000-0003-4739-9760
  • Bacariza-Cortiñas, Manuel
  • Salgado, Angel
  • Estany-Gestal, Ana
  • Figueiras, Adolfo
Interindividual genetic variations contribute to differences in patients' response to drugs as well as to the development of certain disorders. Patients who use non-steroidal anti-inflammatory drugs (NSAIDs) may develop serious gastrointestinal disorders, mainly upper gastrointestinal haemorrhage (UGIH). Studies about the interaction between NSAIDs and genetic variations on the risk of UGIH are scarce. Therefore, we investigated the effect of 16 single nucleotide polymorphisms (SNPs) involved in drug metabolism on the risk of NSAIDs-induced UGIH. We conducted a multicenter case-control study of 326 cases and 748 controls. Participants were sub-grouped into four categories according to NSAID exposure and genetic profile. We estimated odds ratios (ORs) and their 95% confidence intervals (CI) using generalized linear mixed models for dependent binomial variables and then calculated the measures of interaction, synergism index (S), and relative excess risk due to interaction (RERI). We undertook stratified analyses by the type of NSAID (aspirin, non-aspirin). We observed an excess risk of UGIH due to an interaction between any NSAID, non-aspirin NSAIDs or aspirin and carrying certain SNPs. The greatest excess risk was observed for carriers of: rs2180314:C>G [any NSAID: S = 3.30 (95%CI: 1.24-8.80), RERI = 4.39 (95%CI: 0.70-8.07); non-aspirin NSAIDs: S = 3.42 (95%CI: 1.12-10.47), RERI = 3.97 (95%CI: 0.44-7.50)], and rs4809957:A>G [any NSAID: S = 2.11 (95%CI: 0.90-4.97), RERI = 3.46 (95%CI: −0.40-7.31)]. Aspirin use by carriers of rs6664:C>T is also associated with increased risk of UGIH [OR: 2.22 (95%CI: 0.69-7.17) vs. OR: 7.72 (95%CI: 2.75-21.68)], yet larger sample size is needed to confirm this observation. The joint effect of the SNPs s2180314:C>G and rs4809957:A>G and NSAIDs are more than three times higher than the sum of their individual effects. Personalized prescriptions based on genotyping would permit a better weighing of risks and benefits from NSAID consumption
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients, A Mini-Review

  • Bradbury, Melissa|||0000-0003-4974-8899
  • Borràs, Eva|||0000-0002-3859-9907
  • Pérez-Benavente, Assumpció|||0000-0003-1872-9003
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Sabidó, Eduard|||0000-0001-6506-7714
In this manuscript, we review the management strategies available for high-grade serous ovarian cancer patients and the molecular advances that are helping improve our understanding of the tumor and its response to treatment. We emphasize the role that proteomics is now playing in the study of ovarian cancer tumors and how its integration with genomics can guide the development of new biomarkers and therapeutic targets. High-grade serous ovarian cancer (HGSC) remains the most common and deadly subtype of ovarian cancer. It is characterized by its late diagnosis and frequent relapse despite standardized treatment with cytoreductive surgery and platinum-based chemotherapy. The past decade has seen significant advances in the clinical management and molecular understanding of HGSC following the publication of the Cancer Genome Atlas (TCGA) researchers and the introduction of targeted therapies with anti-angiogenic drugs and poly(ADP-ribose) polymerase inhibitors in specific subgroups of patients. We provide a comprehensive review of HGSC, focusing on the most important molecular advances aimed at providing a better understanding of the disease and its response to treatment. We emphasize the role that proteomic technologies are now playing in these two aspects of the disease, through the identification of proteins and their post-translational modifications in ovarian cancer tumors. Finally, we highlight how the integration of proteomics with genomics, exemplified by the work performed by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), can guide the development of new biomarkers and therapeutic targets.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling

  • Bradbury, Melissa|||0000-0003-4974-8899
  • Castellvi, Josep|||0000-0001-5745-9996
  • Méndez Fernández, Olga|||0000-0003-4237-330X
  • Sánchez Iglesias, José Luis|||0000-0002-4542-3969
  • Pérez-Benavente, Assumpció|||0000-0003-1872-9003
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Borràs, Eva|||0000-0002-3859-9907
Despite recent advances in the management of BRCA1 mutated high-grade serous ovarian cancer (HGSC), the physiology of these tumors remains poorly understood. Here we provide a comprehensive molecular understanding of the signaling processes that drive HGSC pathogenesis with the addition of valuable ubiquitination profiling, and their dependency on BRCA1 mutation-state directly in patient-derived tissues. Using a multilayered proteomic approach, we show the tight coordination between the ubiquitination and phosphorylation regulatory layers and their role in key cellular processes related to BRCA1-dependent HGSC pathogenesis. In addition, we identify key bridging proteins, kinase activity, and post-translational modifications responsible for molding distinct cancer phenotypes, thus providing new opportunities for therapeutic intervention, and ultimately advance towards a more personalized patient care.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Early surgery with neuraxial anaesthesia in patients on chronic antiplatelet therapy with a proximal femur fracture, Multicentric randomised clinical trial

  • Anaya, Rafael|||0000-0003-2746-5388
  • Rodriguez Prieto, Mireia|||0000-0002-4462-534X
  • Millan, Angélica
  • Reguant, Francesca
  • Llorca Garcia, Jordi
  • Guilabert, Patricia|||0000-0001-6894-2342
  • Ruiz Pardos, Ana
  • Pantoja, Efrain|||0000-0003-4095-8988
  • Gil Sanchez, José María|||0000-0003-1422-0883
  • Moral, Victoria|||0000-0002-4061-0378
  • Merchán Galvis, Ángela María|||0000-0003-2375-5513
  • Martinez-Zapata, Mª José|||0000-0002-5836-1138
Background: Patients with proximal femur fracture on antiplatelet treatment benefit from early surgery. Our goal was to perform early surgery under neuraxial anaesthesia when indicated by the platelet function test. Methods: We conducted a multicentre randomised open-label parallel clinical trial. Patients were randomised to either early platelet function-guided surgery (experimental group) or delayed surgery (control group). Early surgery was programmed when the functional platelet count (as measured by Plateletworks) was.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Transcriptome innovations in primates revealed by single-molecule long-read sequencing

  • Ferrández-Peral, Luis|||0000-0003-0338-0603
  • Zhan, Xiaoyu
  • Alvarez-Estape, Marina|||0000-0001-8242-1092
  • Chiva, Cristina
  • Esteller-Cucala, Paula|||0000-0003-3048-4280
  • García Perez, Raquel|||0000-0002-2573-6984
  • Julià, Eva|||0000-0002-9722-4662
  • Lizano, Esther|||0000-0003-3304-9807
  • Fornas, Òscar|||0000-0003-2017-9100
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Li, Qiye
  • Marquès i Bonet, Tomàs|||0000-0002-5597-3075
  • Juan, David|||0000-0003-1912-9667
  • Zhang, Guojie|||0000-0001-6860-1521
Transcriptomic diversity greatly contributes to the fundamentals of disease, lineage-specific biology, and environmental adaptation. However, much of the actual isoform repertoire contributing to shaping primate evolution remains unknown. Here, we combined deep long- and short-read sequencing complemented with mass spectrometry proteomics in a panel of lymphoblastoid cell lines (LCLs) from human, three other great apes, and rhesus macaque, producing the largest full-length isoform catalog in primates to date. Around half of the captured isoforms are not annotated in their reference genomes, significantly expanding the gene models in primates. Furthermore, our comparative analyses unveil hundreds of transcriptomic innovations and isoform usage changes related to immune function and immunological disorders. The confluence of these evolutionary innovations with signals of positive selection and their limited impact in the proteome points to changes in alternative splicing in genes involved in immune response as an important target of recent regulatory divergence in primates.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin

  • Moura, David S.
  • Peña-Chilet, María|||0000-0002-6445-9617
  • Cordero Varela, Juan Antonio|||0000-0002-7373-5433
  • Alvarez-Alegret, Ramiro
  • Agra Pujol, Carolina|||0000-0003-4843-5786
  • Izquierdo, Francisco
  • Ramos, Rafel|||0000-0001-7970-5537
  • Ortega-Medina, Luis
  • Martin-Davila, Francisco
  • Castilla-Ramirez, Carolina
  • Hernandez-Leon, Carmen Nieves
  • Romagosa Perez Portabella, Maria Cleofe|||0000-0002-9478-7320
  • Vaz Salgado, María Ángeles
  • Lavernia, Javier
  • Bagué Rosell, Sílvia|||0000-0001-9980-7231
  • Mayodormo-Aranda, Empar
  • Vicioso, Luis
  • Hernández Barceló, José Emilio
  • Rubio-Casadevall, Jordi|||0000-0002-3516-6970
  • de Juan Ferre, Ana|||0000-0002-5852-9068
  • Fiaño-Valverde, María Concepción
  • Hindi, Nadia|||0000-0002-5864-762X
  • Lopez-Alvarez, María
  • Lacerenza, Serena
  • Dopazo, Joaquín|||0000-0003-3318-120X
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • Alvarez, Rosa|||0000-0003-0935-8298
  • Valverde Morales, Claudia Maria
  • Martínez Trufero, Javier|||0000-0002-0997-2573
  • Martín Broto, Javier|||0000-0001-7350-6916
Predictive biomarkers of trabectedin represent an unmet need in advanced soft-tissue sarcomas (STS). DNA damage repair (DDR) genes, involved in homologous recombination or nucleotide excision repair, had been previously described as biomarkers of trabectedin resistance or sensitivity, respectively. The majority of these studies only focused on specific factors (ERCC1, ERCC5, and BRCA1) and did not evaluate several other DDR-related genes that could have a relevant role for trabectedin efficacy. In this retrospective translational study, 118 genes involved in DDR were evaluated to determine, by transcriptomics, a predictive gene signature of trabectedin efficacy. A six-gene predictive signature of trabectedin efficacy was built in a series of 139 tumor samples from patients with advanced STS. Patients in the high-risk gene signature group showed a significantly worse progression-free survival compared with patients in the low-risk group (2.1 vs 6.0 months, respectively). Differential gene expression analysis defined new potential predictive biomarkers of trabectedin sensitivity (PARP3 and CCNH) or resistance (DNAJB11 and PARP1). Our study identified a new gene signature that significantly predicts patients with higher probability to respond to treatment with trabectedin. Targeting some genes of this signature emerges as a potential strategy to enhance trabectedin efficacy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Malondialdehyde-modified HDL particles elicit a specific IgG response in abdominal aortic aneurysm

  • Rodríguez-Carrio, J.
  • Cerro-Pardo, Isabel|||0000-0002-2542-5051
  • Lindholt, Jes S.|||0000-0001-9536-4488
  • Bonzon-Kulichenko, Elena|||0000-0003-0852-7520
  • Martínez-López, Diego
  • Roldán-Montero, R.
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Michel, J.B.
  • Blanco-Colio, Luis Miguel|||0000-0002-1560-6609
  • Vázquez, Jesús|||0000-0003-1461-5092
  • Suárez, A.
  • Martín-Ventura, J.L.
High Density Lipoprotein (HDL) plays a protective role in abdominal aortic aneurysm (AAA); however, recent findings suggest that oxidative modifications could lead to dysfunctional HDL in AAA. This study aimed at testing the effect of oxidized HDL on aortic lesions and humoral immune responses in a mouse model of AAA induced by elastase, and evaluating whether antibodies against modified HDL can be found in AAA patients. HDL particles were oxidized with malondialdehyde (HDL-MDA) and the changes were studied by biochemical and proteomics approaches. Experimental AAA was induced in mice by elastase perfusion and then mice were treated with HDL-MDA, HDL or vehicle for 14 days. Aortic lesions were studied by histomorphometric analysis. Levels of anti-HDL-MDA IgG antibodies were measured by an in-house immunoassay in the mouse model, in human tissue-supernatants and in plasma samples from the VIVA cohort. HDL oxidation with MDA was confirmed by enhanced susceptibility to diene formation. Proteomics demonstrated the presence of MDA adducts on Lysine residues of HDL proteins, mainly ApoA-I. MDA-modification of HDL abrogated the protective effect of HDL on cultured endothelial cells as well as on AAA dilation in mice. Exposure to HDL-MDA elicited an anti-HDL-MDA IgG response in mice. Anti-HDL-MDA were also detected in tissue-conditioned media from AAA patients, mainly in intraluminal thrombus. Higher plasma levels of anti-HDL-MDA IgG antibodies were found in AAA patients compared to controls. Anti-HDL-MDA levels were associated with smoking and were independent predictors of overall mortality in AAA patients. Overall, MDA-oxidized HDL trigger a specific humoral immune response in mice. Besides, antibodies against HDL-MDA can be detected in tissue and plasma of AAA patients, suggesting its potential use as surrogate stable biomarkers of oxidative stress in AAA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Developmental RNA-Seq transcriptomics of haploid germ cells and spermatozoa uncovers novel pathways associated with teleost spermiogenesis

  • Castro-Arnau, Júlia|||0000-0002-7091-6757
  • Chauvigné, François|||0000-0001-5571-7517
  • Gómez-Garrido, Jessica|||0000-0001-6409-8009
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Dabad, Marc|||0000-0002-6094-747X
  • Alioto, Tyler Scott|||0000-0002-2960-5420
  • Finn, Roderick Nigel|||0000-0002-8776-3945
  • Cerdà, Joan|||0000-0003-2568-6398
In non-mammalian vertebrates, the molecular mechanisms involved in the transformation of haploid germ cells (HGCs) into spermatozoa (spermiogenesis) are largely unknown. Here, we investigated this process in the marine teleost gilthead seabream (Sparus aurata) through the examination of the changes in the transcriptome between cell-sorted HGCs and ejaculated sperm (SPZ). Samples were collected under strict quality controls employing immunofluorescence microscopy as well as by determining the sperm motion kinematic parameters by computer-assisted sperm analysis. Deep sequencing by RNA-seq identified a total of 7286 differentially expressed genes (DEGs) (p-value < 0.01) between both cell types, of which nearly half were upregulated in SPZ compared to HCGs. In addition, approximately 9000 long non-coding RNAs (lncRNAs) were found, of which 56% were accumulated or emerged de novo in SPZ. The upregulated transcripts are involved in transcriptional and translational regulation, chromatin and cytoskeleton organization, metabolic processes such as glycolysis and oxidative phosphorylation, and also include a number of ion and water channels, exchangers, transporters and receptors. Pathway analysis conducted on DEGs identified 37 different signaling pathways enriched in SPZ, including 13 receptor pathways, from which the most predominant correspond to the chemokine and cytokine, gonadotropin-releasing hormone receptor and platelet derived growth factor signaling pathways. Our data provide new insight into the mRNA and lncRNA cargos of teleost spermatozoa and uncover the possible involvement of novel endocrine mechanisms during the differentiation and maturation of spermatozoa.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma

  • Hernández, Ainhoa|||0000-0003-4678-6662
  • Muñoz-Mármol, Ana Maria|||0000-0003-1008-7763
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Alameda, Francesc|||0000-0002-7302-6901
  • Carrato, Cristina|||0000-0002-1953-8287
  • Pineda, Estela|||0000-0003-2128-747X
  • Arpí Lluciá, Oriol|||0000-0002-5578-2092
  • Martinez-García, Maria
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Gut, Marta|||0000-0002-4063-7159
  • Del Barco Berrón, Sonia|||0000-0002-4951-6871
  • Gallego Rubio, Oscar|||0000-0001-5665-0967
  • Dabad, Marc|||0000-0002-6094-747X
  • Mesia, Carlos
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Domènech Viñolas, Marta|||0000-0003-4827-9170
  • Vidal, Noemí|||0000-0002-2852-6667
  • Aldecoa, Iban|||0000-0001-5774-7453
  • de la Iglesia, Nuria|||0000-0002-1083-7715
  • Balañá, Carmen|||0000-0003-0771-0390
RNA-Sequencing (RNA-Seq) can identify gene fusions in tumors, but not all these fusions have functional consequences. Using multiple data bases, we have performed an in silico analysis of fusions detected by RNA-Seq in tumor samples from 139 newly diagnosed glioblastoma patients to identify in-frame fusions with predictable oncogenic potential. Among 61 samples with fusions, there were 103 different fusions, involving 167 different genes, including 20 known oncogenes or tumor suppressor genes (TSGs), 16 associated with cancer but not oncogenes or TSGs, and 32 not associated with cancer but previously shown to be involved in fusions in gliomas. After selecting in-frame fusions able to produce a protein product and running Oncofuse, we identified 30 fusions with predictable oncogenic potential and classified them into four non-overlapping categories: six previously described in cancer; six involving an oncogene or TSG; four predicted by Oncofuse to have oncogenic potential; and 14 other in-frame fusions. Only 24 patients harbored one or more of these 30 fusions, and only two fusions were present in more than one patient: FGFR3::TACC3 and EGFR::SEPTIN14. This in silico study provides a good starting point for the identification of gene fusions with functional consequences in the pathogenesis or treatment of glioblastoma.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer

  • Duro Sánchez, Santiago|||0000-0002-3829-7562
  • Nadal-Serrano, Mercedes|||0000-0002-1299-495X
  • Lalinde-Gutiérrez, Marta|||0000-0002-9858-8775
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Morancho, Beatriz|||0000-0003-3369-8647
  • Escorihuela, Marta|||0000-0001-9074-2339
  • Pérez-Ramos, Sandra|||0000-0002-3612-4027
  • Escrivá-de-Romaní, Santiago|||0000-0001-7816-7589
  • Gandullo-Sánchez, Lucía|||0000-0002-7841-230X
  • Pandiella, Atanasio|||0000-0002-4704-8971
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Rodilla, Verónica|||0000-0003-0512-4179
  • Dijcks, Fred A.|||0000-0002-6023-9422
  • Dokter, Wim .H.A.
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Arribas, Joaquín V.|||0000-0002-0504-0664
Antibody-drug conjugates (ADC) are antineoplastic agents recently introduced into the antitumor arsenal. T-DM1, a trastuzumab-based ADC that relies on lysosomal processing to release the payload, is approved for HER2-positive breast cancer. Next-generation ADCs targeting HER2, such as [vic-]trastuzumab duocarmazine (SYD985), bear linkers cleavable by lysosomal proteases and membrane-permeable drugs, mediating a bystander effect by which neighboring antigen-negative cells are eliminated. Many antitumor therapies, like DNA-damaging agents or CDK4/6 inhibitors, can induce senescence, a cellular state characterized by stable cell-cycle arrest. Another hallmark of cellular senescence is the enlargement of the lysosomal compartment. Given the relevance of the lysosome to the mechanism of action of ADCs, we hypothesized that therapies that induce senescence would potentiate the efficacy of HER2-targeting ADCs. Treatment with the DNA-damaging agent doxorubicin and CDK4/6 inhibitor induced lysosomal enlargement and senescence in several breast cancer cell lines. While senescence-inducing drugs did not increase the cytotoxic effect of ADCs on target cells, the bystander effect was enhanced when HER2-negative cells were cocultured with HER2-low cells. Knockdown experiments demonstrated the importance of cathepsin B in the enhanced bystander effect, suggesting that cathepsin B mediates linker cleavage. In breast cancer patient-derived xenografts, a combination treatment of CDK4/6 inhibitor and SYD985 showed improved antitumor effects over either treatment alone. These data support the strategy of combining next-generation ADCs targeting HER2 with senescence-inducing therapies for tumors with heterogenous and low HER2 expression. SIGNIFICANCE: Combining ADCs against HER2-positive breast cancers with therapies that induce cellular senescence may improve their therapeutic efficacy by facilitating a bystander effect against antigen-negative tumor cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis

  • Diesch, Jeannine|||0000-0002-4667-3468
  • Le Pannérer, Marguerite Marie|||0000-0002-5779-8805
  • Winkler, René|||0000-0002-7570-0242
  • Casquero, Raquel
  • Muhar, Matthias|||0000-0002-3018-9698
  • van der Garde, Mark
  • Maher, Michael|||0000-0002-4956-7185
  • Martínez Herráez, Carolina|||0000-0003-4711-7225
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • Fellner, Michaela
  • Rathert, Philipp|||0000-0003-1477-136X
  • Brooks, Nigel
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Gentilella, Antonio|||0000-0002-6830-2086
  • De La Torre Gómez, Gisela Carolina|||0000-0001-9363-291X
  • Zuber, Johannes|||0000-0001-8810-6835
  • Götze, Katharina S.|||0000-0002-6276-8002
  • Buschbeck, Marcus|||0000-0002-3218-4567
The nucleotide analogue azacitidine (AZA) is currently the best treatment option for patients with high-risk myelodysplastic syndromes (MDS). However, only half of treated patients respond and of these almost all eventually relapse. New treatment options are urgently needed to improve the clinical management of these patients. Here, we perform a loss-of-function shRNA screen and identify the histone acetyl transferase and transcriptional co-activator, CREB binding protein (CBP), as a major regulator of AZA sensitivity. Compounds inhibiting the activity of CBP and the closely related p300 synergistically reduce viability of MDS-derived AML cell lines when combined with AZA. Importantly, this effect is specific for the RNA-dependent functions of AZA and not observed with the related compound decitabine that is only incorporated into DNA. The identification of immediate target genes leads us to the unexpected finding that the effect of CBP/p300 inhibition is mediated by globally down regulating protein synthesis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

ISOTOPE, ISOform-guided prediction of epiTOPEs in cancer

  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Reixachs Solé, Marina|||0000-0001-9446-8082
  • Pérez Granado, Judith|||0000-0002-4098-3000
  • Fugmann, Tim|||0000-0002-7447-7480
  • Sanz, Ferran|||0000-0002-7534-7661
  • Yokota, Jun|||0000-0001-6010-6294
  • Eyras, Eduardo|||0000-0003-0793-6218
Immunotherapies provide effective treatments for previously untreatable tumors and identifying tumor-specific epitopes can help elucidate the molecular determinants of therapy response. Here, we describe a pipeline, ISOTOPE (ISOform-guided prediction of epiTOPEs In Cancer), for the comprehensive identification of tumor-specific splicing-derived epitopes. Using RNA sequencing and mass spectrometry for MHC-I associated proteins, ISOTOPE identified neoepitopes from tumor-specific splicing events that are potentially presented by MHC-I complexes. Analysis of multiple samples indicates that splicing alterations may affect the production of self-epitopes and generate more candidate neoepitopes than somatic mutations. Although there was no difference in the number of splicing-derived neoepitopes between responders and non-responders to immune therapy, higher MHC-I binding affinity was associated with a positive response. Our analyses highlight the diversity of the immunogenic impacts of tumor-specific splicing alterations and the importance of studying splicing alterations to fully characterize tumors in the context of immunotherapies. ISOTOPE is available at https://github.com/comprna/ISOTOPE.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparison of covid-19 and non-covid-19 pneumonia in down syndrome

  • Real de Asua, Diego
  • Mayer, Miguel Angel|||0000-0003-0362-6298
  • Del Carmen Ortega, María
  • Borrel, Jose M.
  • de Jesús Bermejo, Teresa
  • González-lamuño, Domingo|||0000-0002-7578-241X
  • Manso, Coral
  • Moldenhauer, Fernando|||0000-0002-6259-8226
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Hüls, Anke|||0000-0002-6005-417X
  • Sherman, Stephanie L.
  • Strydom, Andre
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Dierssen, Mara|||0000-0003-0853-6865
Whether the increased risk for coronavirus disease 2019 (COVID-19) hospitalization and death observed in Down syndrome (DS) are disease specific or also occur in individuals with DS and non-COVID-19 pneumonias is unknown. This retrospective cohort study compared COVID-19 cases in persons with DS hospitalized in Spain reported to the Trisomy 21 Research Society COVID- 19 survey (n = 86) with admissions for non-COVID-19 pneumonias from a retrospective clinical database of the Spanish Ministry of Health (n = 2832 patients). In-hospital mortality rates were significantly higher for COVID-19 patients (26.7% vs. 9.4%), especially among individuals over 40 and patients with obesity, dementia, and/or epilepsy. The mean length of stay of deceased patients with COVID-19 was significantly shorter than in those with non-COVID-19 pneumonias. The rate of admission to an ICU in patients with DS and COVID-19 (4.3%) was significantly lower than that reported for the general population with COVID-19. Our findings confirm that acute SARS-CoV-2 infection leads to higher mortality than non-COVID-19 pneumonias in individuals with DS, especially among adults over 40 and those with specific comorbidities. However, differences in access to respiratory support might also account for some of the heightened mortality of individuals with DS with COVID-19.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry

  • Stephens, Camilla|||0000-0002-0796-9610
  • Robles Díaz, Mercedes|||0000-0002-2365-2787
  • Medina-Cáliz, Inmaculada|||0000-0003-0471-6658
  • Garcia-Cortes, Miren|||0000-0003-0410-8273
  • Ortega-Alonso, Aida|||0000-0002-8999-4093
  • Sanabria-Cabrera, Judith|||0000-0002-7769-7008
  • Gonzalez-Jimenez, Andrés
  • Alvarez-Alvarez, Ismael
  • Slim, Mahmoud|||0000-0003-2455-1432
  • Jimenez-Perez, Miguel
  • Gonzalez-Grande, Rocio
  • Fernández, M.Carmen
  • Casado, Marta
  • Soriano, German|||0000-0002-9267-6811
  • Roman, Eva|||0000-0001-9084-8555
  • Hallal, Hacibe
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
  • Castiella, Agustin
  • Conde, Isabel|||0000-0001-7863-2233
  • Prieto, Martin
  • Moreno-Planas, Jose Maria
  • Giraldez, Alvaro
  • Moreno-Sanfiel, J.Miguel
  • Kaplowitz, Neil
  • Lucena, M. Isabel|||0000-0001-9586-4896
  • Andrade, Raúl J.
  • Cortés, M.G.
  • Pinazo, Jose
  • García Muñoz, B.
  • Alcántara, Ramiro
  • Hernández, Andrés
  • Escaño, M.D.García
  • del Campo, E.
  • González-Jiménez, A.
  • Sanjuán Jiménez, Rocío
  • Cueto, Alejandro
  • Bonilla, Elvira
  • Di Zeo, D.
  • Niu, H.
  • Villanueva-Paz, Marina|||0000-0003-4728-201X
  • Papineau, A.
  • Pérez Hernández, Manuel José
  • González-Grande, Rocío|||0000-0002-7691-5755
  • López Ortega, S.
  • Santaella, I.
  • Ocaña, A.
  • Palomino, P.
  • Fernández, Maria Carmen
  • Peláez, Gloria
  • Porcel, A.
  • Casado, M.
  • González Sánchez, Mara
  • Millán-Domínguez, R.
  • Fombuena, Blanca
  • Gallego, Rocío
  • Ampuero, Javier|||0000-0002-8332-2122
  • Del Campo, José Antonio
  • Calle-Sanz, R.
  • Rojas, Lourdes
  • Rojas, Ángela|||0000-0003-0853-4800
  • Gil Gómez, Alexandra
  • Vilar, Eduardo
  • Guarner, Carlos|||0000-0001-5957-9481
  • Quijada-Manuitt, María Ángeles|||0000-0002-9624-0177
  • Antonijoan Arbós, Rosa Ma|||0000-0002-7099-5125
  • Sánchez Delgado, Jordi|||0000-0002-5217-6492
  • Vergara Gómez, Mariano
  • Hallal, H.
  • García Oltra, Ester
  • Titos Arcos, J.C.
  • Pérez Martínez, Alfonso
  • Sánchez Cobarro, C.
  • Egea Caparrós, J.M.
  • Zapata, Eva María
  • Arenas, Juan Ignacio
  • Gómez García, Alexandra
  • Esandi, F.J.
  • Blanco, Sonia
  • Martínez Odriozola, Pedro
  • Crespo García, Javier|||0000-0001-8248-0172
  • Iruzubieta, Paula|||0000-0001-9476-1801
  • Cabezas González, Joaquín|||0000-0003-0012-484X
  • Giráldez Gallego, Álvaro
  • Rodríguez Seguel, Elisa
  • Cuaresma, María
  • González-Gallego, Javier|||0000-0002-4386-9342
  • Jorquera, Francisco|||0000-0002-1799-2881
  • Sánchez Campos, S.
  • Otazua, Pedro
  • de Juan Gómez, A.
  • Salmerón, Javier
  • Gila, Ana
  • Quiles, Rosa
  • González, José Manuel
  • Lorenzo, Sara
  • Prieto, Martín
  • Conde Amiel, I.
  • Berenguer, Marina|||0000-0001-9246-4264
  • García-Eliz, María
  • Primo, Joaquín
  • Molés, José Ramón
  • Garayoa, Ana
  • Carrascosa, Miguel
  • Gómez Domínguez, Elena
  • Cuevas, L.
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Montané Esteva, Eva|||0000-0002-1691-7652
  • Barriocanal, Ana María|||0000-0002-4159-519X
  • Arellano, Ana Lucía|||0000-0001-8601-3504
  • Sanz, Yolanda
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Sala, Margarita
  • Masnou Ridaura, H.
  • Bruguera, Miquel
  • Ginès, Pere|||0000-0003-4657-4504
  • Lens, Sabela|||0000-0003-4900-411X
  • Mariño, Zoe|||0000-0001-6321-9534
  • Hernández Guerra, Manuel
  • Moreno Sanfiel, J.M.
  • Fernández del Campo, C.Boada
  • Tejedor, Martián
  • González Ferrer, Ruth
  • Fernández, Conrado
  • Fernández Gil, Marta
  • Montero, José Luís
  • de la Mata, Manuel
  • Fuentes Olmo, Javier|||0000-0001-8637-510X
  • Fernández Bonilla, E.M.
  • Moreno, Julián M.
  • Martínez-Ródenas, Ponciano
  • Gómez Garrido, M.
  • Oliva, C.
  • Rendón, Paloma|||0000-0002-6521-3766
  • García Samaniego, Javier
  • Madejón, Antonio
  • Calleja, Jose Luis|||0000-0002-2265-6591
  • Martínez Porras, J.L.
  • Cabriada, José Luis|||0000-0002-3068-5659
  • Pérez-Moreno, José Manuel
  • Lara, Carmen
Background & Aims: Prospective drug-induced liver injury (DILI) registries are important sources of information on idiosyncratic DILI. We aimed to present a comprehensive analysis of 843 patients with DILI enrolled into the Spanish DILI Registry over a 20-year time period. Methods: Cases were identified, diagnosed and followed prospectively. Clinical features, drug information and outcome data were collected. Results: A total of 843 patients, with a mean age of 54 years (48% females), were enrolled up to 2018. Hepatocellular injury was associated with younger age (adjusted odds ratio [aOR] per year 0.983; 95% CI 0.974-0.991) and lower platelet count (aOR per unit 0.996; 95% CI 0.994-0.998). Anti-infectives were the most common causative drug class (40%). Liver-related mortality was more frequent in patients with hepatocellular damage aged ≥65 years (p = 0.0083) and in patients with underlying liver disease (p = 0.0221). Independent predictors of liver-related death/transplantation included nR-based hepatocellular injury, female sex, higher onset aspartate aminotransferase (AST) and bilirubin values. nR-based hepatocellular injury was not associated with 6-month overall mortality, for which comorbidity burden played a more important role. The prognostic capacity of Hy's law varied between causative agents. Empirical therapy (corticosteroids, ursodeoxycholic acid and MARS) was prescribed to 20% of patients. Drug-induced autoimmune hepatitis patients (26 cases) were mainly females (62%) with hepatocellular damage (92%), who more frequently received immunosuppressive therapy (58%). Conclusions: AST elevation at onset is a strong predictor of poor outcome and should be routinely assessed in DILI evaluation. Mortality is higher in older patients with hepatocellular damage and patients with underlying hepatic conditions. The Spanish DILI Registry is a valuable tool in the identification of causative drugs, clinical signatures and prognostic risk factors in DILI and can aid physicians in DILI characterisation and management. Lay summary: Clinical information on drug-induced liver injury (DILI) collected from enrolled patients in the Spanish DILI Registry can guide physicians in the decision-making process. We have found that older patients with hepatocellular type liver injury and patients with additional liver conditions are at a higher risk of mortality. The type of liver injury, patient sex and analytical values of aspartate aminotransferase and total bilirubin can also help predict clinical outcomes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Role of common cell culture media supplements on citrate-stabilized gold nanoparticle protein corona formation, aggregation state, and the consequent impact on cellular uptake, The Role of common cell culture media supplements on the nanoparticle protein corona formation, aggregation state, and the consequent impact on cellular uptake

  • Barbero, Francesco|||0000-0001-8704-0651
  • Michelini, Sara|||0000-0001-9470-3337
  • Moriones, Oscar Hernando|||0000-0003-0310-0210
  • Patarroyo, Javier|||0000-0002-3703-666X
  • Rosell Aluja, Jordi|||0000-0001-6575-3722
  • Freixanet Gustà, Muriel|||0000-0001-9872-3079
  • Vitali, Michele|||0000-0001-8618-8988
  • Martín, Luna
  • Canals, Francesc|||0000-0002-0650-1135
  • Duschl, Albert|||0000-0002-7034-9860
  • Horejs-Hoeck, Jutta|||0000-0002-0984-204X
  • Mondragón, Laura|||0000-0002-3257-045X
  • Bastús, Neus G.|||0000-0002-3144-7986
  • Puntes, Víctor|||0000-0001-8996-9499
Sodium citrate-stabilized gold nanoparticles (AuNPs) are destabilized when dispersed in cell culture media (CCMs). This may promote their aggregation and subsequent sedimentation, or under the proper conditions, their interaction with dispersed proteins can lead to the formation of a NP-stabilizing protein corona. CCMs are ionic solutions that contain growth substances which are typically supplemented, in addition to serum, with different substances such as dyes, antioxidants, and antibiotics. In this study, the impact of phenol red, penicillin-streptomycin, l-glutamine, and β-mercaptoethanol on the formation of the NP-protein corona in CCMs was investigated. Similar protein coronas were obtained except in the presence of antibiotics. Under these conditions, the protein corona took more time to be formed, and its density and composition were altered, as indicated by UV-vis spectroscopy, Z potential, dynamic light scattering, and liquid chromatography-mass spectrometry analyses. As a consequence of these modifications, a significantly different AuNP cellular uptake was measured, showing that NP uptake increased as did the NP aggregate formation. AuNP uptake studies performed in the presence of clathrin- and caveolin-mediated endocytosis inhibitors showed that neither clathrin receptors nor lipid rafts were significantly involved in the internalization mechanism. These results suggest that in these conditions, NP aggregation is the main mechanism responsible for their cellular uptake.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Global analysis of the association between pig muscle fatty acid composition and gene expression using RNA-Seq

  • Valdés Hernández, Jesús|||0000-0001-5314-0988
  • Ramayo-Caldas, Yuliaxis|||0000-0002-8142-0159
  • Passols Manzano, Magí|||0000-0002-6853-4119
  • Sebastià, Cristina|||0000-0003-2250-6451
  • Criado Mesas, Lourdes|||0000-0002-1115-4131
  • Crespo-Piazuelo, Daniel|||0000-0001-7896-2507
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Castelló Farré, Anna|||0000-0001-8497-6251
  • Sánchez Bonastre, Armando|||0000-0001-9160-1124
  • Folch, Josep M.|||0000-0003-3689-1303
Fatty acids (FAs) play an essential role as mediators of cell signaling and signal transduction, affecting metabolic homeostasis and determining meat quality in pigs. However, FAs are transformed by the action of several genes, such as those encoding desaturases and elongases of FAs in lipogenic tissues. The aim of the current work was to identify candidate genes, biological processes, and pathways involved in the modulation of intramuscular FA profile from longissimus dorsi muscle. FA profile by gas chromatography of methyl esters and gene expression by RNA-Seq were determined in 129 Iberian × Duroc backcrossed pigs. An association analysis between the muscle transcriptome and its FA profile was performed, followed by a concordance and functional analysis. Overall, a list of well-known (e.g., PLIN1, LEP, ELOVL6, SC5D, NCOA2, ACSL1, MDH1, LPL, LGALS12, TFRC, GOT1, and FBP1) and novel (e.g., TRARG1, TANK, ENSSSCG00000011196, and ENSSSCG00000038429) candidate genes was identified, either in association with specific or several FA traits. Likewise, several of these genes belong to biological processes and pathways linked to energy, lipid, and carbohydrate metabolism, which seem determinants in the modulation of FA compositions. This study can contribute to elucidate the complex relationship between gene expression and FA profile in pig muscle.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Systematic Collaborative Reanalysis of Genomic Data Improves Diagnostic Yield in Neurologic Rare Diseases

  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Matalonga, Leslie
  • Pujadas, Montserrat
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Tonda, Raúl
  • Artuch, R.|||0000-0002-3422-9685
  • Gallano, Pia|||0000-0001-8104-2197
  • Garrabou, Glòria|||0000-0001-8973-9933
  • González, Juan R.|||0000-0003-3267-2146
  • Grinberg, Daniel|||0000-0001-9859-2590
  • Guitart, Maria|||0000-0003-2957-7404
  • Laurie, Steven|||0000-0003-3913-5829
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Luengo, Cristina
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Milà, Montserrat
  • Ovelleiro, David|||0000-0002-9415-2229
  • Parra, Genís
  • Pujol, Aurora|||0000-0002-9606-0600
  • Tizzano, Eduardo F.|||0000-0002-7116-6310
  • Macaya Ruiz, Alfons|||0000-0001-7998-4185
  • Palau, Francesc|||0000-0002-8635-5421
  • Ribes, Antònia
  • Pérez-Jurado, Luis Alberto|||0000-0002-1988-3005
  • Beltran i Agulló, Sergi|||0000-0002-2810-3445
  • Schlüter, Agatha|||0000-0001-6732-1528
  • Rodríguez-Palmero, Agustí|||0000-0002-4141-5515
  • Cáceres, Alejandro|||0000-0001-8551-6695
  • Nascimento, Andrés
  • García-Cazorla, Àngels
  • Cueto-González, Anna Mª|||0000-0001-7694-6124
  • Marcé-Grau, Anna|||0000-0001-5762-4023
  • Ruiz Nel Lo, Anna
  • Martínez-Monseny, Antonio
  • Sánchez, Aurora|||0000-0003-1167-1451
  • García, Belén
  • Pérez-Dueñas, Belén|||0000-0002-4979-2788
  • Gel, Bernat|||0000-0001-8878-349X
  • Fusté, Berta
  • Hernández Ferrer, Carles
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Arjona, César
  • Hernando Davalillo, Cristina
  • Natera de Benito, Daniel
  • Picó Amador, Daniel
  • Gómez-Andrés, David|||0000-0001-5654-7791
  • Yubero, Délia
  • Pelegrí-Sisó, Dolors|||0000-0002-5993-3003
  • Verdura, Edgard|||0000-0003-3856-2060
  • García Arumí, Elena|||0000-0003-1848-005X
  • Castellanos, Elisabeth|||0000-0002-8133-5325
  • Gabau, Elisabeth|||0000-0001-8120-7393
  • Tobías, Ester|||0000-0002-9968-3651
  • López-Grondona, Fermina
  • Cardellach, Francesc|||0000-0003-3286-3436
  • García García, Francesc Josep|||0000-0001-9021-0324
  • Munell Casadesus, Francina|||0000-0001-8580-2819
  • Tort, Frederic|||0000-0003-2733-1603
  • Aznar, Gemma
  • Olive Cirera, Gemma
  • Tell-Martí, Gemma|||0000-0003-2728-6961
  • Muñoz-Pujol, Gerard|||0000-0002-6863-3993
  • Paramonov, Ida
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Madrigal, Irene|||0000-0002-7229-1199
  • Valenzuela, Irene|||0000-0003-2350-6058
  • Gut, Ivo|||0000-0001-7219-632X
  • Cusco, Ivon|||0000-0003-2104-9332
  • Trotta, Jean-Rémi
  • Cruz, Jordi
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Milisenda, José César|||0000-0003-0151-7872
  • Ma Grau, Josep
  • Garcia-Villoria, Judit
  • Armstrong, Judith|||0000-0003-0588-9307
  • Cantó, Judith
  • Sala-Coromina, Júlia|||0000-0001-5116-6316
  • Rodríguez-Revenga, Laia
  • Alías, Laura|||0000-0003-2193-6185
  • Gort, Laura|||0000-0003-4746-1034
  • González Quereda, Lidia|||0000-0003-0715-6414
  • Costa, Mar
  • Fernández-Callejo, Marcos
  • López Sánchez, Marcos|||0000-0002-1517-5968
  • Álvarez Mora, María Isabel|||0000-0003-3788-8915
  • Gut, Marta|||0000-0002-4063-7159
  • Serrano, Mercedes|||0000-0002-2056-2428
  • Raspall-Chaure, Miquel|||0000-0002-3132-3342
  • Del Toro, Mireia|||0000-0002-8163-1853
  • Bayés, Mònica
  • Baena Díez, Neus|||0000-0003-0677-240X
  • Spataro, Nino|||0000-0002-2127-2238
  • Capdevila, Núria|||0000-0003-2080-7381
  • Ugarteburu, Olatz|||0000-0003-4214-3301
  • Muñoz-Cabello, Patricia|||0000-0002-5242-9605
  • Romero Duque, Penélope|||0000-0003-3509-1320
  • Rabionet, Raquel|||0000-0001-5006-8140
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Calvo-Escalona, Rosa|||0000-0001-9572-4228
  • Urreizti, Roser|||0000-0003-3617-7134
  • Bernal, Sara|||0000-0003-4427-0574
  • Boronat Guerrero, Susana|||0000-0001-7096-5578
  • Balcells, Susana|||0000-0003-1211-1907
  • Vendrell, Teresa
Many patients experiencing a rare disease remain undiagnosed even after genomic testing. Reanalysis of existing genomic data has shown to increase diagnostic yield, although there are few systematic and comprehensive reanalysis efforts that enable collaborative interpretation and future reinterpretation. The Undiagnosed Rare Disease Program of Catalonia project collated previously inconclusive good quality genomic data (panels, exomes, and genomes) and standardized phenotypic profiles from 323 families (543 individuals) with a neurologic rare disease. The data were reanalyzed systematically to identify relatedness, runs of homozygosity, consanguinity, single-nucleotide variants, insertions and deletions, and copy number variants. Data were shared and collaboratively interpreted within the consortium through a customized Genome-Phenome Analysis Platform, which also enables future data reinterpretation. Reanalysis of existing genomic data provided a diagnosis for 20.7% of the patients, including 1.8% diagnosed after the generation of additional genomic data to identify a second pathogenic heterozygous variant. Diagnostic rate was significantly higher for family-based exome/genome reanalysis compared with singleton panels. Most new diagnoses were attributable to recent gene-disease associations (50.8%), additional or improved bioinformatic analysis (19.7%), and standardized phenotyping data integrated within the Undiagnosed Rare Disease Program of Catalonia Genome-Phenome Analysis Platform functionalities (18%).